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Abstract
The E5 protein of Bovine Papillomavirus type 4 (BPV-4) is, at only 42 amino 
acids, the smallest transforming protein identified to date. E5 consists of a N-terminal 
putative a-helical transmembrane body and a hydrophilic C-terminal tail and is 
localised to cellular membranes. E5 transforms fibroblasts, its expression allows 
established NIH3T3 fibroblasts to proliferate in suspension and in the absence of 
mitogens.
Here we analysed the cellular localisation of BPV-4 E5 showing that a form 
of E5 fused with the green fluorescent protein (GFP-E5) is distributed mainly to the 
Golgi apparatus and to a lesser extent to the Endoplasmic Reticulum but could not be 
detected at the plasma membrane.
GFP-E5 was used in transient and stable transfection assays in NIH3T3 cells. 
These studies revealed that, contrary to E5 wt, GFP-E5 expressing cells are not 
morphologically transformed, and cannot proliferate in absence of mitogens, however 
these cells do not exit the cell cycle when maintained in suspension. We concluded 
that GFP-E5 could segregate the two transforming phenotypes of E5 wt. Here we 
investigated at what level of the cell cycle machinery the segregation occurs.
Biochemical analysis revealed that GFP-E5 expressing cells do not sustain 
cyclin D1 and cyclin A expression after serum withdrawal, show an active 
hypophosphorylated form of pRb and pl07 and consequently exit from the cell cycle 
and become quiescent in these growth conditions. Moreover GFP-E5 ability to 
promote transcriptional activation of a heterologous cyclin A promoter in normal 
growth conditions is not maintained in low serum, contrary to E5 wt, and although 
the cyclin A-associated kinase activity in GFP-E5 cells was 1.5 times higher that the 
control in low serum, it was clearly not sufficient to sustain cells growth.
However when maintained in suspension GFP-E5 cells, similarly to E5 wt 
cells, present an up-regulated cyclin D l, can transactivate cyclin A promoter and 
sustain cyclin A expression level and cyclin A-associated kinase activity. 
Interestingly only cdc2, but not CDK2, can be detected in cyclin A 
immunoprecipitates.
xvii
The use of inhibitors of the MAPK pathway revealed that in E5 wt cells the 
level of cyclin D1 and cyclin A expression is independent from this pathway. In 
GFP-E5 cells, however, cyclin D1 is down-regulated but cyclin A is still elevated 
after treatment with the inhibitors.
From these data we conclude that GFP-E5 cells ability to grow in suspension 
correlates with the ability to up-regulate cyclin A expression and cyclin A-associated 
kinase activity and that the up-regulation is independent from MAPK pathway and 
cyclin D1 expression level. Moreover, we show here, in both E5 and GFP-E5 cells, 
that the principal cyclin-dependent kinase associated with cyclin A is cdc2 suggesting 
that the viral protein may act on the G2/M phase transition of the cell cycle.
xviii
CHAPTER 1: INTRODUCTION
1.1 The hallmarks of cancers
After twenty-five years of rapid advances, cancer research has generated a 
rich and complex body of knowledge, revealing cancer to be a disease involving 
dynamic changes in the genome (Hanahan and Weinberg, 2000). The observations of 
human cancer and animal models argue that tumour development proceeds via a 
process formally analogous to Darwinian evolution, in which a succession of genetic 
changes, each conferring a type of growth advantage, leads to the progressive 
conversion of normal human cells into cancer cells (Nowell, 1976; Hanahan and 
Weinberg, 2000). As the evolution allows the survival of the fittest individual, so too 
in the case of carcinogenesis, it is those mutations in individual genes which render 
cells most capable of evading normal homeostatic mechanisms that are selected in 
cancer cells. Developing cancer cells selected mutations having two basic functions: 
mutations in genes, called oncogenes, that increase the activity of the proteins they 
encode for, or mutations which inactivate the function of tumour suppressor genes. A 
successful cancer cell, predominantly of epithelial origin, is required to have 
mutations in at least four to seven genes (Cahill et al., 1999). Because the probability 
of a single cell simultaneously acquiring these mutations is extremely small, this 
sequential process of acquisition of mutations can only be achieved if cells bearing 
the initial mutation clonally expand until the population increases to many millions. 
This process of clonal expansion must then be repeated so that subsequent mutations 
can be accumulated and cells become progressively better adapted to an independent 
life. This process is observable clinically, as disease progression is characterised by 
an increased growth rate, ability to invade neighbouring normal tissue and to 
metastasise. Hanahan and Weinberg identify six ‘hallmark features’ of the cancer cell 
phenotype: disregard of signals to stop proliferating and of signals to differentiate; 
capacity for sustained proliferation; evasion of apoptosis; invasion; and angiogenesis 
(Hanahan and Weinberg, 2000).
More than 100 clinically distinct types of cancer have been recognised, each 
having a set of symptoms and requiring a specific course of therapy. However, most 
of them can be grouped into four major categories:
Leukaemia: abnormal numbers of white cells are produced by the bone 
marrow.
Lymphomas: abnormal numbers of lymphocytes are produced by the spleen 
and lymph nodes.
Sarcomas: solid tumours grown from derivatives of embryonic mesoderm, 
such as connective tissue, cartilage, bone, muscle and fat.
Carcinomas (the most common form of cancer): solid tumours grown from 
epithelial tissue. Epithelial tissue comprises the internal and external body 
surface coverings and their derivatives and thus include skin, glands, nerves, 
breasts and the linings of the respiratory, gastrointestinal, urinary and genital 
systems (Pelczar et al., 1986).
1.1.1 How do mutations occur ?
Mutations in the context of carcinogenesis include: point mutations which 
cause amino acid substitution; frame-shift mutations or mutations to stop codons 
which truncate the protein product; chromosomal imbalance or instability resulting in 
amplification, overexpression or inappropriate expression of particular genes; loss of 
a gene or its fusion with another gene as a result of chromosomal breakage and 
rearrangement resulting in a chimeric protein with altered function/s; epigenetic 
modifications to DNA of which the most important is the methylation of cytosine in 
CpG islands leading to gene silencing (Bertram, 2000).
The vast majority of mutations that give rise to cancer are not inherited, but 
arise as a consequence of errors in replication, or chemical damage to DNA that may 
lead to the incorrect reading of the damaged DNA by DNA polymerase (reviewed in 
Bertram, 2000). The possibility of a mutation to occur and consequently the risk of a 
cancer to develop are increased by the exposure to external agents that can be 
grouped in three main categories: chemicals agents (carcinogens and mutagens), 
physical agents (UV, ionising radiation) and biological agents (infection by 
pathogens).
Chemical damage occurs as a consequence of exposure to exogenous agents, 
these agents are defined as mutagens and the mutations induced can act as a 
molecular fingerprint indicating exposure to these environmental factors; when 
mutations induce development of cancer these factors are classified as carcinogens.
2
In 1775 a high incident of tumour in workers exposed to coal tar was reported. It was 
perhaps the earliest example of an environmental carcinogen and led ultimately to the 
identification of the poly cyclic aromatic hydrocarbon 3,4-benzopyrene and other 
polycyclic hydrocarbons in coal tar and the discovery of their action as skin 
carcinogens in laboratory animals.
Since then the realisation that some human cancers have an environmental 
origin and could be linked directly to chemical exposure grew rapidly and the list of 
carcinogenic chemicals expanded. The development of rapid in vitro assays, principal 
among these the Ames test conducted in Salmonella (Ames, 1984), for the detection 
of environmental mutagens provided an additional burst of the growing awareness of 
the presence of potential carcinogens in food and the environment.
Ionising radiation can cause single and double-strand breaks of the DNA 
helix, and can also induce indirect damage as a consequence of radiolysis of water to 
yield free radicals (reviewed in Hall and Angele, 1999).
Ultraviolet irradiation is absorbed by DNA bases and is sufficiently energetic 
to induce chemical reactions. Probably the most important among these occurs 
between two adjacent thymidines in the DNA helix and results in covalent cross 
linking to form a cyclobutane-linked thymidine dimer. This becomes an obstacle to 
DNA polymerase and disturbs normal base pairing and can consequently give rise to 
mutations. It is not surprising therefore that the 90% of skin cancers arise in sun- 
exposed areas.
Many different infectious agents have been implicated in various cancers, 
namely bacteria and viruses. Among these, viruses have been mostly studied in 
relation to tumour formation. Epstein-Barr virus (EBV), Hepatitis B virus (HBV), 
Human T cell leukaemia virus-1 (HTLV-1) and several types of papillomaviruses are 
consistently linked to specific malignancies (zur Hausen, 2001) and are discussed in 
detail in section 1.3.
1.2 Cancer and cell cycle
In almost all instances deregulation of cell proliferation and suppression of 
cell death together provide the underlying platform for neoplastic progression. 
Tumour cells have typically acquired damage to genes that directly regulate their cell
cycle. These are involved in signalling pathways which stimulate proliferation 
(oncogenes) or act as check-points to cell proliferation or induce cell death (tumour 
suppressors).
1.2.1 The cell cycle
The cells cycle is divided into four phases: G l, S, G2 and M and it has the 
duration of about 24 hours in cell cultured in vitro. In vivo, most mammalian cells are 
quiescent; few are cycling at any time, this state of quiescence is called GO state. The 
decision to divide occurs when cells respond to extracellular signals such as growth 
factors and cellular adhesion to extracellular matrix (ECM). Growth factors and the 
ECM bind to and activate specific cellular transmembrane receptors tyrosine kinases 
(RTKs) and integrins respectively, and induce a series of cytoplasmatic signal 
transduction cascades.
The best characterised pathways initiated by receptors tyrosine kinases, such 
as epidermal growth factor receptor (EGF-R) and platelet growth factor receptor 
(PDGF-R) among others, are the Mitogen Activated Protein Kinase (MAPK) 
pathway and the phosphatidyl inositol 3’kinase (PI3-K) pathway. The outcome of 
these kinase cascades is the activation of nuclear transcription factors that leads to an 
increased expression of the cell cycle machinery components and consequently to the 
progression of the cell cycle. G l progression normally relies on stimulation by 
mitogens and if the growth factors are removed early in this phase, cells will revert to 
a quiescent state. However, once beyond a specific point in G l, named the 
Restriction Point (R-point), cells are committed to divide and no longer require 
extracellular growth factors to complete the cell cycle.
The immediate response of growth factors stimulation is the increased 
expression of D types cyclins (Dl, D2 and D3) in the early-mid G l phase. These 
cyclins complex with cyclin-dependent kinases 4 and 6 (CDK4, CDK6) and stimulate 
their kinase activity. The primary cell cycle target of the cyclin D/CDK cascade is 
cyclin E (Geng et al., 1999). In combination with another cyclin-dependent kinase, 
CDK2, cyclin E is responsible for the progression from G l to S phase. The activity of 
cyclin D/CDK and cyclin E/CDK2 allows cells to pass through the R-point. Early on 
in S phase, cyclin D and E are targeted by ubiquitination to be degraded by 
proteosomes. At this time, cyclin A levels raise activating CDK2 and enabling S 
phase progression (Chapter 5). Finally cyclin A and cyclin B associate with cdc2 to
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promote entry to mitosis and are degraded at G2-M transition and at the end of the M 
phase respectively.
The fundamental role of the cyclin/CDK complexes, defined as the “cell cycle 
engines”, is the phosphorylation of crucial proteins responsible for carrying out the 
cellular changes leading to cell division. Active cyclin D/CDK complexes 
phosphorylate the retinoblastoma protein (pRb). pRb is a tumour suppressor protein 
that, in its active state, binds and inhibits transcription factors, especially E2F family. 
When pRb is phosphorylated it releases the E2F transcription factors, enabling the 
expression of numerous genes whose products are important for S phase entry 
(Weinberg, 1995). Cyclin E/CDK2 complex continues the phosphorylation of pRb 
and pRb-related proteins (pl07 and pl30). Because cyclin E is itself E2F responsive, 
cyclin E/CDK2 acts through positive feedback freeing factors required for its own 
transcription. The cyclin/CDK complexes are tightly regulated via phosphorylation 
events. An activating phosphorylation of CDK, by the CDK-activating kinase (CAK), 
stabilises the cyclin/CDK complexes and increases their activity, however two 
negative phosphorylation events can repress the kinase activity of the complexes 
occupying the ATP-binding region of CDKs. A family of phosphatases (cdc25A, B 
and C) act to remove the inhibitory phosphorylations and enhance cyclin/CDK 
complexes activity.
An additional control on cyclin/CDKs activity is played by the CDK 
inhibitors (CKIs). There are two families of CKI: the INK4 family, inhibitors of 
CDK4 and CDK6 that can directly block cyclin D/CDK kinase activity and cause Gl 
phase arrest (four INK4 inhibitors are known: pl6, pl5, pl8 and pl9); and the CKI 
p21, p27 and p57 that regulate both cyclin/CDK4-6 and cyclin/CDK2 complexes 
(Sherr and Roberts, 1995; Sherr, 1996).
1.2.2 Alteration of the cell cycle components in cancer
Disruption of normal cell cycle control is associated with oncogenesis 
suggesting that cell cycle regulatory proteins, such as cyclins and CDKs, may play a 
direct role in the transformation process by functioning as oncogenes.
As mentioned above, D-type cyclins act as growth factor sensors. The 
deregulation of cyclin D synthesis makes cell cycle progression less dependent on 
growth factors and can consequently contribute to oncogenesis. Indeed cyclin D1 is 
overexpressed in many human cancers as a result of gene amplification or
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translocations targeting the D1 locus (Hunter and Pines, 1994). Amplification of 
chromosome l lq l3  detected using in situ fluorescence hybridisation (FISH) (region 
where the cyclin D1 gene maps) is frequent in a broad spectrum of common adult 
cancer, including squamous cell carcinoma of head and neck (43% of cases on 
average), oesophageal carcinomas (30%), bladder cancer (15%), primary breast 
carcinoma (13%) (reviewed in Donnellan and Chetty, 1998). In oesophageal, hepatic 
and head and neck cancers D1 gene amplification is correlated with protein over­
expression, however in cancers (breast, colorectal tumour and melanomas) where 
gene amplification is a rare event, aberrant over-expression of cyclin D1 protein has 
also been seen (Hall and Peters, 1996). That cyclin D1 can directly contribute to 
oncogenesis is supported by studies with transgenic mice, in which targeted 
overexpression of D1 in mammary epithelial cells leads to cell hyperproliferation and 
eventually tumour formation (Wang et al., 1994; Geng et al., 1999).
In human cancers the alteration of cyclin E and cyclin A is a rare event. Few 
cases of cyclin E amplification have been reported in established tumour cell lines, 
however the protein is overexpressed in carcinomas of breast and stomach among 
others (Kim et al., 2001). In studies on a human hepatocellular carcinoma, it was 
found that the hepatitis B virus was integrated into the cyclin A locus with the 
disruption of the region encoding the N-terminal portion of the protein, comprising 
the destruction box. This integration resulted in the production of a non-degradable 
HBV preS-cyclin A chimeric protein, overexpression of which was thought to 
contribute to transformation of liver cells (Wang et al., 1992). Mutations in cyclin A 
have not been documented in other tumours or cell lines. Moreover transgenic mice 
expressing a mutated non-degradable form of cyclin A do not show tumour 
development, although present abnormatilities that may be preneoplastic in 
mammary glands (Bortner and Rosenberg, 1995).
Another controller of the G1 restriction point is pRb (together with the other 
pocket proteins). Mutation in pRb is found in 100% of retinoblastoma cancers and 
pRb is inactivated by mutations or by interaction with viral protein (like HP Vs E7, 
see section 1.4.2) in other types of cancers (reviewed in DiCiommo et al., 2000). As 
expected also mutations that involve the CDK inhibitors, such as pl6, pl5 and pl9 
have been frequently found in human cancers: in biliary track carcinoma, 
oesophageal carcinoma and nasopharyngeal carcinoma among others. Reciprocally a
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mutation in CDK4 that prevents its interaction with p l6  has been found in melanoma 
(Wolfel et al., 1995). A loss or decrease in the level of p27 protein is seen in many 
human cancers and low p27 levels correlate with aggressive tumour growth 
(reviewed in Slingerland and Pagano, 2000).
The detection of the deregulation of the cell cycle components may have a 
prognostic potential in cancers. Moreover, the observations that the majority of 
human neoplasia has an aberrant pRb pathway involving pRb deletion and/or CDK 
and Cyclin D hyperactivation lead to the hypothesis that modulators of CDK may 
have a role in the treatment of human malignancies.
1.3 Viruses and cancer
Oncogenic activity has been described for several human viruses and 
worldwide viral infection is thought to contribute up to 20% of all human cancers. 
However, although associated with cancers, oncogenic progression is not part of the 
normal virus cell cycle.
Small DNA viruses, being dependent on their host replicative machinery, 
need to induce cell DNA synthesis in infected cells. Moreover virally encoded 
proteins can bypass check-points in cell cycle progression, playing therefore an 
important role in the normal viral life cycle. However under unusual circumstances 
these proteins can also contribute to viral oncogenesis (Vousden, 1995).
Viruses may contribute to the development of human tumours by different 
mechanisms: altering the expression of host cell proteins at the site of viral DNA 
integration, by interacting directly with proteins involved in the control of cell cycle 
check-point (tumour suppressors) or in signalling pathways.
Within the pathogenesis of virus-associated cancers, the role played by viral 
oncoproteins is conceptually similar to the role of a genetic predisposing mutation 
which will favour the appearance of a tumour in a specific organ, consequently the 
ability of viruses to alter cells in culture has been critical to identifying oncogenes 
and tumour suppressors.
Examples of viruses associated with tumours are: Hepatitis B virus (HBV) 
that has been associated with hepatocellular carcinoma (reviewed in Arbuthnot and 
Kew, 2001); Epstein-Barr virus (belonging to the Herpes virus family) is the
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etiological agent of infectious mononucleosis and has been associated with the 
genesis of Burkitt’s lymphoma and nasopharyngeal carcinoma (reviewed in 
Niedobitek et al., 2001); human T cell leukaemia virus-1 (HTLV-1) is a retrovirus 
that causes adult T cell leukaemia (ATL) (reviewed in Yoshida, 2001). Finally, 
papillomaviruses have been linked to a variety of anogenital cancers, particularly 
cervical carcinoma as elucidated in the following section.
None of these virus infections per se is sufficient to induce cancer. Long 
latency periods, often lasting several decades, the low number of infected individuals 
who eventually develop particular type of cancer and in some instances interactions 
which chemical or physical factors point to requirement for additional genetical 
modifications in cancer development after viral infection (zur Hausen, 1991b).
1.3.1 Papillomaviruses
The first papillomavirus was described in 1933 when Richard Shope (Shope 
and Hurst, 1933) recognised the cottontail rabbit papillomavirus (CRPV) as the 
etiologic agent responsible for cutaneous papillomatosis in the cottontail rabbit. 
Since then papillomaviruses have been characterised from humans, cattle, rabbits, 
horses, dogs, and a variety of other higher vertebrates and different virus genotypes 
exist for each host, for example six Bovine papillomaviruses (BPV) and 85 Human 
papillomaviruses have been identified so far (Jarrett et al., 1984; zur Hausen, 2000). 
The papillomaviruses have therefore proved to be the most complex group of 
pathogenic viruses (zur Hausen, 1999).
Papillomaviruses are small nonenveloped icosahedral DNA viruses that 
replicate in the nucleus of infected cells. All human and most animal 
papillomaviruses are associated with purely squamous epithelial proliferative lesions 
(warts) which can be cutaneous or can involve the mucosal squamous epithelium 
from the oropharynx, the larynx, the oesophagus, or the ano-genital tract. There is a 
group of animal papillomaviruses that induce benign fibropapillomas, which present 
a proliferative dermal fibroblastic component as well as a proliferative squamous 
epithelial component (Howley, 1996).
The genome of the papillomaviruses consist of a single molecule of a double­
stranded circular DNA approximately 8000 bp in size, contained within a spherical 
protein coat, or capsid, composed of 72 capsomeres. The capsid consists of two
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structural proteins: the major capsid protein (LI) that has a molecular weight of 
approximately 55 kDa and represents approximately 80% of the total viral protein 
and the minor protein (L2) with a molecular size of approximately 70 kDa.
The Open Reading Frames (ORFs) are located on one strand of the viral 
DNA, indicating that only one strand serves as a template for transcription (Chen et 
al., 1982). The coding strand for each of the papillomaviruses contains the early (E) 
region which comprises approximately two-thirds of the genome and encodes 
proteins that control the replication and transcription of viral DNA. The remaining 
third of the genome comprises the late region that encodes the viral capsid proteins 
and finally a non coding region defined as Long Control Region (LCR) containing 
the origin of DNA replication, transcription enhancers and promoters.
During infection the virus enters the epithelial cells; upon cell division, one 
daughter cell will remain part of the basal epithelium, while the other daughter cell 
will migrate up to the next layer and start to differentiate. At this stage the viral DNA 
will segregate with the two daughter cells and replicate itself to maintain a certain 
number per cell. The life cycle of the virus is tightly coupled with the differentiation 
process of the epithelial cell: the virus infects the basal and suprabasal layers, 
replicates its genome in the differentiating spinous and granular layers, expresses its 
structural genes and packages its DNA in the squamous layers, and new infectious 
virus is finally released with the keratinised squames (Campo, 1995).
While warts are usually benign and regress spontaneously, papillomaviruses 
can also cause a number of more life-threatening diseases (zur Hausen, 1999). 
Papillomaviruses are implicated in the aetiology of squamous cell carcinomas both in 
humans and in animals and the viruses associated with naturally occurring cancers 
are several HP Vs (zur Hausen, 1987), the cottontail rabbit papillomavirus (CRPV) 
(Rous and Beard, 1935) and the Bovine papillomavirus (BPV) type 4 (Campo et al., 
1980). The characteristics of HPVs and BPVs will be discussed below.
1.3.2 HPVs
HPVs are the most diverse group of DNA viruses involved in human disease 
with 85 different types identified so far. They have traditionally been differentiated 
by sequence divergence; based on criteria adopted by the Papillomavirus 
Nomenclature Committee, the nucleotide sequences of the E6, E7 and LI ORFs of a
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new type should not exceed 90% homology of the corresponding sequence of the 
genomes of known HPVs (Howley, 1996). HPVs fall into two major groups: those 
that infect cutaneous epilhelia and those that infect mucosal surface.
While the viruses often cause benign proliferative lesions or warts, there is a 
subgroup of viruses which cause premalignant and malignant lesions including skin 
cancer (Bunney et al., 1987; Pfister, 1992), upper respiratory tract cancer (Syrjanen et 
al., 1987) and anogenital carcinoma (zur Hausen, 1991a) with carcinoma of the 
cervix being by far the most common cancer.
In 1983 and 1984, respectively two new HPVs, HPV-16 and HPV-18 were 
identified, and their DNAs were molecularly cloned from two cervical carcinoma 
biopsies (Durst et al., 1983; Boshart et al., 1984). As a consequence of this discovery, 
samples worldwide were then assayed and HPV DNA was found regularly in tumour 
biopsy specimens (Munoz, 2000). At the present, after two decades of 
epidemiological work with human specimens, work with animal model and 
experimental work in many laboratories, overwhelming evidence exists to show that 
papillomaviruses are causative agents of squamous cell carcinomas. A further 
indirect evidence for the association between papillomavirus and genital cancer is the 
observation that in adults cervical squamous cell carcinoma has all the characteristics 
of a sexually transmitted disease as observed in 1842 by Rigoni-Stern who reported 
that cervical cancer was extremely rare in virgins and predominant among prostitutes. 
Numerous subsequent studies have clearly established that sexual history, especially 
the number of sexual partners, is the predominant risk factor for cervical cancer 
(Broker and Botchan, 1986).
HPVs cause similar lesions in both males and females (Schiffman and 
Brinton, 1995), however, cancer of the cervix is more common than cancer at other 
sites and, with approximately 471000 new cases diagnosed annually (Lazo, 1999), is 
the second most common type of cancer of women world-wide, after breast cancer. 
The higher incidence of cervical cancer seems due to the nature of the tissue located 
between the mature epithelium of the exocervix and the columnar epithelium of the 
endocervical canal which is immature, metaplastic and hormonally responsive. This 
zone is more susceptible to external insults such as viral infection resulting in the 
production of premalignant and possibly malignant cells (McMurray et al., 2001).
Invasive cervical cancer is preceded by a progressive spectrum of 
abnormalities of cervical epithelium. Preinvasive lesions are classified as cervical
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intraepithelial neoplasia (CIN) grades 1, 2, and 3; or as mild dysplasia, moderate 
dysplasia and carcinoma in situ (CIS). The severity of the lesions is graded by the 
extent to which the non-differentiating basal-like cells replace the normally 
differentiating cervical epithelium. In invasive cervical carcinoma, the abnormal cells 
breach the basement membrane, invade the stromal tissue, and eventually metastasise 
to lymph nodes and to other sites in the body. The time interval between the early 
cervical abnormalities and invasive carcinoma may span several decades (Shah and 
Howley, 1996).
HPVs are found in a large majority of the lesions spanning the entire 
spectrum of cytological abnormalities, but the distribution of HPV types changes 
markedly with increasing severity disease (Bergeron et al., 1992). HPVs rarely found 
in invasive cancers are characterised as low-risk HPVs, in this group HPV types 6,11 
are the most studied. High-risk HPV types, mostly 16, 18, 31, 33 and others are 
found frequently in invasive cancers. The severity of HPV-16 and HPV-18 infection 
is demonstrated also by their ability to immortalise human keratinocytes in cell 
culture while low-risk HPVs do not (Woodworth et al., 1989).
The relationship of HPV genome to the chromosomal DNA may change 
during progression from premalignant to malignant phase of the disease. Most of the 
metastatic cells have integrated HPV sequences (~70%) while the rest have 
predominantly episomal copies (McCance et al., 1985). Viral integration occurs 
randomly in cellular chromosomes, but all viral DNA integration events associated 
with malignant disease, allow for the expression of E6 and E7 proteins. The 
integration often results in the disruption of the E2 gene, which leads to increased 
transcription of E6 and E7 genes (Sang and Barbosa, 1992a). Finally, these proteins 
have been shown to contribute to keratinocytes immortalisation in vitro (Hawley- 
Nelson et al., 1989; Munger et al., 1989a; Barbosa and Schlegel, 1989) and are 
consequently considered the two major oncoproteins of HPVs. Another viral protein, 
E5, has been found to be weakly oncogenic and co-operate with E7 in cell 
transformation (Leptak et al., 1991). The role of E6, E7 and E5 in HPV-associated 
transformation is detailed in section 1.4.
1.3.3 BP Vs
As reported in the previous section HPVs are closely linked with human 
cancers, however due to the lack of suitable system for propagation of HPVs and the
11
absence of animal models in which a sexual transmitted papillomavirus produces 
cervical cancer, the most extensively studied papillomaviruses are BP Vs. These 
papillomaviruses offer the distinct advantage to study the interaction of the virus with 
the natural host, providing the opportunity to study carcinogenesis in a natural system 
(Campo and Spandidos, 1983).
The BP Vs are classified in two main groups: subgroup A comprises the 
fibropapillomaviruses (type 1, 2, 5) and subgroup B the epitheliotrophic 
papillomaviruses: BPVs type 3, 4, and 6 (Jarrett et al., 1984).
The members of subgroup A infect subepithelial fibroblasts as well as 
epithelial cells and induce fibropapillomas with a proliferative dermal fibroblastic 
component and a proliferative squamous epithelial component. The viruses 
belonging to subgroup B infect exclusively the epithelium and induce papillomas 
without fibroblast involvement (Campo et al., 1981; Jarrett et al., 1984). A further 
feature of the subgroup B is the lack of the E6 ORF, present in all other 
papillomaviruses and apparently replaced in this group by an ORF previously 
designed as E8. It has been speculated that the absence of the E6 ORF in subgroup B 
of BPVs is the result of a deletion of this ORF (Jackson et al., 1991) as a 
consequence of the E8 ORF translocation in the previous E6 ORF position. Because 
of the similarities in function between BPV-1 E5 and BPV-4 E8 (see section 1.4.3); 
the latter has recently been renamed BPV-4 E5 (Morgan and Campo, 2000) and will 
be referred to as E5 hereafter.
BPV-1 causes teat frond and penile fibropapillomas; thanks to its ability to 
transform establish murine fibroblasts most of the early research on papillomaviruses 
focused on this virus.
BPV-2 is the agent of common cutaneous warts.
BPV-5 causes rice grain fibropapillomas of the udder.
BPVs 3, 4 and 6 were isolated from cutaneous, alimentary and teat frond 
papillomas, respectively.
BPV-2 and BPV-4 have been associated with malignant progression of 
papillomas in cattle. BPV-4 has been identified as the etiologically agent of upper 
alimentary canal cancer in cattle, (see sections 1.3.3.1, 1.3.3.2 and Campo et al., 
1980). Although necessary in the initial stages of tumour formation in cattle BPV-4 is 
not required for maintenance of these malignancies and viral DNA cannot be
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detected in the cancer (Campo et al., 1985). It has been speculated that the virus is 
involved in one of the early steps of cell transformation and that other factors 
contribute to the establishment and the maintenance of the malignant phenotype 
(Smith and Campo, 1988; see below).
1.3.3.1 BPV-4
In 1980 Campo and co-workers discovered a new bovine papillomavirus 
associated with alimentary cancer in cattle: Bovine papillomavirus type 4 (BPV-4) 
(Campo et al., 1980).
BPV-4 belongs to the subgroup B of bovine papillomavirus (ephiteliotrophic 
papillomaviruses), thus its tissue specificity resembles that of HPVs. For this reason 
and because, as the high-risk HPVs, it is associated with naturally occurring cancer in 
its host, BPV-4 represents one of the best models to clarify the relationship between 
viral infection and carcinoma progression.
The genomic organisation of each papillomavirus is remarkably similar and 
also BPV-4 presents features common to the group.
The genome consists of a single molecule of double-stranded circular DNA of 
7265 bp contained within a spherical capsid composed of 72 capsomeres. The 
genome is divided in three regions: Long Control Region (LCR), a region encoding 
the early products (E) and one encoding the late (L) products.
In the BPV-4 LCR, a region of one kilobase in size, the two major viral 
transcriptional promoters have been mapped: Pl, promoter for the late genes (at 
nucleotide 777), and Pe, promoter for the early genes (at nucleotide 283) (Stamps and 
Campo, 1988; Jackson and Campo, 1995). Viral transcripts are obtained from one 
strand of the genome and seven transcripts have been identified in tumours induced 
by BPV-4 (Smith et al., 1986).
The E l ORF is transcribed into a series of mRNAs and it is not known which 
of them, if any, encodes a functional E l protein. The role/s of E l has not been 
established for BPV-4, but in BPV-1 it is a nuclear phosphoprotein with ATPase 
activity (MacPherson et al., 1994), which binds to the viral origin of replication 
(Ustav et al., 1991).
The E2 protein has three functional domains: a central region that joins the 
transactivation domain at the N-terminus with the DNA binding domain at the C-
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terminus. E2 acts as a dimer and the dimerisation is mediated by the C-terminal 
region. In HPVs and BPV-1, as well as regulating transcription, E2 is involved in 
viral replication. In BPV-4 the transcriptional activity of E2 has been characterised: 
the protein binds to the three E2 binding sites of the LCR and induces promoter 
activity, disruption of these sites causes a dramatic reduction in E2 promoter 
activation (Jackson and Campo, 1991).
The E4 ORF is transcribed into several RNA species (Stamps and Campo, 
1988). The exact function of the E4 protein has not been identified in BPV-4, 
however, in HPVs, E4 interferes with cytokeratin assembly (Doorbar et al., 1991; 
Roberts et al., 1993) and consequently with the differentiation programme of the cell, 
favouring the production of viral progeny instead. Like HPV-1 E4 (Breitburd et al.,
1987), BPV-4 E4 was observed only in differentiated layers of the papillomas 
(Anderson et al., 1997) coincident in time and in location with the vegetative 
replication of viral DNA (Campo et al., 1994a), it is therefore reasonable to assume 
that BPV-4 E4 shares similar functions as well as similar localisation within the 
papillomas with HPV-1 E4.
The E7 and E5 ORFs are the transforming proteins of the BPV-4 (Pennie et 
al., 1993) and they are described in detail in section 1.4
Other early ORFs have no ATG codon and are assumed to have no function.
The LI and L2 ORFs encode the structural proteins of the virion; they are 
transcribed into a 2.8 kb RNA capable of encoding LI, and a 4.2 kb RNA which has 
the capacity to encode both LI and L2. These RNAs are found only in papillomas, in 
agreement with the lack of structural proteins in transformed cells (Campo et al., 
1994a).
The short L3 and L4 ORFs do have ATG start codons but their function, if 
any, is not known.
1.3.3.2 BPV-4 and Cancer
As mentioned above, in healthy cattle, BPV-4 induces benign papillomas that 
regress spontaneously after approximately a year (Jarrett, 1985). However, in cattle 
grazing on bracken fern the papillomas can progress to squamous cell cancer (Campo 
and Jarrett, 1986). The progression of papillomas to carcinomas has been 
experimentally reproduced by infecting cattle with BPV-4 and feeding them on a diet 
of bracken, thereby confirming the viral-environmental nature of the disease (Campo
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et al., 1994b). Although the connection between virus infection and the development 
of cancer has been established, BPV-4 presence it is not required for the progression 
or the maintenance of the malignant state (Campo et al., 1985). When 70 cases of 
cancers in cattle, including premalignant lesions and primary cancers of alimentary 
canal and secondary metastatic deposits, were analysed for the presence of BPV-4 
DNA by Southern blot, the viral genome was detected only in two cases 
(transforming papilloma of the oesophagus and carcinoma of the tongue) (Campo et 
al., 1985). On the contrary in young productive papillomas the virus was detected in 
91% of the cases. Similar situation is observed in vitro.
In vitro BPV-4 can transform established murine fibroblasts (NIH3T3 and 
C127) (Campo and Spandidos, 1983; Smith et al., 1987). NIH3T3 cells transformed 
by the whole genome of BPV-4 cloned in pAT153, were anchorage-independent, 
grew in low serum, lost contact inhibition and were tumourigenic in nude mice. 
Conversely, complete morphological transformation of C127 mouse fibroblasts 
requires cooperation between the viral DNA and the tumour promoter 12-o- 
tetradecanoylphorbol- 13-acetate (TPA) (Smith and Campo, 1988). Moreover when 
cell lines were analysed for the presence of the BPV-4 genome only 9 out of 60 
harboured BPV-4 DNA and no relationship was observed between the presence of 
the viral genome and the transformed phenotype (Smith and Campo, 1988).
On the basis of these observations the authors proposed for BPV-4 an “hit- 
and-run” mechanism: viral infection would induce permanent changes in the infected 
cells, which would be susceptible to environmental carcinogens, and would be able 
to escape immunosurveillance in immunosuppressed animals (Smith and Campo,
1988).
BPV-4 ability to transform primary bovine cells has also been assessed 
(Jaggar et al., 1990). Primary bovine fibroblasts (PalF) from the foetal palate were 
chosen for these studies thanks to their characteristics: being non-established cells, 
belonging to the natural host of BPV-4 and deriving from one of the sites of virus 
infection. Contrary to fibropapillomaviruses (BPV-1 and BPV-2), able to fully 
transform primary bovine fibroblasts, BPV-4 did not induce any modification in PalF 
cells. However the transfection of the BPV-4 genome together with an activated ras 
caused morphological transformation, anchorage-independent growth and extended 
the cell life-spans (Jaggar et al., 1990); nevertheless these cells were neither immortal 
nor tumourigenic (Jaggar et al., 1990; Pennie et al., 1993). BPV-4 transformed cells
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achieved immortalisation only when transfected with HPV-16 E6 (Pennie et al., 
1993) and tumourigenic status when a mutant p53 was added to the transfection 
(Scobie et al., 1997).
The data collected from in vitro experiments point to the conclusion that the 
BPV-4 genome does not contain all the necessary information to fully transform 
primary cells and reinforce the early in vivo observations of a necessary cooperation 
between the virus and cofactors (bracken fern) for the progression of benign 
papillomas to premalignant and malignant stage.
Further analyses in vitro were carried out to better define the molecular 
mechanisms of the synergism between virus and chemicals. The first candidate in 
these investigations was one of the most potent mutagens in bracken fern: 5,7,3’,4’- 
tetrahydroxyflavone quercetin (Evans et al., 1982). Primary bovine fibroblasts 
transfected with BPV-4 genome and an activated ras and treated with quercetin (20 
or 45 pM) induced tumours in nude mice approximately four weeks after injection 
(Pennie and Campo, 1992). Moreover, in E7-transformed PalFs cells quercetin 
substitutes for HPV-16 E6 in cell immortalisation, for BPV-4 E5 in conferring 
anchorage-independent from substratum and for mutated p53 for inducing 
tumourigenity (Caimey and Campo, 1995). Other studies showed that BPV-4 can 
synergise also with both TPA and the tumour initiatior 7,12- 
dimethylbez[a]anthracene (DMBA) with enhanced production of tumours 
(Gaukroger et al., 1993).
It has been shown that, in both primary and established murine fibroblasts, the 
transfection of a subgenomic fragment of BPV-4 genome was sufficient to induce the 
morphological phenotypes conferred by the full BPV-4 genome (Smith and Campo, 
1989; Pennie et al., 1993). This region encodes the E5 and E7 ORFs. BPV-4 DNA 
digested with enzymes that cut within the E7 ORF (Smith and Campo, 1989) and 
mutant constructs lacking the 3 ’third of the E7 ORF (Jaggar et al., 1990) abolish 
BPV-4 ability of transformation. Moreover E7 ORF does not need any other viral 
gene to morphologically transform PalFs (Pennie et al., 1993). Although 
morphologically transformed E7 expressing PalFs are incapable of anchorage- 
independent growth. The ability to grow independently from substratum is conferred 
when E5 is co-transfected in E7-cells, leading to the conclusion that this phenotype is 
provided by E5. In primary bovine fibroblasts it has not been possible to evaluate if
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the sole E5 expression and an activated Ras can induce anchorage-independent 
growth because the transfected cells did not survive selection.
Recently, however, O’Brien and Campo (1998) showed that in NIH3T3 cells 
the sole E5 expression confers to the fibroblasts the ability to grow in low serum and 
independently from substrate, providing a system for the evaluation of the viral 
protein effects on the cell proliferation machinery, without the confounding influence 
of other viral oncogenes (O'Brien and Campo, 1998).
The transforming mechanisms of E7 and E5 are detailed in section 1.4
1.4 Transforming proteins of the Papillomaviruses
In the study of papillomaviruses, the transforming proteins have received the 
most attention in the attempt to determine the mechanisms by which they override 
the normal cellular control on proliferation.
The transforming properties of the onco-papillomaviruses have been mapped 
in the early region, in particular in the E6, E7 and E5 genes. These proteins 
contribute to the transformation process to different extent in different 
papillomaviruses: E6 and E7 are the major transforming protein of HPVs while in 
BPV-4, which lacks the E6 ORF, E7 and E5 play a fundamental role in 
transformation and in BPV-1 E5 is the major transforming protein.
The characteristics of these proteins are discussed in detail below.
1.4.1 E6
The E6 proteins of HPVs are approximately 150 amino acid long 
polypeptides that have an apparent molecular mass of 18 kDa. All the HPV E6 
proteins present four Cys-X-X-Cys motifs that permit the formation of two zinc 
fingers (Barbosa et al., 1989; Grossman and Laimins, 1989). The disruption of these 
motifs results in a defective E6 protein (Sherman and Schlegel, 1996).
The E6 genes of various HPV types were shown to immortalise human 
mammary epithelial cells (HMEC) (Wazer et al., 1995; Liu et al., 1999), and, in 
cooperation with E7, immortalize human foreskin keratinocytes (HFK) in vitro 
(Munger et al., 1989a; Hawley-Nelson et al., 1989). Moreover, recently HPV-16 E6 
has been shown to induce the formation of malign tumour in skin of transgenic mice 
(Song et al., 1999). E6 is one of the earliest expressed proteins during infection and is
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believed to provide several functions that alter the cellular environment, to favour the 
viral replication. Different studies have provided evidence to sustain this hypothesis: 
E6 blocks apoptosis through both p53 degradation and in a p53-independent way, 
alters transcription of cellular genes, interacting with transcriptional coactivators and 
increases cellular life-span through increased telomerase activity.
E6 encoded by high-risk HPV (type 16 and 18) was shown to bind to p53 in 
vitro (Werness et al., 1990), to induce its degradation (Scheffner et al., 1990) via 
binding to an ubiquitin ligase called E6-associated protein (E6AP) (Huibregtse et al., 
1991; Scheffner et al., 1993). Interestingly E6 from low-risk HPVs showed a reduced 
ability to bind to p53, could not induce detectable degradation of the protein and 
presented a lower efficiency in the modulation of p53 transcriptional control then E6 
proteins from high risk HPVs (Crook et al., 1991; Crook et al., 1994).
Further evidence for the ability of HPV-16 E6 to inactivate p53 function was 
obtained in vivo by the observation that expression of E6 in the eyes of transgenic 
mice suppresses apoptosis during lens development (Pan and Griep, 1994). These 
same studies however showed that E6 mediated apoptosis could occur in both p53- 
dependent and -independent way (Pan and Griep, 1994; Pan and Griep, 1995). More 
recently Jackson and Storey (2000) demonstrated that E6 genes from mucosal and 
cutaneous subtypes of HPV were all capable of blocking apoptosis induced by 
ultraviolet radiation but only the HPV-16 E6 induced p53 degradation (Jackson and 
Storey, 2000). These data suggested that the modulation of p53 plays some role in the 
inhibition of apoptosis by E6, but does not account for all.
Evidences that E6 may interfere with apoptosis via a p53-independent 
pathway came when Thomas and Banks (1998) showed that HPV-16 and -18 E6 can 
interact with Bak, a pro-apoptotic protein expressed at high levels in the upper layers 
of differentiating epithelium (Thomas and Banks, 1998). This interaction leads to 
degradation of Bak by ubiquitination, again through interaction with E6AP, and 
consequently reduction of apoptosis. E6 from low-risk HPV types (like HPV-11) 
shows a weaker interaction with Bak than HPV-16 and -18 E6.
Another E6 cellular target, only recently emerged, is CBP/p300
transcriptional co-activator (Patel et al., 1999; Zimmermann et al., 1999).
Interestingly CBP/p300 is a p53 transcriptional coactivator and the interaction with 
E6, mediated by the C-terminal zinc finger of the viral protein, correlates with down- 
regulation of p53 transcriptional activity (Zimmermann et al., 1999).
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Among other functions, E6 can up-regulate the activity of the cellular 
telomerase complex (Klingelhutz et al., 1996) in human keratinocytes and mammary 
epithelial cells. Telomerase is an enzyme that controls the telomeric DNA at the ends 
of linear chromosomes and is inactive in normal cells (with the exclusion of stem 
cell) where telomeres shorten with each cell division until they reach a critical short 
length beyond which cells senescence. It has been shown that E6 mutations that do 
not increase telomerase map to the internal portion of protein in the zinc-finger 
domains and central region, suggesting that these regions of E6 are necessary for 
telomerase activation. Despite the increased activity of the telomerase, however, 
telomere length is not increased and HFK cells are not immortalised by the sole 
expression of E6 (Klingelhutz et al., 1996). These data question the relevance of 
telomerase activation.
E6 reveals a remarkable pleiotropism in binding further host-cell proteins. It 
interacts with the calcium-binding protein ERC 55 (Chen et al., 1995) with paxillin 
(Tong and Howley, 1997) and with the mammalian homologue of Drosophila disc 
large tumour suppressor protein (hDLG) (Lee S.S. et al., 1997) and targets the latter 
for proteosome-mediated degradation (Gardiol et al., 1999). The interaction between 
hDLG and E6 is mediated by the C-terminus of the viral protein and at least one PDZ 
domain of hDLG; interesting HPV-11 (a low risk HPV) fails to induce hDLG 
degradation (Lee S.S. et al., 1997; Gardiol et al., 1999). As for hDLG, a correlation 
between the ability to bind paxillin and HPVs transformation ability exists (Tong and 
Howley, 1997). Although these interactions may lead to substantial functional 
consequences for E6 expressing cells, they are, at present, not fully understood (zur 
Hausen, 2000).
The two most prominent functions of E6 can be summarized as follows: it 
induces the overcome of the Gl/S check-point control in DNA damaged cells by 
binding to p53, in addition it leads to immortalisation that may result from a large 
number of modifications, primarily the alteration of the telomerase enzyme.
BPV-1 E6 is a 137 amino acids long protein with two zinc finger motifs 
(Barbosa et al., 1989). The expression of BPV-1 E6 is sufficient to induce anchorage- 
independent growth and focus formation in C127 cells (Schiller et al., 1984; Neary 
and DiMaio, 1989). The mechanism of BPV-1 E6 induced cell transformation is 
unknown. Recently an interaction between the BPV-1 E6 protein and the focal
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adhesion associated protein paxillin, the trans-Golgi network-specific clathrin 
adaptor complex and CBP/p300 have been described (Tong and Howley, 1997; Tong 
et al., 1998; Zimmermann et al., 2000) although the biological relevance of these 
interactions remains to be established.
BPV-4, as all bovine papillomaviruses of subgroup B, lacks the E6 ORF.
1.4.2 E7
The E7 proteins of HPVs are primarily nuclear proteins of approximately 18 
kDa in size (Howley, 1996); they present amino acid sequence similarities to 
adenovirus E1A protein and based upon this homology they have been divided into 
domains. In HPV-16 E7 these domains are the CR1, from amino acid 1 to 20, CR2, 
containing residues 21-39 and CR3 composed of amino acids 40-98 (Phelps et al., 
1988; Phelps et al., 1992). HPV-16 E7 has two casein kinase II phosphorylation site 
at serine 31 and 32 (Barbosa et al., 1990) and two Cys-X-X-Cys zinc binding 
domains in the CR3 (Barbosa et al., 1989) that mediate protein dimerisation.
The major function of E7 during HPV infection is the stimulation of cell 
cycle progression by favouring the exit of quiescent cells from GO and entry into S 
phase. To achieve its target E7 interacts with numerous cellular proteins mainly 
involved in the regulation of cell growth such as pRb and the pocket proteins, Ap-1 
transcription factors, cyclins and CDKs inhibitors (CDIs).
HPV E7 induces transformation of rodent cell lines (Phelps et al., 1988), can 
cooperate with Ras to transform primary rodent fibroblasts (Matlashewski et al., 
1987; Phelps et al., 1988) and in combination with E6 extend the life span of primary 
human cells (Munger et al., 1989a; Hawley-Nelson et al., 1989).
Two groups of regulatory interactions mainly contribute to the ability of 
HPV-16 E7 to over-ride cell cycle control at the Gl/S boundary: E7-driven activation 
of cellular E2F-dependent genes and the direct interaction of the viral protein with 
the inhibitors of the cyclin-dependent kinases.
Certainly the best characterised function of E7 is its ability to bind the pRb 
protein and pRb related pocket proteins (Munger et al., 1989b). pRb and the pocket 
proteins operate as signal transducers connecting the cell cycle with the transcription 
machinery (Weinberg, 1995). They bind to transcription factors, mainly the E2F 
family, and prevent expression of genes important for progress through the cell cycle. 
When the cell is ready to enter the cell cycle, cyclin-dependent kinases inactivate
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pRb, pl07 and pl30 by sequential phosphorylation of their specific sites, free the 
transcription factors and induce cell cycle progression. E7 interferes with this 
equilibrium binding to pRb, p!07 and pl30 and mimicking the phosphorylation 
event. The transcription factors are consequently available to promote the 
transcription of genes required for S phase progression with the result of a premature 
cell stimulation into S phase.
Genetic studies of HPV-16 E7 revealed the presence of a pRb binding site 
within the CR2 domain (Barbosa et al., 1990); this region presents the LXCXE motif, 
that has been found in other viral proteins able to interact with pRb (ElA  and 
SV40T). The same region is responsible for the E7 interaction with pl07 and pl30. 
Moreover, it has been shown that E7 does not only interact with pRb but it triggers 
its proteolytic degradation via ubiquitin-proteasome pathway (Boyer et al., 1996) 
resulting in an increase level of free transcriptionally active E2F.
Interestingly the E7 proteins from low-risk HPV types 6b and 11 bind pRb 
with about ten fold lower efficiency, on average, than the E7 proteins of HPV type 16 
and 18 (Munger et al., 1989b). A single difference in the sequences next to their 
respective LXCXE motif is though to be responsible for the difference in binding 
efficiency: HPV-6 E7 contains a glycine at amino acid 22, while HPV-16 E7 
possesses an aspartic acid at equivalent position (Sang and Barbosa, 1992b). The 
substitution of the glycine at position 22 with an aspartic acid conferred to HPV-6 E7 
higher affinity for pRb and the ability to transform NIH3T3 cells to the same degree 
as HPV-16 E7 (Sang and Barbosa, 1992b). In addition to the motif within the CR2 
domain, a region in the CR3 seems also to be required for the E7/pRb interaction 
(Patrick et al., 1994).
Beside modulation of the pocket proteins/E2F pathway E7 has been shown to 
interact with other proteins involved in gene transcription control, principally 
members of the AP-1 family of transcription factors, that includes c-Jun, JunB, JunD 
and c-Fos. Specific mutation analysis and binding data to c-Jun indicate that E7 zinc 
finger motif, but not pRb binding domain, is involved in this interaction (Antinore et 
al., 1996).
As described above HPV-16 E7 can override cell cycle control at the Gl/S 
boundary, these observations pointed to the possibility that E7 can neutralise or 
bypass the inhibitory effects of the CDK inhibitors: p21 and p27. Studies revealed
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that E7 blocks the ability of CKIs to inhibit CDK activity through the direct binding 
and sequestration of p21 and p27 (Zerfass-Thome et al., 1996; Funk et al., 1997).
Cells expressing E7 show increase kinase activity associated with cyclin E 
and cyclin A and this activity is sustained even in the presence of growth arrest 
signals such as serum deprivation and anchorage-independent growth (Zerfass et al., 
1995; Schulze et al., 1998; Ruesch and Laimins, 1998). E7-induced S phase entry is 
not accompanied by cyclin D activation (Schulze et al., 1998); these observation are 
consistent with the observation that cyclin D is not required for S phase entry of cells 
expressing pRb-inactivating viral protein. The effects of E7 on de-regulation of 
Cyclin E/CDKs and cyclin A/CDK2 may contribute to extending the duration of 
‘replicative competence’ in host cell (McMurray et al., 2001).
In contrast to HPV E7 little is known about BPV-1 E7. The protein has been 
detected in BPV-1 transformed cells and it presents an apparent molecular mass of 15 
kDa (Jareborg et al., 1992). No independent transformation activity has been detected 
for BPV-1 E7. A recent report showed that C127 expressing BPV-1 E7 are more 
sensitive to Tumour Necrosis Factor a-induced apoptosis in a pRb-independent way 
(Liu et al., 2000).
The transforming functions of BPV-4 have been mapped to a genome region 
that encodes the E5 and E7 genes (Jaggar et al., 1990). The E7 protein of BPV-4 is 
98 amino acids long and, similarly to HPV-16 E7, has a putative pRb binding domain 
as well as two Cys-X-X-Cys zinc binding domains, however BPV-4 E7 lacks the 
casein kinase II phosphorylation site (serine 31 and 32 in HPV-16 E7). It is not 
known if BPV-4 E7 binds to pRb but deletions of the second zinc binding domain or 
mutations in the putative pRb binding domain abolish cell transformation by E7 or by 
the complete BPV-4 genome, demonstrating that these sites are crucial for the role of 
E7 in cell transformation (Jaggar et al., 1990). In vivo the E7 protein was detected 
from the basal to the squamous layers of papillomas, it was consistently present in 
the nucleus of the basal and suprabasal cells and in the cytoplasm of the spinous and 
squamous layers (Anderson et al., 1997). In vitro, in transient expression 
experiments, BPV-4 E7 was localised mainly in the cytoplasm, and only some cells 
showed nuclear localisation (Pennie et al., 1993). The sole expression of BPV-4 E7 
can induce growth and morphological changes in PalF cells expressing an activated 
Ras. For this reason the protein has been considered the major transforming protein
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of BPV-4. However, E7 expressing cells do not grow in suspension or in absence of 
mitogens, and these phenotypes are the results of the additional expression of BPV-4 
E5 (Pennie et al., 1993; see below).
1.4.3 PVs E5
As presented above the transforming and immortalising activities of high-risk 
HPVs are attributed to E6 and E7 proteins, however another viral protein, E5, has 
been found to be weakly oncogenic and to cooperate with E7 to transform cells 
(Leptak et al., 1991; Pirn et al., 1992; Leechanachai et al., 1992; Bouvard et al., 1994; 
Faulkner Valle and Banks, 1995). On the contrary, in BPVs, E5 is the major 
transforming protein.
The amino acid sequence of E5 proteins is not well conserved between HPVs 
or animal viruses although these proteins present homologies in the physico-chemical 
properties: they are generally small, highly hydrophobic and membrane localised 
(Figure 1.1).
BPV-1 E5 has been the most extensively characterised among the members of 
the E5 protein family and is consequently considered the prototype of the group. The 
structural similarity of the HPVs and BPV-4 E5 proteins to BPV-1 E5 has motivated 
studies on their potential transforming activities.
HPVs E5 are discussed in detail in the section below followed by BPV-1 E5 
and BPV-4 E5 (Figure 1.1).
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a. Human PV E5s (-80 aa) b. Animal BPVs E5 (-40 aa)
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Figure 1.1 The E5 family members are small membrane-localised peptides
Highly schematic representation of human and animal PVs E5 proteins. The 
cylinders represent a-helices transmembrane segments, established in BPV-1 E5 and 
postulated in other E5s.
1.4.3.1 HPVs E5
The E5 O RF of both high-risk and low-risk HPVs encodes a hydrophobic 
peptide that is poorly conserved between different virus types. Most HPV E5s are 
- 8 0  residues, with the exception o f  HPV-83 E5 which is only 47 residues (Brown et 
al., 1999). The best studied E5, from HPV-16, is an 83 residue hydrophobic protein 
with three hydrophobic peaks and less hydrophobic troughs and consequently likely 
to form three transmembrane a-helices (Bubb et al., 1988). Further biochemical 
analysis o f  the HPV-16 E5 protein containing a N-terminal epitope tag expressed in 
transiently transfected COS cells revealed that HPV E5s exist as predominantly ER- 
localised, monomeric membrane proteins (Conrad et al., 1993).
The protein is expressed in productive infections and is thought to play a 
critical function in the early expansion of an infected cell clone. The O R F encoding 
E5 is frequently deleted in cervical carcinoma cells (Schwarz et al., 1985) suggesting 
that E5 does not play an essential role in maintaining the malignant phenotype of
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cervical carcinoma cells (zur Hausen, 1994). In vitro HPV E5 proteins cannot 
immortalise primary mouse or human cells, although both HPV-6 and HPV-16 E5s 
stimulate mitogenesis in primary keratinocytes and induce growth stimulation of 
primary rat kidney epithelial cells in cooperation with HPV-16 E7 (Straight et al., 
1993; Bouvard et al., 1994). HPV-16 E5 can cause tumourigenic transformation of 
mouse keratinocytes (Leptak et al., 1991) and fibroblasts (Leechanachai et al., 1992; 
Pirn et al., 1992).
Unlike E6 and E7 proteins which abrogate the effects of negative cellular 
regulators, the major biochemical function of E5 proteins appears to be through 
cellular tyrosine kinase growth factors receptors. Human keratinocytes expressing 
HPV-16 E5 display elevated levels of epidermal growth factor receptor (EGF-R) on 
their surface, apparently due to increased receptor recycling. In these cells the 
receptor displays increased tyrosine phosphorylation in response to epidermal growth 
factor (EGF) treatment (Straight et al., 1993; Straight et al., 1995; Crusius et al.,
1998). The expression of HPV-16 E5 in mouse fibroblasts (3T3-A31) leads to 
anchorage-independent growth and the efficiency of colony formation is increased by 
EGF treatment (Pirn et al., 1992), in NIH3T3 the expression of human EGF-R is 
required to induce anchorage-independent growth transformation by HPV-16 E5 
(Leechanachai et al., 1992). Also E5s of low risk HPVs (HPV-6, -11 E5a) can 
cooperate with EGF in the transformation of rodent fibroblasts (Straight et al., 1993; 
Crusius et al., 1997). The exact mechanisms of receptor activation by E5s are 
unknown. Different results have been reported on the ability of HPV-16 E5 to 
physically interact with growth factor receptors. Conrad and co-workers showed that, 
when overexpressed in COS-7 cells, a tagged HPV-6 E5 associated with a number of 
growth factor receptors included EGF-R, whereas HPV-16 E5 could not interact with 
any (Conrad et al., 1994); Hwang and co-workers however showed a direct binding 
of HPV-16 E5 to EGF-R in the same cell system (Hwang et al., 1995). In the former 
studies, both E5s were epitope tagged, and anti-tag antibodies were used to 
coimmunoprecipitate the proteins, while in the latter HPV-16 E5 was not tagged and 
anti-E5 peptide antibodies were used. It is possible therefore that the hydrophilic tag 
may have interfered with the immunoprecipitation. However, HPV-16 E5 does not 
appear to promote ligand-independent activation (autophosphorylation) of the EGF-R 
(Straight et al., 1993) and association between E5 and EGF-R has not yet been shown 
in human keratinocytes.
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The E5 protein from HPV-16 binds to the 16 kDa protein (Conrad et al., 
1993; Faulkner Valle and Banks, 1995). This protein is the subunit c of the VO sector 
of the vacuolar ATPase (V-H+-ATPase), and a component of the Gap Junctions (GJ). 
The V-H+-ATPase proton pump is a multi-subunit enzyme responsible for the 
acidification of many endomembrane compartments including Golgi apparatus, 
secretory vesicles, endosome and lysosomes (Nelson, 1989; Finbow et al., 1991). The 
GJ provide sites for the movement of low molecular mass solutes from cell-to-cell; 
as component of the GJ the 16 kDa protein is defined as ductin. We will be referring 
to it as 16K hereafter.
It has been shown that in E5-expressing keratinocytes there is a delay in the 
acidification of the endosomes and the pH of the endosomal compartment does not 
drop below 6 (Straight et al., 1995). This inhibition of endosomal pH acidification 
may not be sufficient to prevent EGF-EGF-R dissociation but does allow increased 
recycling of the unoccupied receptor and this may account for the increased EGF-R 
numbers observed in E5 cells (Straight et al., 1993; Straight et al., 1995) and the 
enhanced mitogenic signalling from occupied EGF-R. Although binding of E5 to 
16K has not been shown in human keratinocytes, the co-expression of E5 and the 
bovine vacuolar ATPase subunit c in COS-1 cells has shown a complex containing 
both proteins (Conrad et al., 1993). Recent studies dissociate the binding of HPVs E5 
to 16K from its effects on EGF-R activation (Rodriguez et al., 2000). Mutants of E5 
which did not interact with 16K efficiently activated the EGF-R receptor in 
keratinocytes stably expressing these forms of E5. Other reports have questioned the 
functional significance of E5/16K interactions (Adam et al., 2000; Ashby et al., 2001; 
Briggs et al., 2001). Using a panel of HPV-16 E5 mutant forms, Adam et al (2000) 
showed that the interaction of E5 and its mutants with 16K, tested in COS-1 cells, is 
not sufficient to inhibit V-H+-ATPase activity in Saccaromyces cerevisiae model 
system (Adam et al., 2000); recent data from the same group reinforced these 
observations demonstrating that the binding between HPV-16 E5 and 16K has to 
result in the disruption of the stability and assembly of the V-H+-ATPase to be 
effective (Briggs et al., 2001). However, HPV-16 E5, BPV-1 E5 and BPV-4 E5 did 
not perturb V-H+-ATPase activity in any detectable way in S. pombe (Ashby et al., 
2001), leaving the importance of E5s/16K interaction still an open question.
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The interaction between E5 and 16K may have other biological 
consequences: 16K has been reported to be a component of gap junctions (Finbow et 
al., 1991) and human epithelial cells expressing HPV-16 E5 show a reduced capacity 
for GJ Intercellular Communications (GJIC) (Oelze et al., 1995). Loss of 
communication is a common feature of a variety of transformed and tumour cells and 
it has been proposed that oncogenes could operate, in part, by blocking gap junctions 
and allowing cells to escape the growth regulation imposed by surrounding normal 
cells (Yamasaki, 1990).
There are downstream effects of E5 expression in both rodent fibroblasts and 
human keratinocytes. Ligand-dependent activation of EGF-R leads to up-regulation 
of c-Fos and c-Jun mRNA and cells expressing HPV-16 E5 have supraphysiological 
levels of these AP-1 component mRNAs in response to serum and EGF but also in 
response to PDGF, although there are small increase in both mRNAs in serum free 
media (Leechanachai et al., 1992; Bouvard et al., 1994). There is an enhanced 
activation of MAP kinases ERK 1 and ERK 2 in cells expressing HPV-16 E5 
following EGF stimulation, and this activation is prolonged by E5 expression (Gu 
and Matlashewski, 1995; Crusius et al., 1997). Additionally, HPV-16 E5 can mediate 
an EGF-R-independent activation of MAPKs in response to some forms of osmotic 
shock (Crusius et al., 2000). Therefore it appears that the various pathways activated 
by interaction of EGF with the EGF receptor are enhanced and prolonged in the 
presence of HPV-16 E5.
1.4.3.2 BPV-1 E5
BPV-1 induces fibropapillomas, tumours with both a fibroblastic and an 
epithelial component. The precise role of E5 in the virus life cycle is not known 
however, it is hypothesised that in basal keratinocytes E5 is involved in the initiation 
and maintenance of the transformed state of these cells and it may contribute to viral 
maturation, through the stimulation of DNA synthesis in differentiated cells during 
vegetative replication (Burnett et al., 1992). In vitro E5 can transform murine 
fibroblast lines (NIH3T3, C127), mouse keratynocytes cells p i 17 (Leptak et al., 
1991) and human dermal fibroblasts (HDFs) (Petti and Ray, 2000). The expression of 
E5 in fibroblasts and keratinocytes leads to induction of DNA synthesis, causes
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malignant transformation and confers the ability to grow in suspension, in the 
absence of mitogens, and tumorogenicity in nude mice.
The E5 gene encodes a 44 residues peptide with an extremely hydrophobic 
amino terminal region (two-third of the protein) and a predominantly hydrophilic C- 
terminus. Immunoprecipitation studies using an antibody against the carboxyl- 
terminus of E5 showed that E5 ORF encodes a 7 kDa polypeptide, which fractionates 
exclusively with cellular membranes and, in non-reducing condition, migrates as a 14 
kDa dimer (Schlegel et al., 1986). The hydrophobic N-terminus region of E5 forms a 
a-helical secondary structure (Surti et al., 1998) and acts as a membrane anchor, 
while E5 dimerisation is thought to be mediated by cysteine residues in the 
hydrophilic C-terminus via disulphide bond formation (Horwitz et al., 1988). Recent 
data revealed that residues within the transmembrane domain also play a role in 
protein dimerisation (Adduci and Schlegel, 1999). Immunocytochemistry and 
immunoelectron microscopy studies revealed that E5 is located within both the 
Endoplasmic Reticulum (ER), the Golgi apparatus and, to a lesser degree, at the cell 
surface, and revealed that the protein is a type II transmembrane protein, i.e. with its 
C-terminus oriented intraluminally in endomembranes (Burkhardt et al., 1989).
The small size of E5 and its ability to tolerate mutations led to the hypothesis 
that it acted by modifying the activity of cellular proteins, rather than through 
intrinsic enzymatic activity. In 1989 Martin et al. showed that E5 affected the 
function of the EGF-R in NIH3T3 cells, providing the first demonstration that E5 
could modulate the activity of cellular proteins involved in growth control (Martin et 
al., 1989). However, a direct interaction of E5 with EGF-R has never been 
demonstrated. On the contrary the interaction between BPV-1 E5 and the platelet- 
derived growth factor (3 receptor (PDGF|3-R) is well established (Petti et al., 1991; 
Drummond-Barbosa et al., 1995). In rodent fibroblasts (C127 and FR3T3), stably 
transformed by E5, the mature and immature forms of PDGF|3-R are constitutively 
phosphorylated on tyrosine residues and in these cells both mature and immature 
precursor forms exist in stable complexes with E5 (Petti et al., 1991). Several studies 
have confirmed the requirement of E5-PDGF(3-R interaction and receptor activation 
for E5 transforming activity (Nilson and DiMaio, 1993; Petti and DiMaio, 1994; 
Goldstein et al., 1994; Drummond-Barbosa et al., 1995; Klein et al., 1998). Cells that 
normally do not express PDGF|3-R e.g. normal mouse mammary gland (NMuMG)
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epithelial cells, lymphoid Ba/F3 and 32D cells, cannot be transformed by E5, but can 
be made susceptible to E5-induced transformation by the introduction of a gene 
encoding the PDGFp-R, but not genes encoding other growth factor receptors 
(GFRs) (Nilson and DiMaio, 1993; Goldstein et al., 1994). In Ba/F3 and 32D cells 
only the co-expression of human PDGFp-R and E5 generates a mitogenic signal 
which allows the lymphoid cells to grow in an IL-3-independent manner and 32D 
cells become tumourigenic (Goldstein et al., 1994). As corollary, cells selected for 
their resistance to mitogenic stimulation by PDGF are also resistant to transformation 
by E5 (Riese and DiMaio, 1995). Moreover treatment of E5-transformed C127 cells 
with a specific inhibitor of the PDGFp-R tyrosine kinase activity (AG1295) results in 
a loss of constitutive tyrosine phosphorylation of the PDGFp-R and a reversion of 
morphological transformation that was completely reversible upon removal of the 
inhibitor (Klein et al., 1998). Treatment with AG1295 prevents IL-3-independence of 
Ba/F3 cells co-expressing the PDGFP-R and E5 (Klein et al., 1998). Like PDGF and 
its viral oncogenic form v-sis (Devare et al., 1984), E5 induces dimerisation and 
trans-phosphorylation of the receptor (Lai et al., 1998; Lai et al., 2000). When 
complexed with E5, the PDGFp-R associates with c-Src homology domain 2 (SH2)- 
containing proteins. The p85 subunit of phosphatidyl inositol 3 ’kinase (PI3-K), 
phospholipase (PLCy) and Ras-GTPase activating protein, all associate with 
E5/PDGFp-R complexes (Lai et al., 2000).
The binding of E5 and the PDGFP-R is mediated entirely by transmembrane 
(TM) hydrophobic domain of the viral protein (Goldstein et al., 1992a; Adduci and 
Schlegel, 1999). Mutants in alanine residue at position 17, 21, and 24 inhibit E5 
association with PDGFp-R suggesting that these residues are crucial for the 
association with PDGFp-R. Moreover, E5 TM contains functional domains that 
separately regulate homologous (E5/E5) interaction and heterologous (E5/PDGFP-R) 
interaction (Adduci and Schlegel, 1999).
PDGFp-R participates in complex formation with E5 via transmembrane (Thr 
513) and juxtamembrane (Lys 499) residues (Petti et al., 1997). In light of these data, 
DiMaio and co-workers proposed that the E5/PDGFp-R complex may be stabilised 
largely by an electrostatic interaction between the opposite charged juxtamembrane 
lysine 499 of PDGFp-R and aspartic acid 33 of E5 and by a hydrogen-bond or 
packing interaction between the transmembrane threonine 513 of PDGFp-R and 
glutamine 17 of E5 (Meyer et al., 1994; Petti et al., 1997; Klein et al., 1998; Klein et
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al., 1999). Surti and co-workers (1998) suggested that E5 dimer might serve as 
molecular scaffold for dimerisation and ligand-independent activation of PDGF|3-R 
(Surti et al., 1998). The model predicts that on each face of the dimer aspartic acid is 
contributed by one E5 monomer and glutamine by the other and this could explain 
why dimerisation-defective E5 mutants could not induce receptor dimerisation and 
activation.
From the above, it could be concluded that the interaction and activation of 
PDGFp-R is the key element and probably the sole requirement for the E5 
transforming pathway but other reports question the validity of this conclusion.
E5 can transform cultured epidermal keratinocytes p i 17 (Leptak et al., 1991), even 
though they do not appear to express PDGF|3-R. Recently, Adduci and co-workers 
analysed E5 mutants that were defective for binding and/or activating PDGFp-R but 
could still transform cells (Adduci and Schlegel, 1999). Interestingly, some 
transforming mutants exist as stable E5 tetramers and bind the PDGFp-R but cannot 
induce its phosphorylation. These studies show that E5 tetramers may have 
transforming activity and point to the existence of an E5 transforming mechanism 
independent from the PDGFp-R or, at least, independent from its phosphorylation. In 
NIH3T3 cells E5 mutants defective for PDGFP-R activation, induce the 
phosphorylation and activation of PI3-K in a PDGFp-R independent way as shown 
by the use of a specific inhibitor of PDGFp-R phosphorylation (AG1296). These 
mutants can still form foci and sustain growth in suspension cells but are unable to 
support growth factor-independent proliferation of NIH3T3 cells (Suprynowicz et al., 
2000). In cells expressing E5 wild type (wt) the drug treatment diminished PI3-K 
phosphorylation by 70%, but did not completely abolish it, leading to the conclusion 
that the residual drug-resistant activation of PI3-K may depend on a similar PDGFp- 
R-alternative pathway hypothesised for the mutants. Some of the discrepancies from 
in vitro cell transformation studies may be cell type specific. For example one of the 
mutants (Q17S) that Suprynowicz et al. (2000) reported unable to activate the 
PDGFp-R, behaves differently in a different system, C127 cells, where it increases 
PDGFp-R phosphorylation 7-fold (Klein et al., 1998). For these reasons the data 
should be cautiously interpreted.
In 1990 Goldstein and Schlegel found that the 16K (see section 1.4.3.1) 
specifically co-precipitated with the E5 protein in COS-1 and NIH3T3 cells
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(Goldstein and Schlegel, 1990). Mutational analysis revealed that the binding of E5 
protein to 16K is mediated entirely by the intramembrane hydrophobic domain, the 
same region that is responsible for the E5/PDGF|3-R interaction (Goldstein et al., 
1992a). Confirmation of this came from the fact that none of the missense mutations 
in the hydrophilic C-terminus of the E5 protein affected binding with the 16K 
protein, including a number of mutations that severely inhibit transformation and/or 
block dimerisation. In particular, the association between E5 and the 16K is mediated 
by an interaction between Q17 in E5 and glutamic acid (Glu 143) in the fourth TM 
domain of 16K (Andresson et al., 1995). Mutational analysis revealed that a 
truncated form of 16K, lacking the fourth a-helix, and a point mutation, with 
glutamic acid 143 to arginine substitution, allowed NIH3T3 cells to grow in soft 
agar, although with lower efficiency than E5 wt. This might indicate that mutations 
within the fourth TM domain or the interaction of E5 with the 16K affect the normal 
function of V-H+-ATPase and lead to cell transformation (Andresson et al., 1995).
The interaction between E5 and 16K might impair the normal activity of the 
V-H+-ATPase in the acidification of endomembrane compartments. Shapiro and co­
workers looked at the pH of the Golgi apparatus in NIH3T3 expressing E5. They 
reported that E5 cells display an elevated pH in the Golgi lumen when compared to 
control cells as a consequence of the possible inhibition of V-H+-ATPase activity by 
E5 (Schapiro et al., 2000).
As reported before the 16K protein is a component of the Gap Junctions (GJ). 
Similarly to what shown for HPV-16 E5 expressing cells, primary bovine fibroblasts 
(PalF) expressing BPV-1 E5 show closure of the GJIC (Ashrafi et al., 2000).
As with the role of the PDGFJ3-R in E5-mediated transformation pathway, 
there are discordant opinions about the importance of the interaction of E5 with 16K. 
Some studies found that the interaction with 16K may be required for transforming 
activity but it is not sufficient since transformation-defective mutants can still bind to 
16K (Goldstein et al., 1992b). Similarly, Sparkowski et al (1996) showed that E5 
transforming activity can be dissociated from the interaction since mutants that do 
not associate with 16K protein are still transforming (Sparkowski et al., 1996).
The demonstration that E5 activates immature PDGFp-R forms that are 
localised in the Golgi apparatus led to the hypothesis that this organelle could be a 
critical location for E5 during cell transformation. To test this a form of E5 bearing a
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KDEL (E5/KDEL) retrieval signal for the ER was used in transformation studies in 
NIH3T3 and C l27 cells. The results showed that the Golgi location is required for E5 
transforming activity since E5/KDEL cannot induce focus formation in mouse 
fibroblasts (Sparkowski et al., 1995). Surprisingly this form of E5 can still bind to 
16K protein and to the immature form of PDGFp-R and induce phosphorylation of 
both mature and immature forms of the receptor. The transformation deficiency of 
the E5/KDEL form is thought to depend on the sequestration of the PDGFp-R 
complexed with E5/KDEL in the ER where the PDGFp-R cannot transmit a 
mitogenic signal (Sparkowski et al., 1995). The wild type form of the viral protein, 
however, could activate PDGFp-R from the Golgi apparatus, without necessarily 
moving to the plasma membrane, or proceed together with it to the cell surface
Although necessary, the Golgi location is not sufficient for E5 transformation 
since mutants unable to transform are still localised in this subcellular compartment 
(Klein et al., 1999; Adduci and Schlegel, 1999; Schapiro et al., 2000). The 
importance of the E5 Golgi location has been stressed by the finding that NIH3T3 E5 
expressing cells present a more alkalinised Golgi compartment but not gross 
morphological alterations to this organelle (Schapiro et al., 2000). In this work the 
authors studied how Golgi alkalinisation is associated with the transforming ability of 
E5 using the following mutants: (I) those non-transforming and cable of PDGFp-R 
phosphorylation and not localised in the Golgi, (E5/KDEL); (II) those non­
transforming, and incapable of PDGFp-R activation but localised in the Golgi and 
(III) those that are transforming, Golgi localised and either capable or incapable of 
PDGFp-R activation. When the Golgi pH was measured in NIH3T3 stably 
expressing the mutants the authors found a perfect correlation between the ability of 
the mutants to induce Golgi alkalinisation and to transform cells, suggesting an E5 
transforming mechanism independent of PDGFp-R activation. Schlegel and co­
workers proposed that inactivation of the V-H+-ATPase and alkalinisation of the 
Golgi apparatus could be a crucial activity of E5 (Schapiro et al., 2000). The 
acidification of the Golgi apparatus may regulate the transport/processing of itinerant 
proteins and lipids and have pleitropic effects on cellular processes.
1.4.3.3 BPV-4 E5
The BPV-4 E5 protein shares some structural features with BPV-1 E5 (Figure 
1.2). It is only 42 residues with a putative transmembrane domain, the hydrophobic
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N-terminal region (residues 1-30) and a hydrophilic C-terminal “tail” of 12 residues 
(Jackson et al., 1991). BPV-4 E5 is expressed in vivo only in the basal and suprabasal 
layers of early papillomas and its expression decreases in late stage papillomas 
(Anderson et al., 1997). In vitro E5 is transforming in NIH3T3 cells. Established 
murine fibroblasts expressing E5 grow in low serum concentration and in suspension 
(O'Brien and Campo, 1998). Moreover, E5 confers ability to grow in low serum, to 
escape contact inhibition and to grow in suspension to primary bovine fibroblasts co­
expressing BPV-4 E7, HPV-16 E6 and an activated Ras (Ashrafi, 1998; O'Brien et 
al., 1999).
E5 has been subjected to a limited genetic analysis in the attempt to identify 
important functional domains and segregate transforming functions of the protein. 
These studies revealed that the hydrophilic “tail” (31-42 amino acids) is critical since 
neither a form of E5 lacking the last 12 amino acids or the chimera comprising the 
BPV-4 E5 body and the BPV-1 E5 “tail” are capable of promoting anchorage- 
independent growth, although the reciprocal chimera is still transforming (Ashrafi, 
1998; O'Brien et al., 1999). The truncated form of E5 is non-transforming both in 
PalFs and NIH3T3 cells (Ashrafi, 1998; O'Brien and Campo, 1998; O'Brien et al.,
1999). Mutation of the asparagine residue in position 17, potentially functionally 
homologous to glutamine 17 in BPV-1 E5, to serine, tyrosine or alanine produce 
forms of BPV-4 E5 partially transforming, non transforming and hypertransforming 
respectively, pointing to the importance of this residue for E5 transforming ability in 
PalF cells (Ashrafi, 1998; O'Brien et al., 1999). The substitution of two amino acids 
that could alter the potential a-helix conformation of the hydrophobic domain 
emphasise the importance of the nature of these residues for E5 activity (Ashrafi,
1998); (see Chapter 3 and 6).
It is not known if E5 can interact with growth factor receptors to promote 
their activation, but it can bind with the 16K protein in vitro (Faccini et al., 1996), 
induces down-regulation of GJIC in PalF cells (Ashrafi et al., 2000) and alkalinises 
the Golgi apparatus (R. Schlegel, personal communication) in NIH3T3 cells. It has 
been shown, however, that binding to 16K may be necessary but not sufficient for 
E5-induced transformation or GJIC down-regulation since non transforming mutants 
can still bind to 16K but do not inhibit GJIC (Ashrafi et al., 2000). Moreover 
asparagine in position 17 is not crucial for E5/16K association contrary to glutamine
33
17 for BPV-1, and the hydrophilic domain is dispensable (Ashrafi et al., 2000). Even 
if not necessary the inhibition of GJIC may be important for fibroblasts 
transformation in vitro and for the establishment of transformed cells in vivo: E5 may 
interfere with the GJIC activity in infected tissue and affect basal and suprabasal cell 
transformation by removing them from homeostatic control exerted by surrounding 
non-transfected cells (Jackson et al., 1996).
In transiently transfected PalFs E5 is present in the perinuclear membranes, 
the endoplasmic reticulum and the Golgi apparatus (Pennie et al., 1993). The 
importance of BPV-4 E5 Golgi location has been underlined by recent observations. 
Ashrafi and co-workers have shown that PalF and NIH3T3 cells expressing E5 
present a down-regulation of surface MHC I (histocompatibily complex class I) 
expression (Ashrafi et al., 2002). MHC I is synthesised in the ER, post-translationally 
modified in the Golgi and transported in the plasma membrane (Cresswell et al.,
1999). This process appears inhibited in cell expressing E5, it is still unclear if this is 
due to a direct effect of E5 on MHC I (i.e. E5/MHCI interaction) or is a consequence 
of the lack of Golgi acidification observed in E5 expressing cells. In PalF cells a 
down-regulation of the MHC I protein level and transcripts have been also observed 
(Ashrafi et al., 2002). In light of these data the authors proposed a model by which 
E5 produced early in the infection process, would directly affect immune 
recognitions and clearance of virally-infected cells favouring viral persistence and 
subsequently the development of the malignancy.
In NIH3T3 cells transformation by E5 is associated with up-regulation of 
cyclin A expression and associated kinase activity and, surprisingly, with the up- 
regulation of the cyclin-dependent kinase inhibitor p27 level in all growth condition 
tested (O'Brien and Campo, 1998). In these cells E5 does not increase cyclin E 
expression level or the cyclin E-CDK2 kinase activity. Recently O’Brien et al., 
demonstrated that in NIH3T3 E5 expressing cells p27 is prevented in its function as 
CDK2 inhibitor because it is sequestered by an elevated pool of Cyclin D1/CDK4 
complexes that retain their kinase activity in normal growth conditions or in absence 
of mitogens (O'Brien et al., 2001). Consequently the sequestration of p27, the 
inactivation of pRb and the increased expression of cyclin A and its associated 
activity provide all the requirements to allow mitogen-independent proliferation of 
NIH3T3 E5 transformed cells.
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BPV-1 E5 BPV-4 E5
Figure 1.2 BPV-1 E5 and BPV-4 E5
Amino acids sequence and transmembrane configuration o f  BPV-1 E5 and BPV-4 
E5. The amino acids that have been shown critical for cell transformation are shaded 
in BPV-1 E5 (Horwitz et al., 1988; Horwitz et al., 1989).
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1.5 Project aims
How BPV-4 E5 is able to induce cell transformation is poorly understood; its 
small size has led to the hypothesis that E5 may act by modifying the activity of 
cellular proteins as it has been shown for BPV-1 E5, rather than through a direct 
enzymatic activity.
Thus the initial aim of this thesis was to define whether E5 cellular location is 
crucial for its transforming activity. Consequently a routine detection system had to 
be identified to allow cellular localisation of the protein. All previous attempts to 
visualise E5 within the cells failed, with the exception of one case (Pennie et al., 
1993), either using anti-E5 antibodies or antibodies against small tag-epitopes at the 
N-terminus of E5 (e.i. HA). To overcome these problems we decided to construct a 
fusion form of E5 with the Green Fluorescence Protein (GFP). GFP is a naturally 
fluorescence protein from the jellyfish Aequorea victoria and has become an 
important molecular biology tool; when used as a tag on other proteins GFP allows 
study of their expression and localisation in live, as well as in fixed cells. We used 
GFP-E5 in localisation studies.
Additionally, studies of GFP-E5 transforming ability in NIH3T3 cells were to 
be undertaken to confirm that the transforming abilities of E5 had been maintained in 
its GFP fusion form and in the attempt to identify new cellular targets of E5. NIH3T3 
GFP-E5 expressing cells were analysed for their ability to grow in absence of 
mitogens and in semi-solid media. Biochemical studies to define the changes on the 
cell cycle machinery due to GFP-E5 expression were carried out in different growth 
conditions.
In the attempt to segregate the transforming functions of E5 protein and to 
define its possible functional domains a panel of mutants have been generated and 
tested for transformation in primary bovine fibroblasts (PalFs) co-expressing BPV-4 
E7, HPV-16 E6 and an activated Ras (Ashrafi, 1998; O'Brien et al., 1999). Here, in 
the attempt to expand our information on E5 transformation abilities, we wanted to 
carry out transformation studies of E5 mutant forms in NIH3T3 cells.
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In PalFs it has been shown that the altered phenotypes observed for E5 
mutants compared with the wt protein do not depend on the expression level of the 
proteins (O'Brien et al., 1999). To establish if a mis-location of the mutants may be 
an explanation for their different transforming ability, we generated fusion forms of 
these peptides with GFP and analysed their cellular location.
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CHAPTER 2: MATERIAL AND METHODS
2.1 Material
2.1.1 Antibodies
Babco Covance Research Product, 
Richmond, USA
Anti-GFP (B34N) mouse monoclonal
Bioquote Limited, Yorkshire, UK Anti Protein Disulphide Isomerase (PDI) 
mouse monoclonal
Cell Signaling technology, Beverly , USA Anti phospho-S780 pRb rabbit polyclonal
Jackson Immunoresearch Laboratories, 
West Grove, PA, USA
Texas Red dye -conjugated AffiniPure 
Sheep Anti-Mouse IgG (H+L)
Texas Red dye -conjugated AffiniPure 
Goat Anti-Rabbit IgG (H+L)
Fluorescein (FITC)-conjugated AffiniPure 
Goat Anti-Rabbit IgG (H+L)
Fluorescein (FITC)-conjugated AffiniPure 
Sheep Anti-Mouse IgG (H+L)
MBL Medical & Biological Laboratories, 
Nagaya, Japan
Anti-GFP rabbit polyclonal
New England Biolabs, Hertfordshire, UK Anti-Mouse IgG, HRP-linked Antibody 
Anti-Rabbit IgG, HPR-linked Antibody
PharMingen, San Diego, USA Anti-Human pRb (G3-245) mouse 
monoclonal
Santa Cruz Biotechnologies, SantaCruz, 
USA
Anti-cyclin A rabbit polyclonal, 
Anti-cyclin E rabbit polyclonal 
Anti-cdc2 mouse monoclonal 
Anti-CDK2 (M2) rabbit polyclonal 
Anti-p27 rabbit polyclonal 
Anti-cyclin D1 mouse polyclonal 
Anti-pl30 rabbit polyclonal 
Anti-pl07 rabbit polyclonal
Sigma Chemical Co., Ltd., Dorset, UK Anti-a-tubulin mouse monoclonal 
Anti-total ERK 1/2
Anti-phospho ERK 1/2
2.1.2 2.1.2 Bacterial Hosts
Invitrogen Life Technologies, Ltd., E.coli DH5a competent cells
Paisley, UK
2.1.3 Buffers
2X HEPES buffered saline (HBS) 280 mM NaCl, 10 mM KC1, 1.5 mM Na2- 
HP04.2H20 , 50 mM HEPES
Kinase buffer 50 mM HEPES, 50 mM NaCl, 10 mM 
MgCl2, 1 mM DTT
Kinase lysis buffer 50 mM HEPES pH 7.5, 150 mM NaCl, 1% 
(v/v) NP40 detergent, 2.5 mM EGTA pH 
8, 10 mM NaF, 10 mM, |3- 
glycerolophosphate, 1 mM Sodium 
Orthovanadate, 1 mM DTT,
Mini Proteinase inhibitor cocktail (Roche)
Kinase reaction Buffer 0.05 p-g/pl Histone HI, 20 pM ATP, 
10 (iCi y-32P-ATP, IX Kinase Buffer
10X loading buffer for PCR 0.45% (w/v) bromophenol blue, 1% (w/v) 
sodium dodecyl sulphate (SDS), 100 mM 
EDTA, 2.5% (w/v) Ficoll 400 in TE
Phosphate buffered saline (PBS) 137 mM NaCl, 44 mM KC1, 1.4 mM 
KH2P 0 4, 8.5 mM Na2HP04
SDS-Polyacrylamide Gel Electrophoresis 
(SDS-PAGE)-Lysis buffer
100 mM Tris-base pH 6.8, 2% (w/v) SDS, 
20% (v/v) glycerol
2X SDS gel loading buffer 4% (w/v) SDS, 0.2% (w/v) bromophenol 
blue, 20% (v/v) glycerol and 100 mM Tris, 
pH6.8, 200 mM DTT
5X TBE buffer 40 mM Tris-base, 16 mM acetic acid, 1 
mM EDTA, pH8.0
TBS 0.2 M Tris-base, 1.5 M NaCl, pH 7.6
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TE 10 mM Tris-HCl, 1 mM EDTA pH 8.0
Transfer buffer 39 mM glycine, 48 mM Tris-base, 0.037% 
(w/v) SDS, 20% methanol
Tris-glycine electrophoresis buffer 25 mM Tris-base, 250 mM glycine, 0.1% 
(w/v) SDS
2.1.4 Cells
CELLS TYPES DESCRIPTION GROWTH MEDIUM
NIH3T3 Swiss mouse embryo 
fibroblasts
Dulbecco’s Modified 
Eagle’s Medium,
10% New Born Calf Serum
1 mM sodium pyruvate 
0.375% sodium carbonate
2 mM glutamine
COS-7 Cells expressing SV-40 T 
Ag, derived from the 
African green monkey 
kidney cell line CV1
Dulbecco’s Modified 
Eagle’s Medium,
10% Foetal Calf Serum
1 mM sodium pyruvate 
0.375% sodium carbonate
2 mM glutamine
CHO-1K (CHO) Chinese hamster ovary 
cells
Special Liquid Medium 
10% Foetal Calf Serum
1 mM sodium pyruvate 
0.375% sodium carbonate
2 mM glutamine
2.1.5 Cell Culture Materials
SUPPLIER MATERIAL
Harlan Sera-Lab Ltd., Crawley Down, 
UK
Foetal Calf Serum
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Invitrogen Life technologies Ltd., 
Paisley, UK
New born Calf Serum
IX Dulbecco s Modified Eagles Medium
200 mM glutamine
Geneticin, G418 sulphate
7.5% sodium bicarbonate
100 mM sodium pyruvate
2.5% Trypsin
Sigma Chemical Co., Ltd., Poole, Dorset, 
UK
10X Dulbecco s Modified Eagles Medium
2.1.6 Chemicals, enzymes & kits
SUPPLIER CHEMICALS AND ENZYMES
Ambion the RNA company™, Oxon, UK DNA-free™
Amersham Pharmacia Biotech pic, 
Amersham, Bucks, UK
ECL Western detection agent 
Hybond ECL, nitrocellulose membrane 
[y32P] dATP
Rainbow coloured protein molecular 
weight markers (220-14 KDa; 45-2.5 
KDa)
Becton Dickinson, Michingam, USA Bacto-Agar
Biogenesis Ltd., Bournemouth, UK RNAzolB
Bioline, London, UK X-gal, 5-bromo-4-chloro-3-indolyl-(3-D- 
galactopyranoside
Calbiochem San Diego California MAPK inhibitor PD98059
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Fisher Scientific Equipment, 
Loughborough, UK
Acetic acid 
Butan-l-ol 
Chloroform
di-potasium hydrogen orthophosphate 
anhydrous
Ethylene diamine tetra acetate (EDTA) 
disodium salt
Dimethyl sulfoxide (DMSO) 
Hydrochloride acid 
Magnesium chloride 
Magnesium sulphate 
Methanol
Potassium chloride
Potassium dihydrogen orthophosphate
Propan-2-ol
Sodium acetate
Sodium carbonate
Sodium chloride
Sodium dodecyl sulphate (SDS)
Sodium hydroxide
Invitrogen Life technologies Ltd., 
Paisley, UK
All DNA restriction enzymes and 
appropriate buffer concentrates (unless 
otherwise stated)
Agarose (ultrapure electrophoresis grade) 
Tris-base
100 bp DNA ladder 
1 Kb DNA ladder 
Low DNA mass ladder
James Burrough Ltd., Witham, Essex, 
UK.
Ethanol
Merck Eurolab Ltd., Dorset, UK Calcium chloride 
Glycerol
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Molecular Probes, Inc. Oregon, USA A-((4-(4,4-difluoro-5-(2-thienyl)-4 bora- 
3a,4a-diaza-s-indacene-3- 
yl)phenoxy)acetyl)sphingosine) 
BODIPY®TR ceramide
Perkin Elmer Cetus, Norwalk, USA GeneAmp RNA PCR core kit 
GeneAmp PCR core kit
Promega Ltd., Chilworth Research 
Centre, Southampton, UK
Luciferase Assay System 
Reporter Lysis 5 X Buffer 
MAPK inhibitor U0126
Qiagen Ltd., Dorking, Surrey, UK QIAprep Miniprep kit 
QLAprep Maxiprep kit 
QIAquick gel extraction kit 
QLAquick PCR purification kit 
Effectene Transfection Reagent
Roche UK, Lewes, East Sussex, UK Complete™ Mini, pro tease inhibitor 
cocktail tablets
Severn Biotech Ltd., Kidderminster, 
Worcester, UK
Acrylamide
Sigma Chemical Co., Ltd., Poole, Dorset, 
UK
Ampicillin
Bicinichonic acid solution 
Bovine Serum Albumin 
Copper(II) sulphate (pentahydrate 4% 
(w/v) solution)
Crystal violet 
DL-Dithiothreitol 
Ethidium bromide 
Kanamycin 
HEPES
Methocel MC 4000 
Paraformaldehyde
Phenol:Chloroform:Isoamyl Alcohol 
(25:24:1 (v/v))
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Penicillin
Protein-A sepharose 
Saponin
Sepharose CL 4B 
TEMED
Tween 20 (Polyoxyethylene sorbitan 
monolaurate)
Stratagene Ltd, Cambridge, UK Cloned Pfu DNA polymerase 
10X cloned Pfu buffer
Transgenomic, Northumberland, UK Calf Intestinal Alkaline Phosphatase 
(CLAP) RNase A 
T4 DNA ligase
Upstate biotecnology 
New York, USA
Histone HI
Vector Laboratories, Burlingame, USA VECTASHIELD® Mounting Medium H- 
1000
2.1.7 Equipment and Plasticware
SUPPLIER EQUIPMENT
Becton Dickinson Labware, Plymouth, 
UK
Falcon 1059 polypropylene tubes 
Falcon 2059 polypropylene tubes 
Falcon 2098 polypropylene tubes 
Sterile Plastic pack syringes 
18 gauge sterile syringe needles 
60, 90 and 150 mm tissue culture dishes 
cell strainers 40pm Nylon
Bibby sterilin Ltd., Stone, Staffs, UK 60, 90 and 150 mm bacteriological petri 
dishes
Sterile plastic universal containers
Costar Corporation, High Wycombe, 
Bucks, UK
24 well tissue culture plates 
96 well tissue culture plates 
Disposable Cell scrapers
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Elkay Laboratory products UK Ltd., 
Eastleigh, Hampshire, UK
Microcentrifuge tube
Gelman Sciences, Northampton, UK Sterile 0.2 pm acrodisc filters
Ilford Ltd., Mobbrrley, Cheshire, UK Ilford PANF 50 black and white film
Nunc, Roskilde, Denmark T25, 80, and 175 cm2 tissue culture flasks 
Cryotubes
Technical Photo Systems., Cumbernauld, 
UK
Fuji RX medical X-ray film
Whatman International Ltd., Maidstone, 
Kent, UK
Whatman 1 filter paper
2.1.8 Other Materials
SUPPLIER MATERIALS
Beatson Institute Central Services LB-Medium (Luria-Bertani Medium) 
Streptomicine 
Sterile distilled water 
Sterile glycerol
Sterile phosphate-buffered saline (PBS) 
Sterile phosphate-buffered saline plus 
EDTA (PE)
Merck Ltd., Poole, UK Silicone grease
Premier Brands, Adbaston, Stafford, UK Marvel (Dried Skimmed milk)
2.1.9 Plasmids
pZipneoSV (XI) (referred to as pZipneo throughout the text) consists of a Moloney 
murine leukaemia virus (MoLV) transcriptional unit, including the long terminal 
repeats (LTRs), and pBR322 sequences. This construct has a unique BamHI cloning 
site and also contains DNA sequences derived from the transposon Tn5, which 
encodes G418-resistance (neomycin resistance) in mammalian cells (Cepko et al., 
1984).
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pZipneoHAE5 contains nucleotides 236-590 of the BPV-4 genome cloned into the 
BamHI sites of the vector pZipneo. The sequence coding for the influenza virus 
haemagglutinin type-1 (HA1) epitope is inserted at the 5 of the BPV-4 E5 sequences.
pwt929 is a luciferase reporter plasmid for the human cyclin A promoter. The 
plasmids carries a fragment of the human cyclin A promoter (region between -754 bp 
and +175 bp). This plasmid construct was a gift to Dr Vincent O’Brien from Dr 
William Fahl, University of Wisconsin, USA (Kramer et al., 1996).
pEGFPC3 is an eukaryotic expression plasmid that encodes the enhanced green 
fluorescence protein (EGFP) (which contains the double amino-acid substitution of 
Phe-64 to Leu and Ser-65 to Thr, to increase the fluorescence of 35 times). The 
EGFP expression is driven by the CMV promoter and the multiple cloning site is 
between the EGFP sequences and SV40 poly A site.
pEGFPN2 is an eukaryotic expression plasmid that encodes the enhanced green 
fluorescence protein (EGFP) (which contains the double amino-acid substitution of 
Phe-64 to Leu and Ser-65 to Thr). The multiple cloning site is between the immediate 
early promoter of CMV and the EGFP sequence.
pcPEP-GFP expresses the signal peptide/membrane anchoring domain of the rabbit 
neutral endopeptidase fused with GFP. The fusion protein is inserted in the multiple 
cloning site of pcDNA3 vector (Invitrogen). The plasmid is a kind gift of Dr. Maria 
Simonova, Center for Molecular Imaging Research, Massachusetts General Hospital 
and Harvard Medical School (Simonova et al., 1999).
2.1.10 Water
Distilled water for the preparation of buffer stocks was obtained from a Millipore 
MilliRO 15 system, and for protein, enzyme, RNA or recombinant DNA procedures 
was further purified on a Millipore MilliQ System to 18 MQ/cm. Sterile distilled 
water for making up tissue culture media was supplied by the Beatson Institute for 
Cancer Research Technical Service.
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2.2 Methods
2.2.1 Molecular biology
2.2.1.1 Oligonucleotides synthesis and purification
Oligonucleotides were synthesised by the Beatson Institute technical services 
staff on an applied Biosystems model 381A DNA Synthesiser or 392 DNA/RNA 
Synthesiser using the manufacturer’s protocols and Cruachem reagents.
The oligonucleotides were purified by precipitation with butan-l-ol. One ml 
butan-l-ol was added to 150 pi oligonucleotide solution and microcentrifuged at 
14000 rpm for 20 minutes at room temperature. Excess butanol was removed by 
centrifugation under vacuum and the primer dissolved in an appropriate volume of 
sterile distilled water or TE pH 8.0. Primer concentration was determined as 
described in section 2.2.1.12.
2.2.1.2 Amplification of DNA by polymerase chain reaction (PCR)
All the reagents were provided from Stratagene with the exception of dNTPs 
which were obtained from Perkin-Elmer Core DNA PCR Kit. Primer sequences were 
designed such that they were complementary to opposite strands and opposite end of 
the DNA of interest.
For the cloning of BPV-4 E5 in pEGFPC3 and pEGFPN2 (2.1.9), at the C and N 
terminus of the green fluorescent protein respectively, the forward E5 primer 
correspond to the first 11 amino acids of the influenza virus haemagglutinin (HA) 
and the reverse primer to nucleotide 455-434 of the BPV-4 genome. The primers 
were designed to carry the specific restriction sites as required from the cloning 
strategy (see table 2.1). The constructs obtained have been named GFP-E5 and E5- 
GFP respectively. For the cloning of GFP in pZipneo the forward primer 
corresponded to the first 21 nucleotide of the GFP protein and the reverse primer to 
the last 21 of GFP sequence. For the cloning of GFP-E5 in pZipneo the forward 
primer corresponded to the first 21 nucleotide of GFP and the reverse primer to 
nucleotide 455-434 of the BPV-4 genome.
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Table 2.1 Oligonucleotides PCR primers
Vector primer name primer sequence
pEGFPC3 E5C3 forward 
E5C3 reverse
5’tta cgt tgc aag ctt atg tac cca tac gat gtt cca 3’ (Hindlll) 
5’ate ttc tac ctg cag tea ate cca tcc ate taa ccg 3’ (PstI)
pEGFPN2 E5N2 forward 
E5N2 reverse
5’tta cgt tgc aag ctt atg tac cca tac gat gtt cca 3’ (Hindlll) 
5’ate ttg gat ccc ate cca tcc ate taa ccg agt aat 3’ (BamHI)
pZipneo GFP forward 
GFP reverse
5’tta cgt gga tcc gag aca tgg tga gca agg geg 3’ (BamHI) 
5’ate tac gga tcc tea ctt gta cag etc gtc cat 3’ (BamHI)
pZipneo GFP-E5 forward 
GFP-E5 reverse
5’tta cgt gga tcc gag aca tgg tga gca agg geg 3’ (BamHI) 
5’ate tac gga tcc tea ate cca tcc ate taa ccg 3 ’ (BamHI)
pEGFPC3 E5C3 forward
E5KDEL
reverse
5’tta cgt tgc aag ctt atg tac cca tac gat gtt cca 3’ (Hindlll)
5’tgc ctg cag tea caa etc gtc ctt etc aga ate cca tcc ate taa 3’ 
(PstI)
pEGFPC3 E5C3 forward
E5GGEV
reverse
5’tta cgt tgc aag ctt atg tac cca tac gat gtt cca 3’ (Hindlll)
5 ’tgc ctg cag tea aac etc tcc tcc tcc aga ate cca tcc ate taa 3’ 
(PstI)
NB: in bo d is the restriction site sequence; in brackets is the name of the restriction
enzyme.
All reaction mixtures comprised 200 pM of each dATP, dGTP, dCTP and 
dTTP, IX cloned Pfu buffer (200 mM Tris-HCl pH 8.8, 20 mM M gS04, 100 mM 
KC1, 100 mM (NH4)2S 04, 1% Triton X-100, 1 mg/ml nuclease free BSA), 40 pmoles 
of each primer, 2.5 units Pfu polymerase (a thermolabile DNA polymerase from 
pyrococcus furiosus) and 1 pg of DNA. The mixtures were aliquoted into 0.5 ml 
GeneAmp PCR reaction microfuge tubes in a final volume of 100 pi.
The tubes were placed into the PCR machine (Perkin-Elmer Cetus type 9600 
thermocycler) and heated to 95°C for 5 minutes to inactivate DNase and ensure all 
DNA duplexes were melted, the DNA was then amplified for 35 cycles at 94°C for 
30 seconds, 55°C for 30 seconds, to allow the primers to anneal to the template DNA, 
followed by 72°C for 30 seconds, to allow extension of the amplimer sequences. 
After completion of the cycles, the reaction was incubated at 72°C for a further 7 
minutes to ensure full extension and then cooled to 4°C. 5 pi of each sample was
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analysed by agarose gel electrophoresis (as described in section 2.2.1.5) to check the 
correct product had been amplified.
2.2.1.3 PCR products purification
The PCR products were cleaned from excess dNTPs, enzyme, and salt using 
the QIAquick PCR purification kit from Qiagen following the manufacturer’s 
recommendations.
2.2.1.4 Restriction enzyme digestion of DNA
Restriction digests were carried out using appropriate enzymes and their 
concentrated buffer solutions according to the manufacturer’s reccomendation.
PCR products were incubated with 5-10 units enzyme in a buffered solution 
ensuring that the total volume of enzyme added did not exceed one tenth of the final 
reaction volume. PCR products were digested in 100 pi final volume overnight at 
37°C.
Small quantities of plasmid DNA (<5 pg) were routinely digested in a 20 pi 
reaction volume for 2 hours at 37°C using 1-2 units enzyme. The digestion fragments 
were analysed by agarose gel electrophoresis as described below.
2.2.1.5 Agarose gel electrophoresis
Horizontal gel cast apparatus from Pharmacia was used. In general, 1% (w/v) 
agarose gels were used, but smaller fragments (100-400 bp) were separated on 2-4% 
gels. Gel mixes containing the appropriate amount of agarose were dissolved in 0.5X 
TBE buffer by heating the solution in a glass conical flask in a microwave until all 
the particles of agarose gel had dissolved. The gel was poured when the agarose was 
hand hot and a comb with the required number and size of teeth placed immediately 
into the gel to form the sample wells. The gel was submerged in 0.5X TBE buffer. 
The samples containing IX loading buffer were loaded in each well along with an 
appropriate size marker (i.e. 100 bp ladder, 1 Kb ladder, DNA mass ladder) into the 
first and/or last well in the gel and run at 70-100 constant voltage, usually until the 
samples blue dye front was 1-3 cm from the end of the gel.
Once run, the DNA fragments were visualised by staining the gel in running 
buffer containing 0.5 pg/ml ethidium bromide with gentle agitation for 10 minutes at
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room temperature. The separated DNA was visualised by illumination with short 
wave (312 nm) UV light and photographed through a red filter onto videoprint paper 
using an Appligene Imager.
2.2.1.6 Isolation and purification of DNA fragments and vectors
All DNA to be used for cloning was purified from contaminants, such as 
residual enzymes from the restriction reaction, which might otherwise interfere with 
subsequent cloning steps. The PCR products were cut out of the gel with a clean 
scalpel blade and the gel slice placed in an Eppendorf tube. Extraction of the DNA 
fragment from the agarose was achieved using a Qiagen Qiaquick gel extraction kit 
following the manufacturer’s instructions.
For vectors bigger than 5 Kb the DNA were purified using extraction with 
phenol: chloroform as follows. In the first round of extraction the DNA sample was 
mixed with an equal volume of phenolxhloroform. The aqueous DNA and organic 
phase were mixed thoroughly by vortexing, then separated by centrifugation in a 
microcentrifuge at 14000 rpm for 5 minutes at room temperature. The upper aqueous 
phase was transferred in a clean Eppendorf tube, care was taken not to transfer any of 
the interphase to the tube, and the extraction process repeated. The aqueous phase 
was transferred to a fresh Eppendorf tube for ethanol precipitation. Ethanol 
precipitation was used to concentrate DNA samples and also to remove solute 
contaminants such as salt. The aqueous DNA solution was mixed with one tenth 
volume of 3 M sodium acetate pH 5.2 and 2-2.5 volumes of ice cold ethanol. The 
sample was then mixed well by inversion several times and then stored at -20°C or, 
alternatively, placed on dry ice for 15-30 minutes to facilitate DNA precipitation. 
The precipitated DNA was collected by centrifugation in a microcentrifuge at 14000 
rpm for 15 minutes at 4°C. The supernatant was discarded, and the pellet was 
washed with 70% ethanol to remove any trace of salt, dried under vacuum before 
resuspension in distilled water.
2.2.1.7 Ligation of DNA fragments
The vector, to be used in the ligation step, was dephosphorylated at its termini 
to prevent its religation. After the vector DNA had been linearised by digestion, the 
reaction mixture was adjusted by adding dephosphorylation buffer and 1 unit of Calf 
Intestinal Alkaline Phosphatase (CLAP) was added to the reaction mixture and
50
incubated at 37°C for 15 minutes. The reaction was stopped by heating to 55°C for a 
further 15 minutes. Another 1 unit of CIAP was added to the reaction mixture and 
incubated at 37°C for 15 minutes. All enzyme activity in the reaction was finally 
stopped by heating to 55°C for further 15 minutes. The DNA was phenol:chloroform 
extracted, ethanol precipitated and then resuspended in an appropriate volume of 
distilled water.
The size and the concentration of both PCR products and plasmid were 
checked by running few pi of each on a 1% agarose minigel with 2 pi of Low Mass 
DNA ladder. The DNA fragment was inserted into dephosphorylated vector (100 ng) 
at a ratio of 3:1 respectively. The vector and inserted DNA were incubated together 
in a reaction of 10 pi final volume, containing IX ligase buffer and 1 unit of T4 
ligase at 15°C overnight. Ligases reactions were then diluted 1:5 adding 40 pi of 
distilled water and 1 to 5 pi of the reaction were used to transform competent 
bacterial cells (section 2.2.1.8).
2.2.1.8 Transformation of bacterial host
All plasmids were propagated in commercially available DH5a E. coli 
competent cells supplied as frozen stocks kept at -70°C until use. Competent cells 
were thawed slowly on ice, and 100 pi aliquots put into a prechilled polypropylene 
culture tube and 1-5 pi of appropriate diluted ligase reaction added and mixed by 
gently moving the pipette tip through the cells while dispensing. The cells were then 
incubated on ice for 30 min before being heat-shocked for 45 seconds at 42°C. The 
tube were then immediately placed on ice for 2 min. 900 pi of L-Broth (1% w/v 
Bactotryptone, 0.5% w/v yeast extract, 1% w/v NaCl) was then added to each 
transformation reaction at room temperature. The tubes were then transferred to a 
shaking 37°C incubator (approximately 225 rpm) for 1 hr to allow expression of the 
antibiotic resistant marker. Following this, 100 pi of cells were spread on an L-agar 
plate containing the appropriate antibiotic. The plate was inverted and incubated 
overnight at 37°C to allow colony formation.
2.2.1.9 Small scale preparation of plasmid DNA (Miniprep)
Small amounts of plasmid DNA were extracted from transformed bacterial 
colonies to identify correct clones.
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Single colonies of bacteria carrying the required plasmid were picked using a 
sterile yellow tip and grown in 5 ml culture of L-Broth containing antibiotic (100 
pg/ml Ampicillin and 50 pg/ml Kanamycin ) at 37°C in a shaking incubator (225 
rpm) overnight. 10 separate colonies were generally picked for screening. Bacteria 
were pelleted from 1.5 ml of overnight culture by spinning in a microcentrifuge 
(14000 rpm) for 30 seconds at room temperature. DNA was prepared using the 
QIAprep miniprep kit following the manufacturer’s instructions.
2.2.1.10 DNA sequencing
The sequences of the new plasmids were checked using Tag terminator 
sequencing on an Applied Biosystems 373A automated DNA sequencer which was 
performed by the Beatson Institute technical service staff.
The region to be sequenced (the insert) first underwent PCR amplification. 
0.5 pg of template DNA (around 1 p i of miniprep preparation) was added to 12 pi 
RQ grade H2O plus 3.2 pmoles of the appropriate primer. 8 pi of dye terminator cycle 
sequencing ready reaction premix (Perkin Elmer) was added to each reaction 
contained in 250 p i thin walled Eppendorf tubes. The samples were placed in a PTC- 
100 programmable thermal controller (Genetic Research Instrumentation Ltd) and 
exposed to 25 cycles of 95°C for 30 seconds , 50°C for 15 seconds and 60°C for 4 
minutes. The PCR products were ethanol precipitated as detailed in section 2.2.1.6 
washed with 70% ethanol and finally dried under vacuum before being given to a 
member of the technical services for loading onto the sequencing gel.
2.2.1.11 Large scale preparation of plasmid DNA (Maxiprep)
The plasmid caring the insert in the correct orientation was used to transform 
25 pi E. coli DH5a competent cells as described in section 2.2.1.8. Bacteria were 
plated onto an L-agar plate containing the appropriate antibiotic and the plate 
inverted and incubated overnight at 37°C to allow colony formation. A single colony 
was picked from this plate using a sterile yellow tip, and used to inoculate a sterile 
universal tube containing 5 ml of L-Broth medium with the appropriate antibiotic. 
The tube was put in a shaking incubator at 225 rpm for 6 hr at 37°C and consequently 
the culture was added to 250 ml (for high copy plasmid) or 500 ml (for low copy 
plasmid) of L-Broth containing appropriate antibiotic and returned to the shaking 
incubator overnight.
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The large scale preparation of plasmid was carried using the Qiagen maxiprep 
kit following the manufacturer’s recommendations. The DNA concentration was 
determined as described below and the plasmid DNA was aliquoted and stored at 
minus 20°C.
2.2.1.12 Quantitation of nucleic acids
The concentration of nucleic acid was determined spectrophotometrically in a 
Beckman DU 650 spectrophotometer. Samples were diluted in TE and transferred to 
a quartz cuvette with a pathway of 1 cm. The spectrophotometer was initially 
calibrated using TE buffer only as a blank. The optical density reading were 
obtained at 260 nm and 280 nm; an OD reading of 1 at 260 nm (A260 = 1) 
corresponds approximately to a concentration of 50 ng/ml of double stranded DNA, 
for oligonucleotides an A26o of 1 was taken to correspond to 35 pg/ml and for RNA 
an A26o of 1 was taken to correspond to 40 pg/ml. The ratio between readings at 260 
nm and 280 nm (A26o'A28o) provided an estimate of the sample purity; a ratio of ~1.8 
indicated that preparations contained essentially no protein or phenol contamination.
2.2.2 Cell Culture
2.2.2.1 Cell culture
All cell culture work was performed following strict aseptic techniques inside 
a laminar flow hoods (Class II Microbiological safety Cabins). Cells were incubated 
in dry or humid incubators containing 5% (v/v) C 02 at 37°C and were routinely 
screened for mycoplasma infection using a fluorescent dye technique.
2.2.2.2 Maintenance of cells in culture
Cells were passaged approximately 1 in 5, just before reaching confluence as 
follows: the medium was removed by aspiration from a T175 flask, cells washed 
with 10 ml of phosphate-buffered saline (PBS). After the PBS was aspired, 5 ml of 
0.25% trypsin in PE were added to the cells for two-three minutes and then removed. 
Trypsin was inhibited by the addition of complete medium and cells were detached 
from the flask. The cell suspension was pelleted by centrifugation at 1000 rpm for 5 
minutes at room temperature, resuspended and seeded at the wanted density.
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22.23  Long term cell storage
To freeze cells stocks for storage, confluent cultures were trypsinised, and 
pelleted as described above. The pellet was then resuspended at a concentration of 
approximately 106 cells/ml in medium containing 50% serum and 10% (v/v) DMSO. 
The DMSO in the medium acts as a cryoprotectant but all solutions must be chilled 
as DMSO is toxic to cells at room temperature. Suspensions were divided into 1 ml 
aliquots in 1 ml Nunc cryotubes and placed in a polystyrene box and frozen, well 
insulated, at -70°C overnight to ensure a slow rate of cooling. The ampoules were 
then transferred to a liquid nitrogen bank containing labelled storage rack until 
required.
Frozen stocks were recovered by removing the ampoules from liquid nitrogen 
and placed into a small, covered bucket of water at 37°C. Once thawed, the cells were 
added to 10 ml of the appropriate pre-warmed growth medium, centrifuged, 
resuspended in fresh growth medium and transferred to the flasks.
2.2.2.4 Transient transfection of NIH3T3
Cells were transfected with pwt 929 luciferase reporter plasmid (lpg) and the 
plasmid expressing appropriated sequences of E5 or E5 mutant forms (2 ^g), using 
the calcium phosphate method. Cells (2xl05) were plated in each well of 6 well plate, 
in 5 ml of DMEM medium containing: 1 mM sodium pyruvate, 0.375% sodium 
carbonate, 10% New Born Calf Serum (NBCS) and 2mM glutamine (DMEM-10) the 
day before transfection. For each well the following mixture was set up: 250 pi of a 
DNA solution (up to 3 pg of total plasmid DNA in H2O containing 250 mM CaCl2) 
was added to 250 pi of 2X HEPES buffered saline (HBS). After 16-18 hours 
precipitates were washed off with 2ml of pre-warmed PBS and incubated in low 
serum (0.5%) or growth serum (10%) for further 24 hours before being analysed.
2.2.2.5 Luciferase Assays
Cells were seeded at 2xl05 cells/ml in DMEM-10 in each well of 6 well 
plates the day before transfection, and transfection was performed using the Effectene 
transfection reagents (Qiagen) following the manufacturer’s recommendations. After 
16-18hr, the cells were washed twice with 2 ml PBS and incubated in DMEM-10 or
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0.5% serum (DMEM-0.5) for a further 24 hr. Cells were then washed twice with 
PBS, the PBS was completely removed by aspiration and 300 pi of IX reporter lysis 
buffer added to each well. Following 15 minutes incubation at room temperature, 
cells were scraped off the culture well and each lysate transferred to a 1.5 ml 
Eppendorf tube. Cell debris was pelleted by spinning lysates at 4°C in a 
microcentrifuge at 14000 rpm for 5 minutes. The supernatant was transferred to a 
second Eppendorf tube taking care not to disrupt the cell pellet. The lysate were 
either assayed for reporter enzyme activity immediately or stored at -70°C.
Luciferase activity was determined using a microplate luminometer TR717 
(Tropix), for each sample, 80 pi of lysate and 120 pi of luciferase assay buffer were 
used. Luciferase activity was normalised for protein content determined using the 
bicinichonic acid solution assay (BCA) as described in section 2.2.5.2.
2.2.2.6 Production of stable transfectants
NIH3T3 and COS-7 cells were transfected with a range of plasmids using the 
standard calcium phosphate-mediated precipitation. Cells were plated at a density of 
0.5xl06 in a 90 mm tissue culture dish the day before transfection. The cells were fed 
with 10 ml of DMEM-10 (10% NBCS for NIH3T3 cells; 10% FCS for COS-7 cells) 
on the day of transfection. For each plate the following mixture was set up: 500 pi of 
a DNA solution (up to 5-10 pg of total plasmid DNA in FLO containing 250 mM 
CaCL) was added to 500 pi of 2X HEPES buffered saline (HBS). The addition of the 
DNA solution to the 2X HBS must be done very gradually with constant but gentle 
mixing. The mixture was incubated for 20 to 30 minutes at room temperature during 
which time a fine precipitate formed, giving a slight blue/grey colour to the 
transfection mix. To resuspend the precipitate the mixture was gently pipetted up and 
down. This mixture was then slowly added to the medium and cells were incubated at 
37°C overnight. After withdrawal of the medium, cells were washed twice in PBS 
and then fresh complete medium was added to the dish. The next day cells were 
selected in medium containing 500 pg/ml G418 for 21-28 days, being fed twice 
weekly. After this time, for NIH3T3 cells, G418-resistant colonies were scored and 
picked from each transfection class in order to expand them clonally. COS-7 cells 
stably transfected were pooled together and expanded.
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2.22,1 Isolation of clonal populations
Single G418 resistant colonies were identified and their position marked 
using a microscope ring marker attachment. The cells were then washed twice in 
sterile PBS. A sterile 6 mm stainless steel cloning rings coated with sterile silicon 
grease at the base was then placed over the identified colony thus providing a 
waterproof seal round each isolated colony. A total volume of 100 pi trypsin 
solution, which had been pre-warmed to 37°C, was pipetted within each cloning ring. 
After 1-2 min an equal volume of complete medium was added and the cell 
suspension transferred to a 24-well plate along with 2 ml medium and returned to the 
37°C incubator for expansion into cell lines.
2.2.2.8 Total RNA extraction from cell lines
Cells were grown in a 175 cm2 (T175) flask to approximately 80% confluence 
following the RNAzol B method of extraction (Biogenesis Ltd, UK). Cells were 
washed twice with ice cold PBS and 10 ml of RNAzol B was added directly to the 
flask. The lysate was transferred to a Falcon 2059 polypropylene centrifuge tube and 
1 ml of chloroform was added with vigorous pipetting. The top of the tube was then 
covered with parafilm and the tube was left on ice for 15 minutes to allow phase 
separation to take place. The tube was then centrifuged in a Sorval RC-5B (HB6 
rotor) at 10000 rpm for 15 minutes at 4°C. The upper, aqueous, phase was transferred 
to a fresh tube and an equal volume of isopropanol added. The samples were mixed 
and stored overnight at -20°C to allow precipitation of RNA and the RNA pelleted by 
centrifugation as before. The pellet was resuspended in 5 ml of 75% ice cold ethanol 
(made with diethylpyrocarbonate (DEPC) -treated RNase-free water), and transferred 
to an Eppendorf tube. The RNA was pelleted in a microcentrifuge at full speed at 4°C 
for 30 min, dried on a speed-vacum centrifuge and then resuspended in DEPC-treated 
RNase free water. Samples were treated with DNA-free (Ambion), following the 
manufacturer’s recommendations, to eliminate any possible residual of genomic 
DNA. Finally the concentration of RNA was measured spectrophotometrically as 
described in section 2.2.1.12. RNA samples were aliquoted and stored at -70°C.
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2.1.2.9 Amplification from RNA reverse transcriptase-PCR (RT-PCR)
RNA was prepared as described above and used as template for reverse 
transcription and PCR amplification of cDNA. Firstly cDNA was synthesised from 
RNA by reverse transcription using the Perkin-Elmer Cetus RNA PCR kit. The 
reaction was carried out according to the manufacturers instructions, to the following 
final concentrations: 2.5 mM MgCk, IX PCR kit buffer II (500 mM KC1, 100 mM 
Tris-HCl), 1 mM of each of dATP, dGTP, dTTP, dCTP, 1 unit RNase inhibitor, =sl 
pg RNA, 2.5 units MuLV reverse transcriptase, 0.15 pM of appropriate reverse 
primer and DEPC-treated water to a final volume of 20 pi. As control, for DNA 
contamination, an identical reaction mix was prepared for each sample excluding the 
addition of reverse transcriptase. To verify that the products obtained had the correct 
dimension a RT-PCR reaction was performed with pZipneoHAE5 plasmid as 
template. Finally, to check the reaction parameters and the quality of the RNA 
parallel mixes were set up utilising the RNA, samples with a reverse for actin 
mRNA.
All samples were placed in the thermocycler and further incubated at 22°C for 
10 minutes, 42°C for 15 minutes, 99°C for 5 minutes, and soaked at 4°C for 5 
minutes. The above reaction volume was increased to 100 pi by adding 2 mM 
MgCl2 , IX kit PCR buffer II, 0.15 pM of the appropriate forward primer and 2.5 
units of Taq polymerase. Amplification proceeded for 2 min at 95°C and then 35 
cycles of 94°C for 30 seconds and 60°C for 30 seconds followed by final extension at 
72°C for 10 minutes using the Perkin-Elmer Cetus 9600 thermocycler. The samples 
were then analysed by agarose gel electrophoresis as described in section 2.2.1.5 to 
ensure correct amplification.
2.2.3 Transformation assays
2.2.3.1 Cell population growth in high and low serum culture (Crystal Violet 
assay)
Cells were seeded in 96 well tissue culture plates, in triplicate, at 5x10 
cells/well in 200 pi of DMEM-10. One 96 well plate of cells was set up for each day 
from day 0 to day 6. The outer wells along the edge of the plate were not used and 
instead 200 pi of growth medium was added to each of these wells to reduce 
evaporation from the inner cell-containing wells. After four hours incubation, during
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which time the cells attached to the bottom of each well, growth medium was 
respectively changed to DMEM containing different serum concentrations (10%; 1%; 
0.5%; 0.2%) in the appropriate wells.
The first plate, corresponding to day 0, was treated with 100 pi of 0.1% 
Crystal Violet in 20% Methanol and assayed. Each day thereafter one plate of cells 
was treated with Crystal Violet to determine the growth characteristics of cells in 
each well. This was carried out at daily intervals for 6 days.
Treatment of cells with Crystal Violet was performed as follows: medium 
from all cells in 96 well plate was aspirated off. Each well was washed with pre­
warmed (37°C) PBS before addition of 100 pi Crystal Violet. The plate was placed at 
room temperature overnight. Crystal Violet solution was removed from each well and 
the well was washed extensively in water then dried at room temperature. Following 
wash with water, 100 pi of 1% alkaline SDS and 0.2 M NaOH was added to each 
well and placed on a horizontal shaking platform for 10 minutes at room temperature.
The absorbance of the solubilized dye in each well was determined 
immediately at 590 nm using a automated microwell plate reader (Dynatech 
MR7000).
2.2.3.2 Flow cytometry analysis (FACS)
Flow cytometry analysis (FACS) was used to analyse the cell cycle profile of cell 
lines in different growth conditions.
Cells were seeded at the density of lxlO6 in a 90 mm dish and grown in 
DMEM-10 or DMEM-0.2 for 24 or 48 hr. Cells were harvested by trypsinisation and 
pelleted at 4°C in PBS. Each pellet was washed twice with ice cold PBS, by 
centrifugation. PBS was aspirated off and the pellet resuspended in a small volume of 
PBS (500 pi) and cells were fixed by slow addition of 4.5 ml of ice cold ethanol. At 
this point samples were store at -20°C or used immediately for analysis as follows.
After one hour on ice, cells were pelleted at 4°C for 5min at 2000 rpm. 
Ethanol was aspirated off and each cell pellet was washed once with ice cold PBS to 
remove any residual ethanol. Cells were then again pelleted at 4°C for 5 min at 2000 
rpm then resuspended in 500 pi of staining solution (PBS containing 250 pg/ml of 
RNAse, 20 pg/ml propidium iodide). Samples were left covered at 4°C for at least 3 
hr before analysis.
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Stained cell samples were filtered through 40 pm nylon cell strainer into 
polystyrene round bottom tubes. Samples were assayed using a Becton Dickinson 
FACScan machine and analysed using the “Modfit v2.0” software package.
2.2.3.3 Anchorage-independent growth
The ability of a cell line to form colonies in semi-solid media is taken as a 
phenotypic measure of its degree of transformation. The extent of transformation of 
cell lines was assayed by plating cells in methyl cellulose based medium (methocel).
Methocel medium was made up as follows: 6.4 g of Methocel MC 4000 
(Fluka) was added to 400 ml of distilled water and autoclaved. The methocel was 
left to dissolve with stirring overnight at 4°C. The final working medium was 
obtained mixing an equal volume of the 1.6% methocel and 2xDMEM containing 2 
mM sodium pyruvate, 0.75% sodium carbonate, 4 mM glutamine and 40% Foetal 
Calf Serum (FCS).
Efficiency of methocel colony formation was determined by adding 2.5-5xl04 
cells to 15 ml of 0.8% methocel medium. The 15 ml mix was plated in two 60 mm 
bacterial petri dishes. Bacteriological petri dishes were used to discourage cells from 
adhering to the bottom of the dishes. Cells were left at 37°C for 2-3 weeks before 
being scored and photographed with PanF 50 technical film.
2.2.3.4 Luciferase assay in stable transfectants
Stable transfectants were seeded at 2xl05 cells/well in a 6 well plate the day 
before transfection. 0.2 pg of pwt929, luciferase gene reporter plasmid, was 
transfected on the cells using Effectene transfection agent (Qiagen) following the 
manufacturer’s recommendations. Cells were incubated with the DNA at 37°C for 
16-18 hr. After withdrawal of the medium, cells were washed twice with pre-warmed 
PBS and incubated in DMEM-10 or DMEM-0.5 at 37°C for further 24 hr before 
being harvested and assayed as described in section 2.2.2.5.
For the assay in suspension cells were transfected as described above. After 
an overnight incubation cells were washed with PBS, trypsinised and transferred on a 
60 mm bacterial petri dish in 7 ml of 0.8% methocel medium (see section 2.2.3.3) 
with 10% NBCS and incubated in a humid incubator for 24 hr. The following day 
cells were pelleted as follows: 5 ml of warmed PBS were added to the dish in order 
to dilute the methocel, the content of the dish was then transferred in a 15 ml Falcon
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tube and cells were pelleted for 5 min at 1000 rpm. The pellet was washed twice with 
warm PBS to eliminate any trace of medium. The PBS was then completely removed 
and the pellet was resuspended in 300 pi of IX reporter lysis buffer and left at room 
temperature for few minutes before being assayed as described in section 2.2.2.5.
2.2.3.5 In situ staining for |3-galactosidase
The plasmid pHSV |3-gal expressing the |3-glactosidase gene was used as 
control for the transformation efficiency of the stable clones.
For the staining 2xl05 cells for each cell line were seeded in a six well plate and 
trasnsfected with pHSV P-gal plasmid using Effectene transfection reagent and 
following the same protocol used for the pwt929 plasmid (see section 2.2.3.4). Cells 
were left at 37°C overnight. The following morning cells were washed with PBS and 
fixed in 2% formaldehyde, 0.2% glutaraldehyde in PBS for 5 min at 4°C.
Cells were further washed with PBS and then incubated overnight at 37°C 
with 4 ml of the reaction mix consisting of 1 mg/ml of X-galactopyranoside, 5 mM 
potassium ferricyanide, 5 mM potassium ferrocyanide, 2 mM magnesium chloride in 
PBS. During the incubation the plates were left in the dark.
(3-galactosidase can catalytically convert X-Galactopyranoside and produce an 
intense blue precipitate, consequently it is possible to distinguish the cells expressing 
the p-galactosidase gene from their blue colour. The number of coloured cells scored 
in each plate is an indication of the transfection efficiency of each cell line.
2.2.4 Immunocytochemistry
2.2.4.1 Cell transfection
Cells were transiently transfected using the standard calcium phosphate- 
mediated precipitation. COS-7 cells were plated in a 8 wells chamber slide, 2xl04 
cells per well in 500 pi of DMEM-10 (10%FCS), and left overnight at 37° C in a 
humid incubator. The following day the medium was removed three hours before 
transfection and replaced with 250 pi of fresh medium. For each well of cells to be 
transfected the following mixture was set up: 12.5 pi of DNA solution containing 0.1 
pg of appropriate plasmid, 250 mM CaCl2 and water, once ready the DNA solution 
was added drop by drop to 12.5 pi of 2x HBS, mixing continuously. The final 
solution of 25 pi was left 20-30 min at room temperature and then gently added to
60
the medium while the chambers were moved gently to disperse the solution 
throughout the medium. The cells were returned at 37°C for a further 3 hours for 
COS-7 cells then washed twice with PBS and incubated with 500 pi. Precipitates 
were washed off 16 hours after transfection for NIH3T3 and CHO cells. Twenty-four 
or forty-eight hours after the last wash, cells were fixed in 3% paraformaldehyde, 
mounted and visualised using the confocal microscope
2.2.4.2 Immunofluorescence
Cells, transfected as described above, were washed twice with PBS and fixed 
with a solution of 3% paraformaldehyde in PBS pH 7.4 (250 pi each well) for 15 
minutes. The paraformaldehyde was removed and each chamber was washed three 
times with 100 mM glycine in PBS and two times with PBS. Cells were either 
mounted at this point (as described below in this section) or permeabilized with 
permeabilising solution (250 pi of 0.1% saponin, 10% FCS, and 20 mM glycine in 
PBS) for 20 min and then blocked in 0.1% saponin, 10% FCS in PBS for 1 hr. After 
removing the blocking solution 100-200 pi of primary antibody, at the appropriate 
dilution, was applied to each well for 1 hr.
After the incubation, the cells were washed 3 times for 5 min with the 
blocking solution and incubated with 200 pi of secondary antibody at the 
recommended dilution for one hr. Cells were finally washed three times with the 
blocking solution and mounted using Vectashield™ solution. All operations were 
carried out at room temperature and during the incubations cells were kept in the 
dark. Cells were analysed at the confocal microscope (Biorad Nikon Diaphot inverted 
microscope) using the appropriate filter.
For the BODIPY® TR ceramide staining, prior to fixation, cells were washed 
twice with 25 mM Hepes (pH 7.5) in DMEM serum free (H-DMEM) and incubated 
with 5 pM of BODIPY-TR in H-DMEM for 30 min at 4°C. Subsequently the cells 
were washed two times with H-DMEM and incubated at 37°C for 30 min. At the end 
of incubation cells were further washed with H-DMEM, then fixed, mounted and 
analysed as described above.
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2.2.5 Protein Analysis
2.2.5.1 Protein preparation and Protein Concentration measurement for 
Western Blot Analysis
For western blot lxlO6 cells were seeded in a 90 mm dish (two for each cell 
lines). The following day the medium was aspirated from the plates and cells 
incubated in 10% or 0.5% medium for further 24 hr. Cells were then washed twice 
with ice cold PBS, the PBS was completely removed by aspiration and a 100 p i of 
boiled SDS-PAGE lysis buffer (2.1.3) was added at the cell monolayer. Cells were 
consequently scraped and transferred in a 1.5 ml microcentrifuge tube and boiled for 
five minutes. Consequentially cells were sonicated using an MSE Soniprep 150 
sonicator. Cell debris was pelleted at 14000 rpm for 10 min at 4°C and the 
supernatant transferred to a new microcentrifuge tube. To measure protein 
concentration 10 p i of total extract were diluted in 490 p i of water and transferred to 
a 500 p i quartz cuvette with a pathway of 1 cm, 10 p i of lysis buffer in 490 pi of 
water were used as blank. The absorbance of each sample was read using a Beckman 
DU 650 spectrophotometer at the fix wavelength of 280 nm. The concentration of 
each sample was calculated knowing that the absorbance of 1.0 OD at 280 nm 
corresponds approximately to a concentration of 1 mg/ml protein. Aliquots of 30 pg 
to 150 pg were made up in lysis buffer and prepared for loading with equal volume of 
2X SDS loading buffer. Samples were boiled for 5 min and protein separated by 
SDS-PAGE as described in section 2.2.5.4.
For the assay in suspension 5xl06 cells were resuspended in 30 ml of 0.8% 
methocel DMEM-10 and transferred on a 150 mm bacterial petri dish and incubated 
in a humid incubator for 24 hr or 48 hr. At the end of the incubation time the cells 
were pelleted as follows: 20 ml of ice cold PBS was added to the dish in order to 
dilute the methocel, the content of the dish was then transferred in a 50 ml Falcon 
tube and cells were pelleted for 5 min at 1000 rpm at 4°C. The pellet was washed 
twice with cold PBS to eliminate any trace of medium, before the last wash cells 
were moved to a microcentrifuge tube and pelleted as above. The PBS was then 
completely removed and the pellet was resuspended in 100 pi of boiled SDS-PAGE 
lysis buffer, boiled for 5 min and then cooled down on ice. Samples were stored at - 
70 or assayed for protein concentration as described above. Protein extracts (30-100 
pg) were then prepared for loading with equal volume of 2X SDS loading buffer.
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2.2.S.2 Protein preparation and Protein Concentration measurement for 
Kinases assays
Cells were seeded in 150 mm tissue culture dishes at 3xl06 cells for dish in 
25 ml of DMEM-10 and left at 37°C overnight. The following day the medium was 
changed and cells left in DMEM-10 or DMEM-0.5 for further 24 hr. The plates were 
then put on a ice bath for 10 min and then washed twice with ice cold PBS. After the 
PBS was completely removed, 500 pi of kinase lysis buffer (2.1.3) were added to the 
cells and carefully distributed on the entire surface of the plate. Cells were frozen by 
placing the plates on methanol/dry ice bath for 30 sec, then thawed on ice and 
transferred in a microcentrifuge tube and frozen in methanol/dry ice a second time or 
store at -70°C.
For the assay in suspension 5xl06 cells were resuspended in 30 ml of 0.8% 
methocel DMEM-10 and transferred on a 150 mm bacteria petri dish (three dishes 
were prepared for each cell line) and incubated in a humid incubator for 24 or 48 hr. 
At the end of the incubation time the cells were pelleted as follows: 20 ml of ice cold 
PBS was added to the dish in order to dilute the methocel, the content of the dish was 
then transferred in a 50 ml Falcon tube and cells were pelleted for 5 min at 1000 rpm. 
The pellet was washed twice with cold PBS to eliminate any trace of medium, before 
the last wash cells were move to a microcentrifuge tube. The PBS was then 
completely removed and the pellet was resuspended in 500 pi of ice cold kinase lysis 
buffer and frozen by placing the tubes on methanol/dry ice for 30 sec, subsequently 
cells were thawed on ice and frozen in methanol/dry ice a second time or stored at - 
70°C.
Lysates were spun at 14000 rpm for 10 min at 4°C and supernatant 
transferred in a fresh microcentrifuge tube and protein measured using BCA/CUSO4 
as described below.
10 pi of protein solution was placed in a 96 well plate in duplicate, 200 pi of 
developing solution consisting of 5 ml BCA and 100 pi of 4% (w/v) CuS04 (copper 
II sulphate pentahydrate solution) was added to the protein samples and the plate 
incubated at 37°C for 30 minutes. The assays is based on the ability of proteins to 
reduce alkaline Cu(II) to Cu(I) in a concentration-dependent manner. BCA is a highly 
specific chromogenic reagent for Cu(I), forming a purple complex with an
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absorbance maximum at 562 nm. After the incubation the absorbance of each sample 
was read at 590 nm using a Dynatech MR7000 automatic plate reader.
The absorbance reading was converted to concentration in pg/ml for each 
sample using a standard curve generated from a series of control BSA solutions of 
known concentration. The actual concentration of each protein sample was calculated 
after multiply by the relevant dilution factor.
2.2.5.3 SDS-Polyacrylamide Gel Electrophoresis
Sodium dodecyl sulphate (SDS) gels containing different concentration of 
polyacrylamide (i.e. 7.5%, 10%, 15%) were used to resolve proteins according to 
their molecular weight. For a single 1 mm, 10% polyacrilamide gel, for example, the 
solution was prepared as follows: 7.8 ml of water, 6.7 ml of 30% acrylamide, 5 ml of
1.5 M Tris-HCl pH 8.8, 0.2 ml 10% SDS, 0.2 ml 10% ammonium persulphate (APS) 
and 8 pi of TEMED.
The resolving gel was poured between two glass plates, previously washed 
with 1% decon, carefully rinsed in water and finally cleaned with 70% ethanol. A 
thin layer of water saturated butan-l-ol was added at the top of the gel and the 
solution left to polymerise at room temperature. The layer of water saturated butan-l- 
ol was washed away at completed polymerisation and a 5% stacking gel was poured 
at the top of the resolving gel.
The stacking gel was prepared as follows: 6.8 ml of water, 1.7 ml of 30% 
acrylamide, 1.25 ml of 1M Tris-HCl pH 6.8, 0.1 ml of 10% SDS, 0.1 ml of 10% APS 
and 10 pi of TEMED.
Once ready, the gel was transferred to an electrophoresis tank filled with 
running buffer, the comb was removed from the stacking gel and each well carefully 
washed. The Rainbow™ protein markers (high molecular weight range 200-14 kDa 
and low molecular weight range 45-14 kDa) and the samples solutions were prepared 
for loading as follows: 50-100 pg of protein extract or 5 pi of the markers were 
mixed with equal volume of 2X loading buffer, boiled for 5 min and then cooled 
down on ice. The samples were loaded into consecutive wells between the high 
molecular weight marker on the left and the low molecular weight marker on the 
right.
The gel was run at 20 mA for approximately 20 min to allow the samples to 
enter in the stacking gel, and at 40 mA constant current for ~2 hr.
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2.2.5.4 Western Blotting
As soon as the blue dye had run off the bottom the gel run was stopped and 
the protein transferred to a nitro-cellulose membrane by semi-dry blotting. The gel 
was removed from the glass plates and soaked for 10 min in transfer buffer (2.3.1), 
while 8 pieces of Whatman 3MM paper and a piece of nitro-cellulose membrane 
(ECL-hybond) of the same dimension of the gel, were wetted in transfer buffer.
Four sheets of the Whatman 3MM paper were placed on the transfer 
apparatus and the nitro-cellulose put on the top of them followed by the gel. Any air 
bubbles between the gel and the membrane were eliminated by gently rolling a 
plastic pipette over the gel. Finally the four remaining Whatman 3MM sheets were 
placed on the top of the gel, the apparatus closed and a voltage of 20V applied for 1 
h.
Once the transfer was completed the membrane was blocked for 1 hr in 5% 
Marvel (dry milk) in TBST (TBS plus 0.1% Tween) at room temperature. 
Subsequently the membrane was washed for 5 min in TBS and incubated with the 
appropriate primary antibody (diluted following supplier’s recommendation in 
3%BSA, 0.02% NaAzide in TBS) and left shaking at 4°C overnight (Table 2.2).
The membrane was then washed three times for 10 min each with TBST and 
incubated in 50 ml of blocking solution containing 1/5000 dilution of the appropriate 
secondary antibody linked to horse-radish peroxidase and left shaking for 1 hr at 
room temperature. After three further washes with blocking solution of 10 min each 
the blot was rinsed in TBST. The membrane was then placed on cling film and 
covered with a detection solution consisting of an equal volume of Amersham 
Enhanced chemiluminescence (ECL) reagents 1 and 2 for 1 min. The liquid was then 
removed from the nitro-cellulose membrane and this was wrapped in cling film and 
placed in a film cassette to be exposed to a Fuji-XR film at appropriated time 
depending on the strength of the signal.
2.2.5.5 Immunoprecipitation and Kinase reaction
Aliquots of 500 pg protein were made up to 500 pi in lysis buffer. 2 pi of the 
appropriate antibody were added to each tubes and the samples placed in rollers at 
4°C for 1.5 hr. Protein-A sepharose was pre-swollen in PBS for 1 hr at 4°C and then 
washed three times with PBS and three times with kinase lysis buffer and finally
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resuspended in kinase lysis buffer to a 50% slurry solution. After the incubation with 
the antibody 12.5 p i of 50% slurry protein A-sepharose were added to each tube then 
placed back on rollers for 1.5 hr. After the incubation 12.5 p i of sepharose CL 4B, 
prepared as a 50% slurry solution in lysis buffer was added to each tube as carrier. 
The samples were spun down for 30 sec at maximum speed at 4°C and the 
supernatant discarded, the sepharose beads were washed three times in ice cold 
kinase lysis buffer and two times in ice cold kinase buffer. After the last wash the 
supernatant was removed and 20 p i of reaction buffer (0.05 pg/pl Histone HI, 20 pM 
ATP, 10 (xCi y-32P-ATP, 50 mM HEPES, 50 mM NaCl, 10 mM MgCl2, 1 mM DTT) 
were added to each tubes and the samples incubated at 30°C for 30 min. The reaction 
was stopped by adding 20 p i of 2X loading buffers and boiling for 5 min. The 
samples were loaded in a 10% acrylamide gel.
At the end of the run the gel was washed in fixing solution (50% methanol 
and 10% acetic acid) for an hour, during which the solution was changed four times, 
and then in 10% glycerol for a following hour. The gel was finally dried for 2 hr at 
80°C in an Appligen Slab gel dryer and exposed to X-ray film for the appropriated 
time and analysed at the phosphorimager.
2.2.6 MAPK inhibitors
The effects of two MAPK inhibitors (PD98059 and U0126) to the cells 
maintained in suspension culture were determined.
For the assay in suspension cells (3xl06) were resuspended in 10 ml of 0.8% 
methocel DMEM-10 containing PD98059 or U0126 inhibitors (final concentration 
50 pM and 20 pM in DMSO respectively). As control cells treated with only DMSO 
were prepared. Plates were incubated in a humid incubator at 37°C for 48 or 72 
hours.
At the end of the incubation time cells were harvested and total protein 
extracted as described in section 2.2.5.1. Protein concentration was measured and 
aliquots of 30 pg were made up in lysis buffer and prepared for western blot analysis 
as described in section 2.2.5.5. PD98059 inhibitor blocks the activation of MEK 
while U0126 specifically inhibits MEK in both active and inactive forms.
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Table 2.2 Summary of antibodies
Antibodies Supplier-Cat. Number Application-Dilution
Cyclin A Santa Cruz sc-596 WB 1:500
Cyclin A Santa Cruz sc-751 IP 1:250
Cyclin D1 Santa Cruz sc-450 WB 1:1000
Cyclin E Santa Cruz sc 481 WB 1:500 
IP 1:250
CDK2 Santa Cruz sc 163 WB 1:500 
IP 1:250
CDC2 Santa Cruz sc-54 WB 1:500
pRb Total Pharmigen-14001A WB 1:1000
pRb Ser-780 NEBiolab-9307S WB 1:1000
pl07 Santa Cruz sc-318 WB 1:5000
pl30 Santa Cruz sc-317 WB 1:5000
p27 Santa Cruz sc-528 WB 1:500
Total ERK 1,2 Sigma M5670 WB 1:1000
Phospho ERK 1,2 Sigma M8159 WB 1:1000
GFP Babco MMS-118 WB 1:1000
a-Tubulin Sigma T9026 WB 1:1000
WB: western blotting 
IP: immunoprecipitation
All solutions were made up in 3% BSA in TBS
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CHAPTER 3: DETECTION AND LOCALISATION OF 
THE BOVINE PAPILLOMAVIRUS TYPE 4 E5 
PROTEIN
3.1 The E5 proteins of papillomaviruses
The E5 protein family is a group of small membrane-localised peptides 
comprising E5 proteins from animal and human papillomavirus (HPVs). The gene is 
not well conserved at the DNA level between HPVs, or animal viruses although there 
is a conservation of the physico-chemical properties in that the proteins are all highly 
hydrophobic and membrane bound (Figure 1.2), (Burkhardt et al., 1989; Conrad et 
al., 1993).
It is notoriously difficult to detect the expression and localisation of this 
group of proteins. Like most viral proteins, they are low-abundance proteins 
expressed at specific stage of the viral cell cycle, moreover their hydrophobic nature 
have rendered their purification extremely difficult because the proteins are 
insoluble. Antibody reagents directed against E5s are consequently limited and not 
very efficient.
In order to overcome the limitations in the detection of E5 proteins the 
addition of peptides as tags to the N-terminus of the proteins has been used (Schlegel 
et al., 1986; Conrad et al., 1993). Moreover, for most of the studies the E5 ORFs 
have been inserted into vectors where their expression is driven by heterologous, 
strong promoters (Schlegel et al., 1986; Burkhardt et al., 1989; Leechanachai et al., 
1992).
In cells transiently or stably transfected with E5s, the proteins have been 
mostly detected by immunoprecipitation after metabolic labelling of cellular proteins 
with different radioactive amino acids ([35S]-methionine, [35S]-cysteine and [3H]- 
leucine) (Schlegel et al., 1986; Conrad et al., 1993; O'Brien et al., 2001).
3.1.1 Detection of the Bovine Papillomavirus type 4 (BPV-4) E5 
protein
The BPV-4 E5 ORF could not be expressed in bacteria, probably because of 
the high hydrophobicity of the peptide (Jackson et al., 1991). In 1993 Pennie and co­
workers used an antiserum raised in rabbits against a synthetic oligopeptide 
corresponding to C-terminal 10 amino acids of E5. The cellular localisation of the 
viral protein was investigated by immunostaining primary bovine fibroblasts (PalF) 
transiently transfected with a vector expressing the E5 gene. E5 showed a clear 
membrane localisation: it was found in the nuclear membrane, in the endoplasmic 
reticulum (ER), in the Golgi apparatus and occasionally on the cell surface (Pennie et 
al., 1993).
In vitro synthesis and characterisation of BPV-4 E5 was also performed 
(Faccini et al., 1996). BPV-4 E5, tagged with the 11 amino acid sequence from the 
influenza virus haemagglutinin (HA), was in vitro transcribed and translated in the 
presence of microsomes and labelled with [ S]-methionine. A specific band of ~7 
kDa was detected by immunoprecipitation with a monoclonal antibody against HA. 
This is the predicted size of E5 as deduced from its amino acids sequence.
In more recent studies the HA tagged protein was detected in stably 
transformed PalFs by dot blot analysis using the anti-HA antibody (O’Brien et al., 
1999).
Finally BPV-4 E5 was detected in clonal populations of NIH3T3 cells. BPV-4 
E5 was immunoprecipitated with an antiserum raised against the last 10 amino acids 
of the protein after cells had been metabolically labelled with [3H]-leucine. 
Polypeptides of different molecular weights (14, 40 and 46 kDa) could be visualised 
by autoradiography. The authors proposed that the aberrant migration of these 
proteins could be the result of dimers or higher-order oligomer formation by E5 
(O'Brien et al., 2001).
3.2 The Green Fluorescent Protein
3.2.1 Discovery and structure
The green fluorescence protein (GFP) was discovered by Shimomura et al., in 
1962, as a companion protein to aequorin, a chemiluminescent protein from the 
jellyfish Aequorea Victoria (Shimomura et al., 1962). The protein was subsequently 
purified and crystallised, its absorbance spectrum measured and fluorescence 
quantum determined (Morise et al., 1974). Prendergast & Mann (1978) estimated its 
molecular weight at 27 kDa (Prendergast and Mann, 1978). The crucial 
breakthroughs in the use of GFP came, only years later, with the cloning of the gene
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(Prasher et al., 1992) and the demonstration that its expression in other organisms 
creates fluorescence. This revealed that the gene contains all the information 
necessary for the post-translation synthesis of the chromophore and jellyfish-specific 
enzymes are not needed (Chalfie et al., 1994; Inouye and Tsuji, 1994).
The natural fluorescence of GFP depends on a chromophore formed from 
residues 65-67 which are serine-tyrosine-glycine in the native protein (Heim et al., 
1994). Its three dimensional structure consists of eleven p-strands forming a hollow 
cylinder through which is threaded a helix running up the axis of the cylinder. The 
chromophore is attached to the a-helix and is buried in the centre of the cylinder 
(Yang et al., 1996).
3.2.2 Application of the green fluorescent protein
GFP has become a versatile reporter protein for monitoring gene expression 
and protein localisation in a variety of cells and organisms. GFP fluorescence is 
stable, species-independent, and can be monitored non-invasively in living cells by 
both fluorescence microscopy and flow cytometry. Moreover, a variety of N-and C- 
terminal proteins fused with GFP have been constructed and shown to maintain both 
the fluorescence properties of native GFP and the biological function of the fusion 
partners (Kain et al., 1995). In order to overcome some undesirable proprieties of the 
wild type GFP, including low fluorescent intensity when excited by blue light at 470 
nm, a variant form has been produced. A mutant of GFP that fluoresces 35 times 
stronger than the wild type GFP (Cormack et al., 1996) has been combined with a re­
engineered GFP gene sequences containing codons preferentially found in highly 
expressed human proteins. The mutant has been called EGFP (Enhanced GFP) and 
bears a serine to threonine mutation at codon 65 and a phenylalanine to leucine at 
position 64. It presents a single peak of excitation at 490 nm and emits at 510 nm. (I 
will be referring to EGFP as GFP hereafter).
3.2.2.1 Proteins tagged with GFP
There are various cases in the literature where viral proteins have been tagged 
to GFP without any effect on their biological functions.
To detect HPV 11 E5a expression in eukaryotic cells, GFP was fused to the 3’ 
of the E5a gene (Brown et al., 1998). GFP has been inserted into human
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immunodeficiency virus type 1 (HIV-1) genome by replacing the nef gene. The GFP- 
expressing HIV-1 replicated efficiently in established human T cells and GFP was 
maintained in the viral genome during prolonged passages (Lee A.H. et al., 1997). 
GFP was inserted also in a Herpes simplex virus type 1 (HSV-1) genome in frame 
with the capsid protein VP26. The engineered virus was shown to grow as well as the 
wild type in cell culture and the fusion protein was incorporated into intranuclear 
capsids and mature virions (Desai and Person, 1998).
GFP has been used to tag a large number of transmembrane proteins (type I or 
type II) and it does not interfere with the assembly, insertion in lipids bilayer or 
transport of these proteins. TGN38, for example, is a type I integral membrane 
protein which cycles between the trans-Golgi network (TGN) and the cell surface, 
forms of TGN38 fused at the N- or C-terminus of GFP showed identical response to 
drugs and temperature blocks known to perturb intracellular morphology and 
membrane traffic pathways. Moreover GFP did not interfere with the transport of 
TGN38 along the secretory pathway or its retention in TGN (Girotti and Banting, 
1996).
From the properties listed above it appeared that the use of GFP could 
overcome the difficulties encountered so far in the detection of E5. For the nature of 
the research we wanted to pursue, it was necessary to have a reliable and consistent 
system to visualised E5 routinely. For these reasons two fusion forms of E5 with 
GFP were created in the attempt to visualise the location of the viral protein within 
the cell. Moreover, the GFP tagged form of E5 has been utilised in transformation 
assays (growth in absence of mitogens and substratum), to verify that E5 
transforming abilities had been maintained (Chapter 4).
3.3 Experimental work
3.3.1 Construction and detection of BPV-4 E5 fusion forms with 
GFP
3.3.1.1 Cloning and DNA sequencing
In order to obtain two fusion proteins of BPV-4 E5 with GFP the E5 sequence 
was cloned in pEGFPC3 and pEGFPN2 vectors, at the C-terminus and N-terminus of 
GFP respectively using a PCR cloning strategy (section 2.2.1). The constructs were
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consequently sequenced to confirm their identity and called GFP-E5 and E5-GFP 
(Figure 3.1).
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3.3.1.2 Visualisation of GFP-E5 and E5-GFP in transient transfectants
COS-7, NIH3T3 and CHO cells were transiently transfected with plasmids 
expressing GFP-E5 or E5-GFP and the vector expressing GFP alone, using a calcium 
phosphate precipitation method (section 2.2.4.1). Precipitates were washed off three 
hours after transfection for COS-7 cells and 16 hours for NIH3T3 and CHO cells. 
Twenty-four or forty-eight hours after the last wash, cells were fixed in 3% 
paraformaldehyde, mounted and visualised using the confocal microscope as 
described in section 2.2.4.2.
In all three cell types used, GFP transfected cells showed a green fluorescence 
uniformly distributed in the cytoplasm and nucleus, while both GFP-E5 and E5-GFP 
expressing cells presented a well-delineated area of fluorescence adjacent to the 
nucleus (Figure 3.2).
The fact that both fusion forms of E5 presented the same perinuclear 
localisation despite having GFP at the N or C terminus suggested that the cellular 
localisation of the fusion proteins was exclusively due to E5 sequence. However it 
has not been possible to rule out completely that the perinuclear fluorescence of 
GFP-E5 and E5-GFP transfected cells was due to mis-localisation caused by the GFP 
epitope because any attempt to detect BPV-4 E5, or the HA tagged form of E5, with 
an anti E5 antibody or antibodies against the HA epitope failed. However, E5 has 
been shown to have an ER and Golgi location on one previous occasion (Pennie et 
al., 1993).
All cells even with the weakest fluorescence presented a similar distribution 
of GFP-E5, and this excluded the possibility that the cellular location of the GFP-E5 
was due to its over-expression (data not shown). Taken all together these data sustain 
the hypothesis that GFP-E5 and E5-GFP location in the cell is likely to represent 
BPV-4 E5 natural localisation.
Because the two fusion proteins showed an identical cellular localisation in 
all cell types, only GFP-E5 form was utilised in subsequent experiments and all 
transient expression experiments were carried out in COS-7 cells.
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Figure 3.2 Confocal images of GFP, GFP-E5 and E5-GFP expressed in COS- 
7, NIH3T3 and CHO cells
Cells were transfected with 0.1 pg °f DNA, fixed after 24 hr with 3% 
paraformaldehyde and visualised at the confocal microscope. All images have 
been captured with 60X objective lens, images have been further magnified in 
Microsoft Powerpoint.
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3.3.1.3 Visualisation of GFP-E5 in stable transfectants
COS-7 and NIH3T3 cells stably expressing GFP and GFP-E5 were produced 
to confirm that cells could sustain long term expression of the fusion protein and that 
GFP-E5 localises in the same sub-cellular compartment when stably expressed.
GFP and GFP-E5 constructs were transfected in COS-7 and NIH3T3 cells 
using the calcium phosphate-precipitation method as described in section 2.2.2.6. 
After 21-28 days of G418 selection, resistant colonies from COS-7 cells were pooled 
together and expanded. From NIH3T3 plates single, resistant colonies were picked in 
order to expand them clonally as described in Chapter 4.
When analysed at the confocal microscope the cellular distribution of GFP 
and GFP-E5 confirmed the distribution observed in transient expression experiments 
(Figure 3.3, 4.2).
3.3.1.4 Detection of GFP-E5 protein expression in stable transfectants
As mentioned before an important advantage in the use of GFP fusion 
proteins is the possibility to detect expression of otherwise not easily detectable 
proteins, like BPV-4 E5.
In order to visualise protein expression in western blot, whole cell extracts 
(100 pg) from GFP and GFP-E5 expressing cells were prepared and fractionated by 
SDS-PAGE, transferred to a nitrocellulose membrane and probed with an anti GFP 
antibody (Babco). In COS-7-GFP cells a specific band with an apparent molecular 
weight of 27 kDa, corresponding to the reported electrophoretic mobility of GFP, 
was detected. The GFP-E5 expressing cells showed a specific band of -34 kDa. This 
is the predicted size of the fusion protein resulting from the apparent 7 kDa 
molecular weight of E5 and the 27 kDa of GFP (Figure 3.3).
Here we demonstrated that in the GFP fusion form BPV-4 E5 can be easily 
visualised and detected, as predicted, and for the first time its expression could be 
observed in western blot.
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3.3.1.5 Colocalisation of GFP-E5 with ER and Golgi apparatus marker;
The perinuclear fluorescence shown by GFP-E5 and E5-GFP suggested t that 
the signal was coming from the two principal perinuclear cellular organelles tie ER 
and the Golgi apparatus.
In order to define better the exact sub-cellular location of 3FP-1-E5, 
colocalisation studies with an ER or a Golgi apparatus marker were p e r f o r m e d  ussing 
the confocal microscope. The ER marker is an antibody against the P '°kein  
Disulphide Isomerase (PDI) (Vaux et al., 1990), an enzyme that ca ta lys t  the 
rearrangement of disulphide bonds o f  itinerant and resident ER proteins. ThF p ot,tein 
is characterised by a KDEL motif and its presence in the ER is achieved by a ren e  wal 
system (see section 3.3.2). As a Golgi marker we used a Texas-red conjugated 
ceramide homologue (BODIPY^ TR  ceramide) from Molecular Probes that staiis the 
Golgi apparatus through the interaction with endogenous lipids and cholesterol 
(Pagano et al., 1991).
COS-7 cells, transfected with 0.1 pg of GFP-E5, were fixed jn 
paraformaldehyde and pcrmeabilised with 0.1% saponin in PBS. After one h(our 
incubation with the blocking solution cells were stained with anti-PDI antibody 
(dilution 1:200 in blocking solution) for one hour at room temperature. The primary 
antibody was washed off with blocking solution and the secondary antibody iarnti- 
mouse antibody texas-red conjugated) added for one hour. Cells were finally wash<ecj? 
mounted and visualised at the confocal microscopy (section 2.2.4). For the stainijng 
of the Golgi apparatus live transfected COS-7 cells were incubated with 5 of 
BODIPY-TR ceramide and left at 4°C for 30 min to allow the marker to accum ulate 
on the plasma membrane. The cell metabolism was switched back on with a 30 m1in 
incubation at 37°C so that the marker was transported and accumulated in the ( j o  lgi 
apparatus. Cells were then fixed and mounted as described in section 2.2.4.2.
Cells were visualised at the confocal microscope to investigate the relative 
spatial localisation of  the organelles markers and GFP-E5. Appropriate wavelengths 
were used to excite the chromophores ( -5 9 6  nm for texas red, -  490 nm for ^ P )  
and the emission spectra (615 nm for texas red and 510 nm for GFP) were c4P1ured 
with different filters. Signals were captured separately then the pictures from the t\v0 
channels were overlapped and the result analysed. Colocalisation studies are bflsed
the principle that red and green dyes form a yellow image from spectral summation 
when the signals colocalise.
GFP-E5 is partially localised in the ER. When the red signal, coming from the 
ER marker was overlapped with the green of GFP-E5 the two fluorescence could still 
be distinguished and the region of colocalisation, characterised by the yellow 
fluorescence, was only minimal (Figure 3.4 a) maybe due to the partially distribution 
of the ER marker in the Golgi. On the contrary when the Golgi apparatus marker was 
used, most of the green fluorescence of GFP-E5 was converted to yellow showing 
that GFP-E5 is mainly localised in the Golgi (Figure 3.4 b).
The observations that GFP-E5 is located mainly in the Golgi apparatus 
supports what previously reported by Pennie et al (1993), and concords with the 
BPV-1 E5 and HPVs E5 subcellular localisation (Burkhardt et al., 1989; Conrad et 
al., 1993).
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Figure 3.4 a, b GFP-E5 is mainly located in the Golgi apparatus
a) On the left COS-7 cells transiently expressing GFP-E5 and stained with the ER 
marker (anti PDI antibody), on the right the result of the merge between the two 
channels.
b) On the left COS-7 cells transiently expressing GFP-E5 and stained with the 
Golgi marker (BODIPY-TR ceramide), on the right the result of the merge 
between the two channels.
In both a and b yellow colour indicates colocalisation. Images have been captured 
with a 60X objective lens and colour pictures have been magnified in Microsoft 
powerpoint.
Figure 3.4 a, b
a
GFP-E5 ER Staining Merge
b
GFF-E5 GOLGI Staining Merge
3.3.2 The importance of a Golgi location for BPV-4 E5 protein
3.3.2.1 Introduction
Immunochemistry and immunoelectron microscopy studies revealed that 
BPV-1 E5 is located within both ER and Golgi apparatus and to a lesser degree at the 
cell surface. The demonstration that BPV-1 E5 activated immature forms of platelet- 
derived growth factor receptor type (3 (PDGFJ3-R) that are in transit through the 
Golgi led to the speculation that this organelle was a critical location for E5 during 
cell transformation (see Chapter 1). To test this hypothesis a form of BPV-1 E5 
bearing a SEKDEL (BPV-1 E5/KDEL) retrieval signal for the ER (Townsley et al., 
1993) was used in transformations studies (Sparkowski et al., 1995). It is known that 
proteins bearing the KDEL amino acids are resident in the ER thanks to a retrieval 
system that involves a receptor protein that normally accumulates in the Golgi and is 
redistributed in the ER in the presence of ligands after it has picked up its cargo. 
BPV-1 E5/KDEL was localised in the ER and it was deficient for transformation in 
mouse fibroblasts (Sparkowski et al., 1995). These results led to the conclusion that 
the Golgi location is necessary for BPV-1 E5 transforming activity.
In the attempt to test if also BPV-4 E5 required to reside in the Golgi 
compartment or to travel through it in order to transform NIH3T3 cells, a mutant 
form of the viral protein bearing the SEKDEL sequence was generated (O'Brien and 
Campo, 1998). This form of E5 maintained the ability to transactivate the cyclin A 
promoter under normal growth conditions but was not capable of transactivating the 
cyclin A promoter in suspension cells (O'Brien and Campo, 1998); (for the relation 
between transformation activity of E5 and its mutant forms and their ability to 
transactivate cyclin A promoter see Chapter 6). These data suggest that the cellular 
location of E5 is crucial for its ability to transactivate cyclin A promoter and that at 
least a portion of E5 molecules adopt an orientation in which the C-terminus is 
lumenal in membranes compartments. In these studies, however, it has not been 
possible to show where BPV-4 E5/KDEL was localised within the cell.
3.3.2.2 Experimental results and discussion
To confirm that the introduction of the SEKDEL sequence at the C-terminus 
of E5 leads to the retention of the viral protein in the ER, localisation studies were 
performed with a fusion form of the E5 mutant with GFP. As control we used a
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second mutant in which the C-terminus was extended by six amino acids (SGGGEV) 
that have been shown not to influence BPV-1 E5 localisation (Sparkowski et al., 
1995) and BPV-4 E5 ability to transactivate cyclin A promoter both in normal 
condition and suspension culture (O'Brien and Campo, 1998). Also this control 
mutant was expressed as a fusion form with GFP.
The cloning was performed using a PCR strategy utilising the E5C3 forward 
and the E5/KDEL or E5/GGEV reverse primers (section 2.2.1; Table 2.1). The 
constructs obtained are illustrated in Figure 3.5. COS-7 cells were transiently 
transfected with GFP-E5/KDEL, GFP-E5/GGEV and GFP-E5 using the calcium 
phosphate method, precipitates were washed three hours after transfection and cells 
visualised after 16 hr, 24 hr and 48 hr by confocal microscopy.
GFP-E5/KDEL shows a perinuclear localisation comparable to GFP- 
E5/GGEV and GFP-E5 at all different times tested (Figure 3.6 shows staining after 
24 hr incubation). These data demonstrate that the retrieval signal was not sufficient 
to relocate E5 to the ER.
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Figure 3.6 GFP-E5/K DEL and G FP-E5/GGEV mutants show a subcellular  
localisation similar to GFP-E5
COS-7 cells were transiently transfected with 0.1 pg of DNA of specific plasmid, 
fixed in 3% paraformaldehyde and visualised at the confocal microscope 24 hr after 
transfection.
3.3.3 Role of the amino acids secondary structure of BPV-4 E5 in 
the protein cellular location
3.3.3.1 Introduction
The N-terminus, the first 30 amino acids, of BPV-4 E5 comprises a very 
hydrophobic region, theoretically cable of forming a transmembrane a-helix (Figure 
1.2). It has been shown that the secondary structure of the E5 hydrophobic region is 
important for the protein ability to transactivate the cyclin A promoter. Two mutants 
of E5 were tested: A15P-A20P mutant, where the alanine residues at position 15 and 
20 had been converted to a proline, which has the property of forcing a bend in the 
main chain and disrupting an a-helix; A15G-A20G mutant, where the same alanine 
were mutated to glycine residue, a conservative mutation which should not disrupt an 
a-helical conformation. While A15G-A20G shows a low promoter trans-activation 
activity but still significantly above background, the introduction of proline residues 
abolished cyclin A promoter transactivation (Ashrafi, 1998).
These data suggest that substitution of two amino acids could alter the a-helix 
conformation of the hydrophobic domain with consequences for cyclin A promoter 
activation and also emphasise the importance of the nature of these residues for the 
E5 functions.
3.3.3.2 Experimental results and discussion
To determine whether the disruption of the postulated a-helix domain of 
BPV-4 E5 has an effect on protein localisation the E5 mutant forms A15P-A20P and 
A15G-A20G have been used in localisation studies.
A15P-A20P and A15G-A20G were cloned in pEGFPC3 vector, at the C- 
terminus of GFP by PCR using E5C3 forward and E5C3 reverse primers (section 
2.2.1). The constructs obtained were called GFPA15P-A20P and GFPA15G-A20G 
(Figure 3.5). The plasmids were transiently expressed in COS-7 cells for 24 hours, 
cells were then fixed, mounted and analysed at the confocal microscope.
Both mutants show a perinuclear location, similar to E5 wild type (Figure
3.7).
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GFPA15P-A20P
GFPA15G-A20G
Figure 3.7 A double point mutation within the hydrophobic body o f  BPV-4 E5 
does not influence its cellular localisation
COS-7 cells were transiently transfected with 0.1 pg of DNA palsmid, fixed and 
visualised at the confocal microscope 24 hr after transfection.
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3.3.4 Is E5 expressed on the plasma membrane?
3.3.4.1 Introduction
It has been previously reported that BPV-4 E5 is occasionally detected in the 
plasma membrane (Pennie et al., 1993); in the same way BPV-1 E5 has been shown 
to have a predominantly ER and Golgi location and been only in low concentration 
on the surface. While it has been established that the Golgi location is required for 
BPV-1 E5 transforming activity (Sparkowski et al., 1995; Schapiro et al., 2000), the 
relation between the cell surface location of the protein and its transformation ability 
has not been clarified.
3.3.4.2 Experimental results and discussion
In an attempt to define if BPV-4 E5 is present on the cell surface high- 
magnification (100X objective; zoom 6), high-resolution images of COS-7 cells 
transiently expressing (24 hr) GFP-E5 were taken (Figure 3.8). These images 
revealed a distinct localisation of GFP-E5 on individual ER canaliculi extending to 
the periphery of the cell but no fluorescence was detectable on the plasma membrane.
To further analyse the absence of GFP-E5 and E5-GFP from the cell surface 
we performed immunostaining experiments using an anti GFP antibody (MBL) on 
non permeabilised COS-7 cells transiently expressing (24 and 48 hr) GFP-E5 and E5- 
GFP. As a control for these experiments we used the pcPEP-GFP expression vector 
(kind gift from Dr. Maria Simonova, Harvard Medical School). This vector contains 
GFP cDNA fused with the fragment encoding the 27 amino acids residues of the 
positively charged N-terminal cytoplasmatic domain and the 23 residues hydrophobic 
signal peptide/membrane anchoring domain of the rabbit neutral endopeptidase 
24.11, a type II transmembrane protein PEP-GFP (Figure 3.9 b). The authors showed 
by immunostaining and flow cytometry analysis that the N-terminal fragment of 
endopeptidase can target the fusion protein PEP-GFP to the cell surface of COS-1 
cells transiently expressing the construct (Simonova et al., 1999).
PEP-GFP, GFP-E5 and E5-GFP were transiently expressed in COS-7 cells for 
24 and 48 hr. Cells were fixed and stained with an anti-GFP antibody at 1:100 
dilution for one hour at room temperature. Cells were then washed and incubated 
with an anti-rabbit antibody texas red conjugated for a further hour. Finally cells were
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mounted and visualised at the confocal microscope. As graphically explained in 
Figure 3.9 a, the use of the two fusion forms of E5, with the GFP at the N-terminus 
or the C-terminus of the viral protein, would have allowed the detection of their 
expression at the cell surface independently from the orientation of E5 in the 
membrane bilayer.
As shown in Figure 3.10 a, PEP-GFP could be detected on the cell surface 
after 24 hr and 48 hr expression (data not shown) while neither GFP-E5 nor E5-GFP 
gave surface signal when expressed for 24 hours (Figure 3.10 b) or for 48 hours (data 
no shown). GFP does not affect the PEP trafficking through cell membranes despite 
the difference in size between the two proteins indicating that similarly GFP should 
not influence E5 location. These results show that it is not possible to detect BPV-4 
E5 fusion forms on the cell surface and would suggest that GFP-E5 and E5-GFP are 
not expressed on the plasma membrane (Figure 3.10 b). It is however possible that 
the immunostaining approach we have taken is not sensitive enough to detect small 
amount of fusion proteins at the cells surface.
It will be extremely important to clarify whether or not E5 is present on the 
plasma membrane in order to better define a model of possible transforming 
mechanisms by E5. More information could come from studies with the electron 
microscope.
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Figure 3.9 a, b Graphic representation of GFP-E5, E5-GFP and PEP-GFP
a) Possible orientation of GFP fusion forms of E5.
The diagram shows the two possible orientations of GFP-E5 and E5-GFP in the 
membrane bilayer. The use of the two fusion forms of E5, with the GFP at the N- 
terminus or the C-terminus of the viral protein, would have allowed the detection 
of their expression at the cell surface independently from their orientation.
b) The 50 amino acid signal peptide/membrane anchoring domain of the rabbit 
Neutral endopeptidase has been fused at the N-terminus of GFP. PEP is a type II 
transmembrane protein. When expressed at the plasma membrane it has an 
extracellular C-terminus and the N-terminus is orientated towards the cytoplasm.
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Figure 3.10 a, b GFP-E5 and E5-GFP could not be detected on cell surface
a) PEP-GFP transfected in COS-7 cells and stained with anti-GFP antibody;
b) GFP-E5 and E5-GFP transiently expressed in COS-7 cells and stained with 
anti-GFP antibody.
Cells were fixed 24 hr after transfection, stained with GFP antibody (MBL) and 
visualised at the confocal microscope. Each image, starting from the top panel, 
shows, on the left, the fluorescence coming from PEP-GFP, GFP-E5 and E5-GFP 
respectively and on the right the fluorescence coming from the anti-GFP antibody.
Figure 3.10 a, I)
a  PEP-GFP Anti GFP
Intrinsic fluorescence Immunofluorescence
GFP-E5 Anti GFP
Intrinsic fluorescence Immunofluorescence
E5-GFP Anti GFP
Intrinsic fluorescence Immunofluorescence
3.4 Conclusions
The use of GFP has provided an efficient detection system for routinely 
visualising E5. The two fusion forms of the viral protein with GFP (GFP-E5 and E5- 
GFP) show a perinuclear localisation that co-localisation studies have identified as 
Golgi apparatus (Figures 3.2 and 3.4). Similarly BPV-1 E5 and HPV E5s are mainly 
localised in the Golgi (Burkhardt et al., 1989; Conrad et al., 1993;).
The BPV-4 E5 mutant A15P-A20P also localises in the Golgi. This result 
would suggest that the high hydrophobicity of the first 30 residues is sufficient to 
target E5 to the Golgi apparatus and an intact secondary structure of its N-terminus is 
not required to localise the protein to the membrane bilayers. It is possible, however, 
that the E5 secondary structure is not affected by the introduction of proline residues 
and the abolition of A15P-A20P ability to transactivate cyclin A promoter is the 
result of other modifications in E5 activity such as interactions with different cellular 
targets due to residue substitutions. Moreover a form of E5 bearing the ER retrieval 
signal is still mainly localised in the Golgi. There could be various reasons for why 
GFP-E5/KDEL is still localised mainly in the Golgi compartment: (i) it is known that 
proteins bearing the KDEL amino acids sequence although resident in the ER can yet 
slip out of it, since they are able to acquire Golgi specific carbohydrate modifications. 
They are in fact retrieved from Golgi in a sorting process that returns them to the ER. 
It is therefore possible that over expression of ligands causes a saturation of the 
retrograde mechanism and allows protein to escape the control point and move 
towards the Golgi compartment; (ii) BPV-4 E5 could be a type I transmembrane 
protein with a cytoplasmic C-terminus. This means that the KDEL sequence is not 
facing the endomembranes lumen and cannot be recognised by the KDEL-receptors 
which reside in the ER-Golgi intermediate compartment.
The influence of the GFP tag in the retention of E5 in the Golgi could not be 
definitely excluded, however it could be considered unlikely. Using a fragment (PEP; 
50 amino acids) of the rabbit neutral endopeptidase 24.11, that presents similar size 
to BPV-4 E5, fused with GFP, we demonstrated that GFP does not interfere with 
PEP trafficking through cell compartments despite the difference in size between the 
two proteins (Figure 3.10). We conclude that it is unlikely that GFP affects BPV-4 
E5 cellular location. The possible mechanisms of how GFP-E5 could be retained in 
the Golgi will be discussed in Chapter 7.
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CHAPTER 4: CHARACTERISATION OF GFP-E5 
EXPRESSING CELLS
4.1 Introduction
4.1.1 Bovine papillomavirus type 4 and cell transformation
BPV-4 is a weakly transforming papillomavirus, it induces papillomas in the 
mucosal epithelium of upper gastrointestinal tract of cattle; the papillomas are, in 
general, benign and eventually regress spontaneously (Jarrett, 1985), but lesions can 
progress to carcinoma in animals feeding on bracken fern (Campo et al., 1994b).
The transforming functions of BPV-4, in established murine fibroblasts 
(NIH3T3 and C127 cells) have been mapped to the E5 and E7 open reading frames 
(Campo and Spandidos, 1983; Smith and Campo, 1988). The importance of the two 
viral proteins has been confirmed in studies with primary bovine fibroblasts (PalFs) 
(Jaggar et al., 1990). The expression of E5 and E7 ORFs, under the transcriptional 
control of the BPV-4 long control region (LCR) in pSVneo vector or of moloney 
leukaemia virus, MoLV, 5’ long terminal repeat (LTR) in pZipneo vector, is 
sufficient, in co-operation with ras, to drive cells to morphological transformation 
with an anchorage-independent and non-contact inhibited phenotype (Jaggar et al., 
1990). The immortalisation of these cells is achieved only with the addition of HPV- 
16 E6 ORF (Pennie et al., 1993).
An intact E7 ORF is crucial for transformation, as deletion of its 3’ third 
resulted in loss of transformation (Jaggar et al., 1990). E7 expression in co-operation 
with ras induces morphological transformation of PalFs (Pennie et al., 1993), 
however the expression of E5 is required for anchorage-independent growth.
4.1.2 BPV-4 E5 and cell transformation
When expressed in PalFs with an activated Ras, but in the absence of other 
BPV-4 genes, E5 did not display transforming activity (Jaggar et al., 1990). 
However, PalFs transformed by BPV-4 E5, BPV-4 E7, HPV-16 E6 and an activated 
Ras displayed loss of contact inhibition, ability to grow in absence of mitogens and in 
suspension (Pennie et al., 1993; O'Brien et al., 1999) while PalFs expressing BPV-4
E7, HPV-16 E6 and Ras failed to grow under the above conditions (Jaggar et al., 
1990; Pennie et al., 1993) confirming that these phenotypes are dependent on E5 
expression.
Recently it has been demonstrated that the expression of E5 by itself is 
capable of transforming NIH3T3 cells (O'Brien and Campo, 1998), providing a 
system where it is possible to analyse the transforming activities of E5 and its 
mutants avoiding the influence of other viral or cellular oncogenes. NIH3T3 E5 
expressing cells exhibit a transformed morphology, do not exit the cell cycle after 
serum withdrawal and form colonies when maintained in suspension culture (O'Brien 
and Campo, 1998).
In the previous Chapter we have shown that the use of a GFP tagged form of 
E5 has overcome the difficulties in the detection of the viral protein. GFP-E5 could 
be readily observed by immunostaining and routinely detected in western blot. Here 
we want to investigate if E5 could be stably expressed and easily detected in NIH3T3 
and if the viral protein had fully maintained its transforming ability in its fusion form 
with GFP. Because of unforeseen problems only GFP-E5 form was utilised in these 
studies, however we are aware of the importance to test also E5-GFP in the future.
4.2 Experimental Results
4.2.1 Generation of cell lines
Before proceeding with the production of stable NIH3T3 transfectants, GFP 
and GFP-E5 were subcloned into the pZipneo vector (section 2.1.9) to be consistent 
with all the previous E5 transformation studies where the same expression system 
had been used (O'Brien and Campo, 1998; O'Brien et al., 1999). The subcloning was 
performed with a PCR strategy and the constructs were subsequently sequenced to 
confirm their identity (section 2.2.1.10).
NIH3T3 cells were seeded at 0.5xl06 in a 90 mm tissue culture dish the day 
before transfection, three dishes for each transfection class. Cells were transfected 
with 10 p,g of GFP or GFP-E5 plasmids by using the calcium phosphate method as 
detailed in section 2.2.2.6. After 21-28 days of drug selection, with medium 
containing 500 pg/ml of G418, resistant colonies were marked, picked and expanded 
into cell lines for analysis.
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In parallel experiments two plates for each class of transfection were fixed 
and stained with 0.1% crystal violet in 20% methanol (Figure 4.1).
The results obtained from duplicate plates from three independent 
experiments show that GFP-E5 gives more colonies (up to 10 times) than the GFP 
control, implying that the fusion protein confers some survival and/or growth 
advantage to the fibroblasts. It has not been established if this phenotype is the result 
of an anti-apoptotic effect of the fusion protein or a growth advantage conferred by 
GFP-E5.
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Figure 4.1 Colony formation efficiency
NIH3T3 cells transfected with GFP and GFP-E5, fixed and stained after 21-28 days 
o f  G418 selection (0.5 mg/ml). GFP-E5 shows an ability to form colonies up to 10 
times the GFP control. The experiment has been repeated at least three times with 
the same outcome.
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4.2.2 Detection and visualisation of GFP-E5
4.2.2.1 Confocal Microscopy
Being naturally fluorescent GFP allows the study of protein expression by 
direct visualisation of live or fixed cells using fluorescence or confocal microscopy. 
To determine if NIH3T3 were expressing the GFP and GFP-E5 constructs, stable 
transfectants were analysed by confocal microscopy (section 2.2.4.2). Protein 
expression was tested in two GFP clones (GFP n 3 and n 10) and in six GFP-E5 
clones (GFP-E5 n 4, 7, 11, 15, 16, 17) derived from two different transfection 
experiments.
Details of confocal microscopy are described in section 2.2.4. In brief, 2xl04 
cells were seeded in an eight wells chamber slide in 500 pi normal growing medium 
(DMEM 10% NBCS). The following day, cells were fixed in 3% paraformaldehyde 
for 15 min at room temperature, mounted using Vectashield™ and then visualised at 
the confocal microscope.
As shown in Figure 4.2, the transfection and the following selection had been 
successful since NIH3T3 cells were expressing GFP and GFP-E5. The cells showed a 
fluorescence distribution that resembled the one observed in transient expression 
experiments (Figure 3.2): GFP clones presented a uniform cytoplasmic and nuclear 
fluorescence while GFP-E5 cell showed a perinuclear fluorescence (Figure 4.2 a).
4.2.2.2 Western blotting
GFP-E5 and GFP expression was also confirmed through immunoblotting. 
Whole cell extracts (100 pg cellular protein) from two GFP control clones, six GFP- 
E5 clones (the same clones tested above) and from NIH3T3 parental cells, growing in 
normal conditions, were prepared and fractionated by SDS-PAGE (15% 
polyacrylamide gel), transferred to a nitrocellulose membrane and probed with an 
anti GFP antibody (Babco).
Both GFP clones gave a specific band with an apparent molecular weight of
I
| 27 kDa, corresponding to electrophoretic mobility of GFP, while the GFP-E5 clones
i showed a specific band of 34 kDa corresponding to the predicted size of the fusion
I
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protein (Figure 4.2 b). Cellular extracts from untransfected NIH3T3 cells gave no 
signal, confirming the specificity of these bands (Figure 4.2 b).
These results indicate that GFP and GFP-E5 cells express the correct proteins 
and these proteins are not subjected to degradation. For these reasons we considered 
all clones at our disposal suitable for further analysis.
Because all clones showed protein expression and no apparent difference was 
observed among GFP clones or GFP-E5 clones, most of the further experiments were 
carried out with two GFP-E5 clones (mainly n 4 and n 11) and two GFP clones (n 3 
and n 10).
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Figure 4.2 a, b Visualisation and detection o f  GFP-E5 in NIH3T3 cells
a) Confocal images of N1H3T3 clonal populations expressing GFP and GFP-E5
b) Detection o f  GFP and GFP-E5 expression in NIH3T3 clonal populations; 100 
pg of whole cell extracts were fractionated in SDS-PAGE (15% polyacrylamide) 
and the membrane was probed with anti-GFP antibody (1:1000).
All images have been captured with 60X objective lens, GFP-E5 images have 
been further magnified in Microsoft powerpoint.
N1H3T3 cells were used as control. 1 0 3
4.2.3 Transformation assays
Growth factors and anchorage to substratum are two requirements of 
fibroblast cell division in vitro. When nutrients are removed from the growth 
medium or cells are deprived of substrate, fibroblasts exit the cell cycle. Fibroblasts 
transformation often leads to a decreased demand of serum factors and loss of 
anchorage requirement for cell proliferation (Pardee, 1989).
NIH3T3 cells expressing E5 exhibit a transformed morphology, do not exit 
the cell cycle after serum withdrawal and overcome the block in G1 when grown in 
suspension (O'Brien and Campo, 1998). To evaluate if GFP-E5 cells were 
transformed and the extent of their transformation, GFP-E5 clones were assessed for 
morphological transformation, their ability to grow in low serum conditions and 
independently of substratum.
4.2.3.1 Morphological transformation
To determine if the expression of GFP-E5 affected NIH3T3 cells morphology 
live cells were photographed using a Fuji digital camera (Figure 4.3). For completion, 
pictures of NIH3T3 expressing pZipneo empty vector (Z3T3) and E5 were taken. As 
shown before by O’Brien and Campo (1998), E5 cells show a less elongated shape 
compared with Z3T3 cells (Figure 4.3). In contrast, NIH3T3 cells expressing GFP-E5 
do not show an obvious morphological difference from GFP and Z3T3 controls 
(Figure 4.3).
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Figure 4.3 Morphology of Z3T3, E5 wt, GFP and GFP-E5 stable transformants
Phase contrast images illustrate that cells expressing BPV-4 E5 show a modified 
shape then the Z3T3 controls. GFP-E5 cells do not show an obvious morphological 
modification compared to GFP cells.
Images have been captured with a 10X objectives lens.
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4.23.2 Cell population growth in low and high serum
It has been shown that NIH3T3 E5 expressing cells do not exit the cell cycle 
after serum withdrawal, but do not appear to activate autocrine mechanism (O'Brien 
and Campo, 1998). To determine if E5, in its fusion form with GFP, could still 
confer to NIH3T3 cells the ability to escape growth arrest in low serum, GFP-E5 and 
GFP cells were tested in short term and long term growth assays.
4.2.3.2.1 Cell cycle analysis
The full methodology of cell cycle analysis is described in section 2.23.2. In 
brief, cells (lxlO6) were plated in 90 mm culture dishes, in duplicate for each cell 
line. The following day fresh medium, 10% serum, was added to one dish for each 
cell line, while the other was switched to medium containing 0.2% serum and 
incubated at 37°C for a further 24 hr or 48 hr. Cells were then harvested, fixed in 
ethanol and stained with propidium iodide (PI) for DNA content. The samples were 
analysed by FACS scan to determine the percentage of the cells in each phase of the 
cell cycle. Sample data were then modelled on Modfit v2.0 software, to determine 
cell cycle distribution. As controls Z3T3 and E5 cells were tested under the same 
growth conditions.
The profiles for both GFP and GFP-E5 were the same or very similar under 
normal growth conditions. NIH3T3 expressing E5 wt had the highest percentage of 
cells in S phase (35%).
GFP-E5 cells left in 0.2% serum for 24 hr presented a reduced percentage of 
cells in S phase (Table 4.1) and showed an increased accumulation of cells in G0/G1 
(-89%). GFP clones and Z3T3 cells showed a similar behaviour. This profile is 
characteristic of cells that exit from the cell cycle after serum withdrawal. E5 
expressing cells had a high percentage (21%) of cells in S phase (Table 4.1 and 
Figure 4.4) confirming their ability to cycle in low serum conditions (O'Brien and 
Campo, 1998). Similar results were obtained when cells were treated with 0.5% 
serum and incubated for 48 hr (not shown).
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Table 4.1 Summary of the FACS analysis
Cell line Serum
Concentration
G0/G1 phase S phase G2/M phase
Z3T3 10% 65.37% 21.3% 13.33%
0.2% 92.07% 4.7% 3.23%
E5 10% 50.59% 34.99% 14.42%
0.2% 68.38% 21.55% 10.07%
GFP. 10 10% 63.95% 27.32% 8.73%
0.2% 85.67% 4.6% 9.73%
GFP-E5.4 10% 58.33% 29.81% 11.86%
0.2% 88.98% 5.35% 5.67%
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Figure 4.4 Cells cycle analysis by FACS
GFP, GFP-E5, Z3T3 and E5 cells (lxlO6) were tested for the ability to grow in 
growth medium (10% serum) and low serum (0.2% serum) for 24 hr. Cells were 
analysed for DNA content by flow cytometry to identify the percentage of cells in 
S phase. Control cells (GFP and Z3T3) and GFP-E5 clone show an arrest in 
G0/G1 phase when kept in 0.2% serum (Table 4.1).
Figure 4.4
10% Serum 0.2% Serum
Z3T3
E5
GFP.10
S: 21.3%
S: 34.9%
S: 27.3%
1
S: 21.5%
S: 4.6%
GFP-E5.4 S: 29.8% S: 5.4%
1 ±
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4.2.3.2.2 Long term studies of growth in low serum
To further analyse the behaviour GFP and GFP-E5 cells in low serum, we 
extended cell growth studies over a 6 days period.
Cells (5xl03 cells/well) were seeded in 96 well plates in triplicate, one plate 
was set up for each day from day 0 to day 6. After cells had attached to the bottom of 
each well, the growth medium was changed to DMEM containing 10% serum or 
0.5% serum. Population growth was assayed as follows: one plate for each day was 
stained with 0.1% crystal violet in 20% methanol, dye was solubilised and 
absorbance determined at 590 nm by an automatic plate reader (section 2.2.3.1).
All cell tested showed very similar population growth kinetics when 
maintained in normal growth medium containing 10% serum (Figure 4.5), with GFP- 
E5 clones growing faster than GFP, Z3T3 and E5 cells. In concordance with the cell 
cycle analysis data (section 4.2.3.2.1) Z3T3 cells, GFP and GFP-E5 clones did not 
grow in 0.5% serum (or in 1% or 0.2%, data no shown), while E5 cells continued to 
proliferate in LS at the same rate shown in 10% serum.
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Figure 4.5 Cell growth curves
Growth curves representative o f  cell proliferation in high and low serum medium. 
Cell growth was determined by dye staining (section 2.2.3.1) and is expressed as a 
growth index (Y axis) representing the fold change in cell population from day one 
(X axis); the bars represent the standard deviation.
4.2.4 Anchorage-independent growth
The ability of GFP, GFP-E5, Z3T3, and E5 clonal populations to form 
colonies in semi-solid media was assayed by plating cells in methocel-based medium. 
Experimental details are explained in section 2.2.3.3. In brief, 1.25xl04-2.5xl04 cells 
were added to 7 ml of 0.8% methocel medium including 20% Foetal Calf Serum 
(FCS) and plated in 60 mm petri dish. Cells were left at 37°C for 2-3 weeks before 
being scored.
Colony formation efficiency was scored by counting the number of colonies, 
with a diameter greater than 0.1 mm, in three different areas (~16 mm ) of each plate 
and estimating the total number of colonies in the whole dish (the average number of 
colonies in the three areas was divided by 16 to give the number of colonies per mm2 
and then multiplied by the total area of the dish, 2827 mm ). The number of colonies 
was expressed as a percentage of the total number of cells seeded on day 0 (Table
4.2).
Table 4.2 Summary of anchorage-independent growth assay
Cell line
Number of colonies in methocel (%)± SE
Exp.l * Exp. 2 * Exp. 3 # Exp. 4 #
Z3T3 2.9%±0.19 3.6%±0.39 N/D N/D
E5 18.2%±0.98 20.4%±0.52 N/D N/D
GFP.3 3.1%±0.13 3.3%±0.36 2.4%±0.72 2.4%±0.72
GFP. 10 N/D N/D 3.3%±0.27 2.4%±0.72
GFP-E5.4 12.4%±1.45 11.9%±0.59 14%±0.47 13.3%±0.89
GFP-E5.7 N/D N/D 10.4%±0.89 9.5%±0.27
GFP-E5.11 10.9%±0.89 6.9%±0.36 11.4%±1.42 9%±1.52
*2.5x10 cells seeded 
# 1.25xl04 cells seeded 
N/D= not determined
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Figure 4.6 Anchorage-independent growth
Z3T3, E5, GFP and GFP-E5 cells (2.5xl04) were plated in 0.8% methocel-based 
medium. The efficiency of colony formation was determined after 3 weeks scoring 
colonies with a diameter greater than 0.1 mm.
Only E5 and GFP-E5 cells are capable of anchorage-independent growth (Table
4.2).
Phase contrast imagines at 40X final magnification.
Fi
gu
re
 
4.
6
in
uI
Ph
a
• W
• ^  :
•• A  f  %  *
■tV,* ■
•  v
*
«
On
♦ t ,- '•  *
* \  4*
'  *  '
I  - :
* f
Tf
in
Wi
a .
u-a
%  •
41
*
%
3 ?
• ?
• s
. •* §
m  •
Pm
U.
O  v
' * *
♦ A
♦ /V
A* f . •*
I/)
w
I
Hm
N
c
•  *
%
•<
114
In four independent experiments, two carried out using 2.5xl04 cells per plate 
and two with 1.25xl04 cells per plate (Table 4.2), GFP-E5 clones showed an 
appreciable anchorage-independent growth, with clone n. 4 displaying the highest 
efficiency of colony formation 14% (Table 4.2, Figure 4.6). GFP-E5 clones showed 
an efficiency of -3.9 times on average higher than GFP clones, moreover colonies 
larger than 0.25 mm were found only in GFP-E5 plates. It has been shown previously 
that E5 expressing cells showed an efficiency of colony formation approximately 3.5 
times than Z3T3 control cells (O'Brien and Campo, 1998). E5 cells behaviour has 
been confirmed in these experiments where these cells present a colony formation 
efficiency of -  20%.
4.3 Conclusions
The results presented here show that it is possible to produce stable cell lines 
expressing GFP-E5 fusion protein and GFP protein. In these cells proteins could be 
visualised and detected and there was no evidence of protein degradation (Figure
4.2).
In three independent experiments the number of drug-resistant colonies 
obtained from NIH3T3 cells transfected with GFP-E5 was higher than in the GFP 
plates (Figure 4.1). This implies that GFP-E5 confers some survival and/or growth 
advantage to the fibroblasts. Moreover cells expressing GFP-E5, like E5 wt, are 
capable of anchorage-independent growth, a phenotype that is believed to correlate 
with tumour growth in vivo. Surprisingly GFP-E5 cells exit the cell cycle when 
deprived of serum mitogens, in disagreement with E5 cells behaviour (O'Brien and 
Campo, 1998).
It has been shown previously that PalFs cells expressing an E5 mutant form, 
N17S (Chapter 6) and a chimera that retains the first 31 residues of BPV-1 E5 fused 
with the last 10 amino acids of BPV-4 E5 (1E5N-4E5C) can grow in suspension but 
not in low serum, showing that the transformation phenotypes of anchorage- 
independent growth and of growth in low serum can be segregated (Ashrafi, 1998; 
O'Brien et al., 1999).
GFP-E5 resembles the characteristics of the above mutants when expressed in 
NIH3T3 cells. This fusion form of E5 is therefore an important tool with which to 
investigate how the segregation of the two phenotypes occurs in NIH3T3, where the
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sole requirement for cell transformation is the introduction of E5. Moreover in this 
system the analysis can be expanded at the biochemical level thanks to the 
commercial availability of the required reagents. Our initial analysis of biochemical 
changes to key components of the cell cycle machinery will be discussed in Chapter 
5.
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CHAPTER 5: THE EFFECTS OF GFP-E5 ON THE 
REGULATION OF THE CELL CYCLE
5.1 Introduction
5.1.1 The cell cycle
The cell cycle is a series of events that culminates with cell division and 
production of two daughter cells. This process consists of four phases; the S phase in 
which DNA replication occurs; M phase or mitosis when the DNA is segregated and 
the cell actually divides; and two gap phases: G1 (before DNA synthesis) and G2 
(before mitosis). Cell cycle progression is regulated by both intracellular and 
extracellular control mechanisms. Intracellular controls ensure that cell division 
proceeds successfully and responds to irregularities such as DNA damage (Gl/S 
check-point) or incomplete DNA replication (G2/M check-point) (Forsburg and 
Nurse, 1991). The extracellular controls, both cell adhesion and the presence of 
growth factors, may determine cell fate such as proliferation, differentiation or 
programmed cell death. The regulation of cell proliferation by growth factors of 
normal mammalian cells occurs at two levels in the cell cycle: during transition from 
quiescent GO state to the G1 phase, and during progression through the different 
subphases of Gl. Fibroblasts leave the cell cycle and enter a quiescent, GO state, 
when growth factors are removed (Pardee, 1989). Adhesion to substratum is also 
required for cell cycle progression, with the exception of some cells in the 
haematopoietic lineage (Zhu et al., 1996). In fibroblasts, cell cycle control by 
anchorage to substratum has been mapped at the transit through G l into S phase 
(Guadagno and Assoian, 1991).
In cancer cells the intracellular and extracellular check-points are lost and 
growth control is deranged. In particular the Gl/S check-points and the G2/M check­
points are less stringent or even absent. Moreover fibroblast transformation often 
leads to loss of growth factor and anchorage requirements for cell proliferation and 
anchorage-independent growth in vitro is closely correlated with tumourigenicity and 
tumour metastasis in vivo (Shin et al., 1975).
5.1.2 The cell cycle regulators
5.1.2.1 Cyclins and cyclin-dependent kinases
Proper cell cycle progression is accurately regulated by a family of protein 
kinases termed cyclin-dependent kinases (CDKs). CDKs are serine/threonine protein 
kinases that control the transition between successive phases of the cell cycle and 
require binding of regulatory subunits, named cyclins, as an initial step in their 
activation process. In mammalian cells at least nine CDKs (CDK1-CDK9) have been 
described. Their positive regulatory subunits, the cyclins, also constitute a large 
family, so far 12 have been characterised. Cyclins can form catalytically active 
complexes with different types of CDKs in mammalian cells, and different 
cyclin/CDKs complexes are assembled and activated at specific points in the cell 
cycle.
The first cyclin/CDK holoenzyme, which is activated during the G l phase, is 
composed of a D-type cyclin (Dl, D2, or D3) in association with CDK4 or CDK6 
(cyclin D/CDK4-6). The expression of cyclin D-types and their assembly with their 
catalytic partners depends on stimulation by growth factors. (Diehl et al., 1997).
As cells progress through the G l phase, cyclin E is synthesised with a peak 
middle/late Gl. In combination with another cyclin-dependent kinase, CDK2, cyclin 
E is responsible for the progression from G l to S phase (Resnitzky et al., 1994; 
Ohtsubo et al., 1995). At the transition point from G l to S phase cyclin E is degraded 
and CDK2 then associates with cyclin A.
Cyclin A gene expression is regulated at the level of transcription initiation 
with expression being repressed in G l and strongly induced as the cell enters S phase 
(Henglein et al., 1994). Cells maintained in low serum (Firpo et al., 1994) or in 
suspension (Guadagno et al., 1993; Fang et al., 1996) do not express cyclin A and 
cannot progress into S phase. Constitutive expression of cyclin A allows NRK 
fibroblasts to proliferate in suspension (Guadagno et al., 1993).
Finally, both cyclin A and B type cyclins associates with cdc2 to promote 
entry into mitosis; cyclin A binds to cdc2 with a peak of activity in G2 and is then 
suddenly degraded, whereas entry into mitosis is triggered by cyclin B/cdc2. Cyclin B 
destruction is required for exit from mitosis.
It has been shown that de-regulation of cell cycle regulatory proteins, such as 
cyclins, cyclin dependent kinases, and their inhibitors (CKIs) is a hallmark for cell 
transformation (Chapter 1).
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5.1.2.2 Cyclin Dependent Kinase Inhibitors (CKIs)
Another level of control of cyclin-CDK complexes is via a strong inhibitory 
activity by two families of small proteins: the Kip/Cip family composed of p21, p27 
and p57, which target cyclins/CDK2 and cyclins/CDK4-6 complexes and the INK 
family, pl5, pl6, pl9 which target cyclin D/CDK4-6 complexes (Sherr and Roberts, 
1995).
Expression of p21 can be induced by the tumour suppressor p53 in response 
to DNA damage. Up-regulated p21 arrests the cell cycle not only by inhibiting 
cyclin/CDK complexes but also by binding to the DNA polymerase-6 subunit PCNA, 
an important player in replication and repair (Xiong et al., 1992).
Another CDK inhibitor that is structurally related to p21 is p27 (Toyoshima 
and Hunter, 1994). The gene of p27 is transcribed both in proliferating and in 
differentiated cells. The expression of p27 does not appear to be regulated at the 
transcriptional level (Hengst and Reed, 1996) but protein levels seem to change 
during the cell cycle due to translational and post-translational regulation. p27 is 
expressed at high levels in quiescent cells and is rapidly down-regulated upon growth 
factor stimulation. In proliferative cells p27 is present at lower level and apparently is 
sequestered by cyclinD/CDK4-6 complexes which need to overcome a p27 threshold 
to become active (Sherr and Roberts, 1995). Since p27 can interact with multiple 
cyclin/CDK complexes, its availability for inhibition of cyclins/CDK2 complexes 
also depends on the abundance of cyclin D/CDKs (LaBaer et al., 1997).
5.1.2.3 Pocket proteins
The ‘pocket protein’ family includes the retinoblastoma tumour suppressor 
protein (pRb) and two related proteins, pl07 and pl30 (Weinberg, 1995). The term 
‘pocket’ was originally used to describe a conserved structural and functional domain 
of pRB and pl07 that binds to transforming viral oncoproteins and cellular proteins. 
The three members of the pRb family are phospho-proteins and their phosphorylation 
status is modulated during the cell cycle as well as at the cell cycle entry and exit 
transitions in mammalian cells. The growth suppressive activity of pocket proteins is 
mediated through the association with a number of cellular proteins, mainly the 
members of the E2F family of transcription factors, which regulate the expression of 
a number of genes required for cell cycle progression (reviewed in Dyson, 1998).
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Phosphorylation of the pockets proteins in mid-to-late G l phase by cyclin/CDKs 
frees the transcription factors, reactivates transcription and induces cell cycle 
progression.
From recent studies it appears that the pocket proteins, pRb in particular, are 
progressively inactivated by multiple cyclin/CDK complexes and phosphorylation at 
different sites is a prerequisite for distinct molecular functions (Adams, 2001).
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Figure 5.1 The key regulators of the cell cycle progression
Exit of resting mammalian cells from the quiescent state (GO) is triggered by growth 
factors and their specific receptors. The immediate response to growth factors 
stimulation is the increased expression of D type cyclins in early G l .  These cyclins 
bind and activate their associated kinases (CDK4 or CDK6). As cells progress, cyclin 
E and cyclin A are synthesised. Cyclin E, in combination with CDK.2, is responsible 
for the progression through the G l  phase while cyclin A/CD K2 complex enables S 
phase progression. Finally cyclin A and cyclin B associate with cdc2 to promote entry 
into mitosis. The pocket proteins (pRb, pl()7 and p l3 0 )  block cell cycle progression 
by sequestering transcription factors (E2F/DP). Pocket proteins are inactivated by 
multiple phosphorylations by CDKs, resulting in release o f  transcriptional active 
E2F/DP heterodimers. The CDK inhibitors (p 15, p l6 ;  p21 and p27) arrest cells in G l  
by preventing phosphorylation of the pocket proteins; modified from Jansen-Durr,
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5.2 Analysis of the cell cycle components in different growth 
conditions in NIH3T3 cells expressing GFP-E5
In NIH3T3 cells, E5 transformation is accompanied by the up-regulation of 
cyclin D and cyclin A expression and associated kinase activity under conditions 
where the expression of these cyclins is diminished or not detectable in control cells 
(O'Brien and Campo, 1998; O'Brien et al., 2001).
Differently from E5 wt, GFP-E5 expressing cells grow in suspension culture 
but exit the cell cycle after serum withdrawal (Chapter 4). Hence we decided to 
investigate at what level of cell cycle progression the segregation of the two 
phenotypes occurs, by the analysis of the cell cycle components in GFP-E5 cells in 
different growth conditions.
5.2.1 Experimental procedures
5.2.1.1 Western blotting
Cells (lxlO6) were seeded in a 90 mm dish, once attached they were switched 
to growth medium (GM; 10% serum) or low serum (LS; 0.5% serum) for 24 hours 
before being harvested and prepared for western blotting analysis as explained in 
section 2.2.5.1.
For the assay in suspension 5xl06 cells were resuspended in 30 ml of 0.8% 
methocel in DMEM-10 and transferred on a 150 mm bacteria petri dish and 
incubated in a humid incubator for 24 hr or 48 hr. At the end of the incubation time, 
the cells were pelleted as described in section 2.2.5.1.
Samples were loaded in a 10% SDS-polyacrylamide gel and run at 40 mA for 
1.5 hr. The gel was then transferred to a nitrocellulose membrane and the membrane 
probed with specific antibodies (Table 2.2).
5.2.1.2 Kinase assays
For the kinase assays experimental details are described in section 2.2.5.5. In 
brief, from 500 pg aliquots of lysates, obtained from adherent or suspension culture 
(section 2.2.5.2) cyclin A, cyclin E and CDK2 complexes were immunoprecipitated
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using specific antibodies (Table 2.2). Samples were incubated with Histone one (HI) 
substrate and [y32-P ] ATP. The reaction was incubated for 30 min at 30°C and then 
stopped by adding 20 pi of 2X loading buffer. Samples were boiled for 5 min and 
loaded on a 10% polyacrylamide gel. The gel was dried and the intensity of the bands 
was analysed with a phosphorimager.
5.2.1.3 Cyclin A promoter activity measurement
Growing stable transformants cells (2xl05) were plated in 6 well plates, in 
triplicate. The following day cells were transfected with 0.2 pg of luciferase reporter 
plasmid, (luciferase reporter gene under the transcriptional control of the human 
cyclin A promoter, region between -754 bp and +175 bp; section 2.1.9) using 
Effectene transfection reagent. After 16-18 hr, precipitates were washed off with 2 ml 
of PBS and cells incubated in LS or GM for further 24 hr.
For the assay in suspension, cells (2xl05) were seeded in 6 well plates, in 
quadruplicates and transfected as described above. The following day cells were 
washed with PBS and two wells, for each cell lines, were incubated with GM and 
two were trypsinised and transferred on a 60 mm bacteria dish with 7 ml of methocel 
medium (section 2.2.3.3) containing 10% of NBCS. Cells were incubated in a humid 
incubator for a further 24 hr before being harvested and assessed as described in 
section 2.2.3.4.
Luciferase activity was determined using a microplate luminometer TR717 
(section 2.2.3.4).
5.2.1.4 MAPK inhibitors
Experimental details are described in section 2.2.6. Briefly 3xl06 cells were 
seeded in 10 ml of 0.8% methocel 10% NBCS with the addition of PD98059 
(Calbiochem) or U0126 (Promega) inhibitor (final concentration 50 pM and 20 pM 
in DMSO respectively) as control cells were treated in parallel with an equal amount 
of DMSO. Cells were harvested 48 hr and 72 hr later, protein concentration assayed 
and 30 pg of this analysed by western blotting.
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5.2.2 Cell growth in normal and low serum conditions
5.2.2.1 Cyclin D1 and the pocket proteins
Cyclin D1 is the primary D-type cyclin in several cell types. It is known that 
cyclin D1 acts as a growth factor sensor: it is rapidly induced by mitogens and rapidly 
degraded in cells deprived of growth factors (Diehl et al., 1997). Cyclin D1/CDK4-6 
complexes are responsible for the phosphorylation of the pocket proteins. This 
phosphorylation, during Gl, leads to inactivation of pocket proteins as transcriptional 
repressors of fundamental genes required in S phase and allows the bypass of the 
restriction point at the Gl/S transition and the progression of the cell cycle.
pl30 is modulated slightly differently and is accumulated in GO and mid-Gl 
whereas its level is low or not detectable in S phase and G2 phase (Grana et al., 
1998).
Phosphorylated forms of the pocket proteins can be resolved by SDS-PAGE 
thanks to differences in their electrophoretic mobility, with the hyperphosphorylated 
forms running slower than the hypophosphorylated forms. Two different forms of 
p i07 are detectable in most cell types, while in the case of pl30 four forms are 
detectable which are defined as unphosphorylated pl30 and phosphorylated forms 1, 
2 and 3 (Grana et al., 1998). Moreover antibodies raised against specific 
phosphorylation sites of pRb exist (see below).
Given the crucial role of cyclin D1 in the integration of mitogen signal with 
the cell cycle progression we investigated the state of this cyclin in our stable 
trransformants, moreover we analysed the state of pRb, p i07 and pl30 proteins in 
different growth conditions in GFP-E5, GFP, E5 and Z3T3.
As previously shown, NIH3T3 cells expressing E5 sustained the expression 
of cyclin D1 in the absence of mitogens (O'Brien et al., 2001), (Figure 5.2 a). GFP- 
E5 clones showed an increased in the basal level of cyclin D1 compared to GFP 
control, however in both GFP-E5 and control cells the expression of this cyclin 
decreased in cells cultured in low serum (Figure 5.2 a). The data show that cyclin D1 
is still largely mitogen-dependent in these cells.
Cells growing in 10% serum clearly presented hyperphosphorylated forms of 
pRb and pl07 and a low level or absence of pl30. Moreover a pRb form specifically 
phosphorylated at site 780 (serine) could be detected using a phospho-specific
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antibody (Figure 5.2 b). GFP-E5, GFP and Z3T3 cells left in 0.5% serum presented 
changes in the phosphorylation state and/or abundance of pRb, pl07 and pl30. In 
these conditions, in agreement with the expression pattern of cyclin D l, pRb and 
pl07 were found mainly in their hypophosphorylated state, whereas pl30 
accumulated, as is typical of quiescent cells. On the contrary, in E5 expressing cells 
grown in the absence of mitogens, pRb and p i07 are largely hyperphosphorylated 
while pl30 levels are significantly diminished (O'Brien et al., 2001), (Figure 5.2 b). 
In these cells the detection of pRb780 was still possible. Both cyclin D1/CDK4 and 
cyclin E/CDK2 complexes phosphorylate this site. It has been shown that in E5 cells 
cyclin E/CDK2 kinase activity is not elevated in absence of mitogens, leading to the 
conclusion that cyclin D/CDK4 complexes are the principal responsible for pRb 
phosphorylation (O'Brien and Campo, 1998; O'Brien et al., 2001). The failure to 
detect pRb phosphorylation in GFP-E5 cells demonstrated that both cyclin D/CDK4 
and cyclin E/CDK2 were inactive in low serum. These observations are consistent 
with the inability of GFP-E5 cells but not E5 cells, to proliferate in low serum 
(Chapter 4).
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Figure 5.2 a, b Analysis of the cyclin D1 and the pocket proteins expression in 
normal (10%; GM) and low serum (0.5%; LS) conditions
a) Cells were incubated in 10% or 0.5% serum for 24 hr. After treatment, 50 ng of 
total cell extracts were separated in 10% polyacrylamide gel and membranes were 
probed with indicated antibodies. In 10% serum Cyclin D1 is elevated in E5 and 
GFP-E5 cells, while in LS is sustained only in E5. Levels of a-tubulin serve as a 
loading control.
b) After treatment, as above, 100 pg of total cell extracts were separated in 7.5% 
polyacrylamide gel. Membranes were probed with antibodies to total pRb, Ser-780 
pRb phosphorylation site, pl07 and pl30. The different species of the pocket 
proteins are marked. Hyperphosphorylated forms of pRb and pl07 were detected 
in all cell lines grown in GM. Specifically the pRb-Ser780 form was detected. 
After serum withdrawal the active forms of the pocket proteins were observed 
only in E5 expressing cells but disappeared in GFP-E5 and control cells.
Figure 5.2 a, b
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5.2.2.2 Cyclin A promoter transactivation
In NIH3T3 cells and primary bovine fibroblasts the expression of BPV-4 E5 
can promote transcriptional activation of a heterologous (human) cyclin A promoter 
and in both cells types this activity correlates with cell transformation by E5 (Ashrafi, 
1998; O'Brien and Campo, 1998; O'Brien et al., 1999). We decided to measure cyclin 
A promoter activity in our stably transformed cell lines.
Under normal growth conditions GFP-E5 clonal lines show a 3 to 7 fold 
increase in cyclin A promoter activity compared to GFP clone (Figure 5.3 a and 5.9). 
E5 wt shows a 8-15 fold activation of cyclin A promoter activity at the same 
conditions. When cells were maintained in low serum for 24 hr, promoter activity 
remained high in wild type E5 cells but not in GFP-E5 or control cells (Figure 5.3 a). 
Similar results were seen in transient transfection experiments in which cyclin A 
reporter plasmid was co-transfected with pZipneo expressing GFP, GFP-E5, E5 or 
pZipneo empty vector in NIH3T3 cells (Figure 5.3 b).
To investigate whether the differences in cyclin A promoter activity between 
GFP control cells and those expressing GFP-E5 were due to differences in 
transfection efficiency between cell lines, GFP and GFP-E5 cells were transfected 
with the pHSV vector expressing p-galactosidase, using Effectene transfection agent. 
Cells were stained in situ with developing solution for p-galactosidase and 
photographed after an overnight incubation at 37°C (section 2.2.3.5). The number of 
blue cells, used as an indicator of transfection efficiency (~ 10%), did not differ 
between cell lines (data not shown). This demonstrates that the differences in cyclin 
A promoter activity between control cells and those expressing GFP-E5 were not due 
to differences in transfection efficiency between cell lines.
5.2.2.3 Cyclin A protein expression
NIH3T3 cells expressing BPV-4 E5 wt show an increased expression of 
endogenous cyclin A protein under conditions where cyclin A expression is normally 
diminished or is not detectable in control cells (O'Brien and Campo, 1998). As 
shown above, GFP-E5 can promote transcriptional activation of a heterologous 
cyclin A promoter in normal growth conditions, thus we examined whether GFP-E5 
has an effect on the transcriptional activation of the homologous promoter by looking
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at the expression level of the endogenous cyclin A protein. GFP-E5, GFP, E5 and 
Z3T3 cells were utilised in this investigation.
The results showed that, as previously reported by O’Brien and Campo 
(1998), cyclin A expression is up-regulated in E5 expressing cells compared to 
control cells in growth medium and low serum culture (Figure 5.4 a). In normal 
growth conditions GFP-E5 cells do not show an elevation in cyclin A expression 
compare tpo GFP control clones. As expected from the transformation assays and the 
data from the cyclin A promoter trans-activation, GFP-E5 clones show a decreased 
cyclin A expression level in low serum, similarly to GFP clones (Figure 5.4 a).
S.2.2.4 Cyclin A kinase activity
To test if the de-regulation of cyclin A level in GFP-E5 cells was 
accompanied by a variation in cyclin A-associated kinase activity, cyclin A- 
associated complexes were immunoprecipitated from lysates of GFP-E5, GFP, E5 
and Z3T3 cells and the associated kinase activity was assayed with Histone one (HI) 
as a substrate.
A higher level of cyclin A-associated kinase activity was observed in GFP-E5 
clones, up to 2.5 times the GFP control clones kept in normal growth conditions. 
However, little or no difference was observed in GFP-E5 cells compared to control 
under low serum growth conditions (Figure 5.4 b). E5 expressing cells confirmed 
what was previously reported: the cyclin A-associated kinase activity was sustained 
in cells kept in normal and low serum (Figure 5.6), (O'Brien and Campo, 1998). It is 
interesting to note that there was a very good agreement between the cyclin A 
expression level shown by western blotting in normal and low serum and the amount 
immunoprecipited with a specific antibody (compare Figure 5.4 a and 5.6).
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Figure 5.3 a, b Trans-activation of the human cyclin A promoter
Measurement of the cyclin A promoter activation after 24 hr incubation in 10% or 
0.5% serum. The luciferase reading for each sample (stable and short term 
transfection) was corrected according to the following equations: the fold 
induction of luciferase activity is given after normalisation for cellular protein 
content [sample’s luciferase reading - background luciferase reading (Lysis buffer) 
-5- protein concentration of related samples]. The reading obtained with control 
cells (GFP clone or Z3T3 cells for stable transfectans or pZipneo empty vector or 
pZipGFP for short term transfectants) was set at 1, and the luciferase readings of 
the samples were normalised to the control reading.
The mean values from triplicate samples are given for a representative experiment 
and standard deviation (bars) was calculated for each transfection class.
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Transactivation of the cyclin A gene promoter in transient transfectants
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Figure 5.4 a, b Cvclin A expression level and associated kinase activity in 
10% and 0.5% serum
a) Cells extracts (50 pg) were separated in SDS-PAGE (10% polyacrylamide) and 
membranes were probed with indicated antibodies.
Cyclin A is down-regulated in control and GFP-E5 cells after 24 hr in 0.5% serum 
but is sustained in E5 cells. Levels of a-tubulin serve as a loading control.
b) Cyclin A/CDK complexes were immunoprecipitated from 500 pg of total cell 
extracts using a cyclin A polyclonal antiserum (1:250). Cyclin A-associated kinase 
was assayed using Histone HI as substrate.
The amount of incorporated radioactivity was determined by Phosphorimager. The 
reading obtained with control cells was set at 1, and the activity of the samples 
were normalised to the control reading.
Cyclin A-associated activity is elevated up to 2.5 fold in GFP-E5 cells cultured in 
10% serum compared to the control cells.
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5.2.2.5 Cyclin dependent kinase inhibitor (CKI) p27 expression
Active cycling fibroblasts down-regulate the CKI p27. Surprisingly, in 
NIH3T3 E5 cells, transformation is associated with up-regulation of the cyclin kinase 
inhibitor p27 in all growth conditions tested (O'Brien and Campo, 1998). Recent 
studies have shown that high levels of nuclear p27 are tolerated because the inhibitor 
is sequestered by an elevated pool of cyclin D1/CDK4 complexes (O'Brien et al., 
2001). In light of these observations we investigated the state of p27 in GFP-E5 
expressing cells.
In GFP-E5 expressing cells p27 expression is not significantly altered in cells 
grown in normal serum. When cells were kept at 0.5 % serum for 24 hours the p27 
protein level increased in both GFP-E5 and GFP control cells (Figure 5.5). Moreover 
p27 was associated with cyclin A/CDK complexes immunoprecipitated from GFP- 
E5, GFP and Z3T3 cells, kept in low serum. The smaller amount of p27 associated 
with cyclin A in GFP-E5 cells could explain the residual kinase activity observed in 
these cells (Figure 5.6).
These results are concordant with the inability of GFP and GFP-E5 cells to 
sustain cell proliferation in LS (Chapter 4).
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Figure 5.5 State of the CDKI p27 in 10% and 0.5% serum
Cells were cultured in 10% or 0.5% serum for 24 hr. Cells extracts (50 pg) were 
separated in SDS-PAGE (10% polyacrylamide) and membranes were probed with 
indicated antibodies.
The expression of p27 is deregulated in E5 cells in all conditions tested compared 
to Z3T3 control cells. In GFP and GFP-E5 clones p27 is down-regulated in GM 
and up-regulated in LS. Levels of a-tubulin serve as a loading control.
Figure 5.6 Detection of Cyclin A and p27 protein in immunoprecipitated 
complexes
Samples of the cyclin A immunoprecipitates, from 250 pg of total cell extracts, 
were fractionated in 10% polyacrylamide gel. The amount of immunoprecipitated 
cyclin A and associated p27 were determined by immunoblotting. Cyclin A- 
associated HI kinase activity was determined in immunoprecipitated complexes.
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5.2.3 Cell growth in semi solid media
5.2.3.1 Cyclin D1 and the pocket proteins
The extracellular matrix proteins (ECM) are jointly required with mitogens to 
induce cyclin D1 expression: in NIH3T3 cells cyclin D1 mRNA and protein are not 
induced if quiescent cells are stimulated with mitogens in absence of substratum 
(Zhu et al., 1996).
It has been shown that in both NIH3T3 cells and human fibroblasts the 
phosphorylation of pRb protein during the G1 phase of cell cycle requires 
information provided by both mitogens and the extracellular matrix and neither 
signal alone is sufficient for pRb phosphorylation. However, enforced expression of 
cyclin D1 protein in late G1 rescues pRb phosphorylation and entry in S phase in non 
adherent cells (Zhu et al., 1996).
NIH3T3 expressing E5 wt and GFP-E5 grow in suspension culture (O'Brien 
and Campo, 1998), (Chapter 4); therefore we investigated the state of cyclin D1 and 
the pocket proteins in these growth conditions.
In E5 and GFP-E5 cells cultured in suspension for 48 hr cyclin D1 expression 
is significantly up-regulated compared to their respective control cells in the same 
growth conditions (Figure 5.7 a). In E5 and GPF-E5 cells the state of cyclin D1 is 
consistent with the ability of these cells to proliferate in semi-solid medium.
In cells grown in suspension only the hypophosphorylated form of pRb and 
p i07 could be detected in control cells (GFP and Z3T3) while a form of p i07 with a 
different electrophoretic mobility, probably due to protein phosphorylation, was 
observed only in GFP-E5 and E5 cells. Surprisingly it was not possible to detect the 
hyperphosphorylated forms of pRb in GFP-E5 and E5, either with an antibody 
against total pRb (Figure 5.7 b) or with the phospho-specific antibody against serine 
780 (data not shown), despite the good separation between hyper and 
hypophosphorylated forms as shown for adherent cells (Figure 5.7 b). Interestingly 
pRb level increased in E5 expressing cells. pl30 level was similar in control and 
GFP-E5 cells and slightly lower in E5 cells (Figure 5.7 b). Because pl30 accumulates 
in quiescent cells the level of the protein detected is more representative of the 
percentage of quiescent than the proliferating cells in each cell lines.
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Figure 5.7 a, b Analysis of the cyclin D1 and the pocket proteins expression in 
suspension culture
a) Cells were cultured in suspension for 48 hr. Cells extracts (50 p,g) were 
separated in SDS-PAGE (10% polyacrylamide) and membranes were probed with 
indicated antibodies. GFP-E5 and E5 cells show up-regulated expression of cyclin 
D l. (Similar results were obtained after 24 hr incubation data not shown). Levels 
of a-tubulin serve as a loading control.
b) Cells were cultured as above. Cells extracts (100 |ig) were separated in SDS- 
PAGE (7.5% polyacrylamide) and membranes were probed with indicated 
antibodies. The inactive form of pRb was not detected in E5 or GFP-E5 cells, 
surprisingly E5 cells show up-regulation of pRb. pl07 was up-regulated and 
possibly phosphorylated in E5 and GFP-E5 cells. pl30 protein level is only 
slightly down regulated in E5 and GFP-E5 cells. The results are representative of 
two independent experiments.
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5.2.3.2 Cyclin £  expression and associated kinase activity
The expression level of cyclin E and its catalytic subunit CDK2 is anchorage- 
independent in NIH3T3 cells (Guadagno et al., 1993; Zhu et al., 1996), however the 
cyclin E/CDK2 kinase activity is strongly down-regulated in these conditions. We 
determined the level of Cyclin E expression and its associated kinase activity in 
stable transfectants.
The protein level of cyclin E and CDK2 is similar in Z3T3, GFP-E5 and GFP 
cells and only moderately up-regulated in E5 cells (Figure 5.8 a). The cyclin E/CDK2 
activity is only slightly up-regulated in E5 and GFP-E5 expressing cells compared 
with the respective controls (Figure 5.8 b). Nevertheless the cyclin E appears to be 
associated mainly with the active form of CDK2 (Figure 5.12).
When the kinase assay was performed immunoprecipitating CDK2, no kinase 
activity could be detected (Figure 5.8 b). As shown by western blot analysis of the 
immunoprecipitates, the absence of appreciable CDK2 kinase activity is due to the 
inability of the anti-CDK2 antibody to efficiently immunoprecipitate the active form 
of CDK2 (Figure 5.12).
5.2.3.3 Cyclin A promoter transactivation in suspension culture
E5 expressing cells can transactivate the cyclin A promoter when maintained 
in suspension culture (O'Brien and Campo, 1998). Attachment-dependent expression 
of the cyclin A mRNA has been shown in NIH3T3 cells (Guadagno et al., 1993). We 
measured cyclin A promoter activity in our cells lines in suspension culture.
As shown in Figure 5.9 the promoter activity was relatively high in GFP-E5 
cells kept in suspension, up to 5 times the control cells. In the same conditions E5 wt 
expression in NIH3T3 led to ~ 8 fold increase in cyclin A promoter activity (O'Brien 
and Campo, 1998), (Figure 5.9).
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Figure 5.8 a, b Cyclin E and CDK2 expression level and associated kinase 
activity in suspension culture
a) Cells were cultured in suspension for 48 hr. Cells extracts (50 pg) were 
separated in SDS-PAGE (10% polyacrylamide) and membranes were probed with 
indicated antibodies. Cyclin E and CDK2 expression level remains similar in E5, 
GFP-E5 and control cells. Levels of total ERK 1/2 (t-ERK 1/2) serve as a loading 
control.
b) Cyclin E/CDK2 and cyclins/CDK2 complexes were immunoprecipitated from 
500 pg of total cell extracts using cyclin E and CDK2 polyclonal antisera (1:250). 
CDK2 and cyclin E/CDK2 associated kinase was assayed using Histone HI as 
substrate. The amount of incorporated radioactivity was determined by 
Phosphorimager. The reading obtained with control cells was set at 1, and the 
activity of the samples were normalised to the control reading.
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Figure 5.9 Trans-activation of the human cyclin A promoter in suspension 
culture
The measure of the cyclin A promoter activation has been performed as reported 
in Figure 5.3. The reading obtained with control cells (GFP or Z3T3 cells) in 
adhesion and suspension was set at 1, and the luciferase readings of the samples 
were normalised to the control reading. The mean values were obtained from 
duplicate samples. These results are representative of three independent 
experiments.
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5.2.3.4 Cyclin A expression and associated kinase activity
Cyclin E expression level and activity are required for elevated cyclin A 
expression in NIH3T3 cells in adhesion conditions (Zerfass-Thome et al., 1996), E5 
expressing cells however have been shown to bypass this requirement (O'Brien and 
Campo, 1998). It is known that in suspension ectopic expression of cyclin A but not 
cyclin E or CDK2 allows proliferation of NRK cells (Guadagno et al., 1993). Thus 
we investigated the expression level and the associated kinase activity of cyclin A in 
these growth conditions.
In GFP-E5 cells the cyclin A level was significantly elevated compared to 
GFP control clones (Figure 5.10 a). Again these results were consistent with the 
transcriptional activation of the cyclin A promoter in suspension and the anchorage- 
independent growth displayed by GFP-E5 expressing cells (Chapter 4).
Moreover, in non-adherent growth conditions, E5 and GFP-E5 expressing 
cells sustained cyclin A-associated kinase activity up to 5 and 6 times compared to 
the respective control cells (Figure 5.10 b).
Cyclin A is companion of two cyclin dependent kinases, CDK2 and cdc2, at 
different stages the cell cycle. It complexes with the CDK2 at the Gl/S phase 
boundary and the complex-associated kinase activity is required through S phase, 
while cdc2-associated kinase activity is necessary for passage through G2 and mitosis 
(Pagano et al., 1992). Our investigations reveal that cyclin A is mainly, if not 
exclusively associated with the cdc2 (Figure 5.12). We therefore concluded that the 
sustained cyclin A-associated kinase activity detected in suspension culture is due 
mainly to cyclin A/cdc2 complexes.
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Figure 5.10 a, b Cyclin A expression level and associated kinase activity in 
suspension culture
a) Cells were cultured in suspension for 48 hr. Cells extracts (50 pg) were 
separated in SDS-PAGE (10% polyacrylamide) and membranes were probed with 
indicated antibodies. Only GFP-E5 and E5 cells show a sustained expression of 
cyclin A protein following 48 hr incubation in semi-solid medium. Levels of a- 
tubulin serve as a loading control.
b) Cyclin A/CDK complexes were immunoprecipitated from 500 pg of total cell 
extracts using a cyclin A polyclonal antiserum (1:250). Cyclin A-associated kinase 
was assayed using Histone HI as substrate.
In suspension GFP-E5 cells sustained cyclin A-kinase activity up to 6 times the 
control cell. E5 cells show 5 fold activation in cyclin A-associated kinase activity 
compared to Z3T3 cells.
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5.2.3.5 Cyclin dependent kinase inhibitor (CKI) p27 expression
In suspension GFP and GFP-E5 cells showed the same level of p27 
expression although GFP-E5 cells still cycled in these conditions (Figure 5.11). A 
possible explanation for this event is the contribution of cells arrested in G1 present 
in both GFP-E5 and GFP plates in substratum-independent growth conditions (87% 
and 97.2% of no cycling cells respectively, Table 4.2). In these studies E5 expressing 
cells confirm what previously reported, p27 expression level was elevated under 
these growth conditions (O'Brien and Campo, 1998), (Figure 5.11).
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Figure 5.11 Analysis of p27 expression level in suspension culture
Cells were cultured in suspension for 48 hr. Cells extracts (50 pg) were separated 
in SDS-PAGE (10% polyacrylamide) and membranes were probed with indicated 
antibodies. The expression of p27 is sustained in E5 cells, while no gross 
difference is observed in the CKI level between GFP and GFP-E5 clones. Levels 
of a-tubulin serve as a loading control.
Figure 5.12 Cyclin A does not associates with CDK2
Samples of cyclin E, CDK2 and cyclin A immunoprecipitates (E, CDK2, A) were 
fractionated by SDS-PAGE and analysed by western blot using the antibodies 
indicated. As expected from previous observations on cyclin A in total cells 
extracts (Figure 5.10), the amount of immunoprecipitated cyclin A is higher in E5 
and GFP-E5 cells. The active form of CDK2 is predominantly associated with 
cyclin E but cannot be detected associated with cyclin A. On the contrary, cdc2 is 
predominantly associated with cyclin A in E5 and GFP-E5 cells. The inactive 
form of CDK2 was predominantly immunoprecipitated by CDK2 antiserum. 
Finally p27 is associated with cyclin E, CDK2 and cyclin A complexes in similar 
amount for Z3T3, GFP, and GFP-E5 cells but is more abundant in E5 cells were is 
mainly associated with cyclin E/CDK2.
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5.2.4 MAPK inhibitors
It has been shown that anchorage-independent conditions do not prevent cells 
from responding to mitogens and entering the cell cycle (Guadagno and Assoian, 
1991); G0/G1 transition and early G1 events can be stimulated by growth factors 
even when cell division is precluded. Moreover, these studies reported that the block 
in anchorage-independent growth leads to selective inhibition of Gl/S cell cycle gene 
expression (Guadagno and Assoian, 1991). Growth factors activate a series of signal 
transduction cascades among which activation of the mitogen-activated protein 
kinase cascade, Ras-Raf-MEK-ERK is the best characterised. Most studies indicate 
that these signals eventually control G1 phase progression by regulating cyclin D1 
expression.
In GFP-E5 and E5 expressing cells grown in suspension the G0/G1 transition 
events, such as cyclin D1 expression, occur and the cells progress throughout the cell 
cycle as shown by cyclin A up-regulation.
We wanted to determine if the transduction cascade activated by mitogens 
and ultimately the expression of cyclin D1 were a necessary prerequisite for cell 
progression in suspension. To achieve this we utilised inhibitors of the MAPK 
pathways to block the signal cascade and analysed the state of the cell cycle 
components after 48 hr treatment. PD98059 inhibitor blocks the activation of MEK 
while U0126 specifically inhibits MEK in both active and inactive forms.
As shown in Figure 5.13 (top panel) the treatment with the PD98059 inhibitor 
blocked the phosphorylation of ERK 1/2 (p-ERK 1/2), while the level of total ERK 
1/2 (t-ERK 1/2) was not affected. The inhibition of the MAPK pathway induced a 
down-regulation of cyclin D1 level in Z3T3, GFP-E5 and GFP cells but not in E5 
cells. Interestingly cyclin A level did not change in E5 and is minimally effected in 
GFP-E5 contrary to their control cells. Similar results were obtained in Z3T3 and E5 
cells when the treatment was prolonged to 72 hr (middle panel). Surprisingly no p- 
ERK 1/2 down-regulation could be detected in control cells. As mentioned above 
PD98059 inhibits the activation of MEK, thus the phosphorylated ERK 1/2 could 
result from residual activated MEK.
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In GFP-E5 and GFP cells the use of the U0126 inhibitor (bottom panel) 
confirmed the independence of cyclin A expression from MAPK pathway and cyclin 
D1 expression.
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Figure 5.13 Cyclin A expression is independent from the MAPK pathway
Z3T3, E5 cells were treated with PD98059 inhibitor for 48 or 72 hr in suspension 
culture (top and middle panels). GFP and GFP-E5 cells were treated also with 
PD98059 for 48 hr and with U0126 inhibitor for 72 hr (top and bottom panel). The 
activation state of ERK 1/2 kinase after the treatment was assessed by using a 
phosphospecific antiserum (p-ERK 1/2), cyclin D1 and cyclin A expression levels 
were also analysed. Total amount of ERK 1/2 was not influence by the treatment 
(t-ERK 1/2). In Z3T3, GFP and GFP-E5 cells cyclin D1 is down-regulated by the 
inhibitors while in E5 cells cyclin D1 level is independent from the MAPK kinase 
pathway. Cyclin A shows a different pattern: the protein level is sustained after 
inhibitors treatment in both GFP-E5 and E5 cells.
DM= cells treated with DMSO as control
PD= cells treated with 50 pM of PD98059 inhibitor
U0= cells treated with 20 pM of U0126 inhibitor
NIH3T3 10%= parental NIH3T3 cells grown at 10% serum in adhesion
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5.3 Conclusions
GFP-E5 cells did not cycle in low serum but could proliferate in suspension. 
Cyclin D1 was down-regulated in GFP-E5 grown in LS and consequently only the 
hypophosphorylated, repressing forms of pRb and pl07 were detected and pl30 was 
accumulated. However, in suspension culture, where GFP-E5 cells continued to 
proliferate (Chapter 4), cyclin D1 expression was up-regulated and pl07 was 
phosphorylated. Surprisingly the hyperphosphorylated form of pRb was not detected. 
Overall the state of these cell cycle components was consistent with the proliferative 
profile of GFP-E5 cells in the different growth conditions.
Previous studies have demonstrated a correlation between BPV-4 E5 
transformation ability and trans-activation of cyclin A promoter. In NIH3T3 and PalF 
cells only E5 wt and its transforming mutants can trans-activate the cyclin A 
promoter. In addition mutants that transactivate the cyclin A promoter confer to 
PalFs the ability to grow in suspension, and mutants that strongly trans-activate the 
promoter permit cells growth in low serum (Ashrafi, 1998; O'Brien and Campo, 
1998; O'Brien et al., 1999).
GFP-E5 expressing cells follow the pattern described above: a heterologous 
cyclin A promoter was trans-activated in normal growth conditions but not in low 
serum, conditions that induced cells to withdraw from the cell cycle (Chapter 4). 
However, in semi-solid medium GFP-E5 clones were able to trans-activate the cyclin 
A promoter up to 5 times the control cells. These data, together with the previous 
studies on E5 wt and its mutants, support the hypothesis that an unknown threshold 
of cyclin A promoter trans-activation correlates with cell transformation, as judged 
by growth in suspension.
Accordingly GFP-E5 cells showed a sustained cyclin A expression and 
associated kinase activity when cultured in suspension but down-regulated cyclin A 
expression and its associated kinase activity in LS.
Moreover, we showed that the cyclin A-associated kinase activity in E5 and 
GFP-E5 cells grown in suspension is mainly due to cyclin A/cdc2 complexes 
(Chapter 7).
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The data obtained with the MAPK inhibitors suggest that in E5 cells 
the expression of cyclin D1 and cyclin A was not affected by the inhibition of the 
MAPK pathway. The MAPK cascade was required to sustain cyclin D1 expression in 
GFP-E5 cells, however cyclin A level was not effected by the inhibition of this 
pathway. From these results it was possible to hypothesise that adherent GFP-E5 
cells require growth factors to sustain cyclin D1 expression and its kinase activity and 
to reach a sufficient level of cyclin A and cyclin A-associated kinase activity to allow 
cell cycle progression. In contrast the ability of GFP-E5 cells to grow in suspension 
was determined by the ability to sustain cyclin A expression and associated kinase 
activity independently from cyclin D1 expression and cyclin E/CDK2 activity.
We conclude therefore that the ability of GFP-E5 expressing cells to 
overcome the G1 arrest induced by loss of cell adhesion correlates with the status of 
cyclin A expression and of its cdc2 associated kinase activity and reinforce the 
hypothesis that E5 transforming ability is at least in part, due to the ability of the viral 
protein to deregulate cyclin A expression (Ashrafi, 1998; O'Brien and Campo, 1998; 
O'Brien et al., 1999).
157
CHAPTER 6: MUTANT FORMS OF BPV-4 E5
6.1 Introduction
BPV-4 E5 transforms established murine fibroblasts conferring anchorage- 
independent growth and ability to grow in absence of mitogens. When expressed in 
PalFs in collaboration with BPV-4 E7, HPV-16 E6 and an activated Ras, E5 
expression induces, in addition to the phenotypes mentioned above, loss of contact 
inhibition. In an attempt to segregate different transforming functions of E5 and 
therefore to define its functional domains, a panel of E5 mutants and chimeras 
between BPV-4 E5 and BPV-1 E5 were made and tested in PalFs (Ashrafi, 1998; 
O'Brien et al., 1999).
BPV-4 E5 shares some structural and functional homology with BPV-1 E5 
(Figure 1.2) suggestive of a similar mechanism of cell transformation. The extensive 
genetic analysis of BPV-1 E5 revealed the presence of critical amino acids in the 
hydrophobic body (Horwitz et al., 1988; Kulke et al., 1992) and the requirement of 
the hydrophilic C-terminus (tail) for transformation activity (Settleman et al., 1989; 
Horwitz et al., 1989). Other studies have shown that binding of BPV-1 E5 to ductin 
requires the N-terminal hydrophobic domain and specifically a glutamine at position 
17 is important in this protein function (Goldstein et al., 1992a; Goldstein et al., 
1992b). In the hydrophobic body of BPV-4 E5 the residue of position 17 is an 
asparagine (N), potentially functionally homologous to glutamine 17 in BPV-1 E5. 
To test this hypothesis asparagine 17 was mutated to serine, tyrosine, or alanine. The 
mutation to alanine (N17A) produced a hypertransforming protein with great ability 
of inducing anchorage-independent growth, cell growth in low serum and escape 
from contact inhibition; the introduction of tyrosine (N17Y) at the same position 
completely abolished the transforming capacity of E5, whereas mutation to a serine 
(N17S) made cells capable of anchorage-independent growth but not in low serum 
(O'Brien et al., 1999).
Further investigations revealed that the 12 hydrophilic amino acids (tail) at 
the BPV-4 E5 C-terminus are critical since neither a form of BPV-4 E5 lacking this 
region (E5T) nor the chimera comprising the BPV-4 E5 body and the BPV-1 E5 
“tail” (4E5N-1E5C) are capable of promoting anchorage-independent growth, growth 
in low serum or loss of contact inhibition, although the reciprocal chimera (1E5N- 
4E5C) still allows PalFs to grow in suspension (Ashrafi, 1998; O'Brien et al., 1999).
To test the importance of the secondary amino acid structure of the E5, two mutants, 
carrying a double modification in the hydrophobic N-terminus hypothesised to be a 
transmembrane a-helix (Figure 1.2), were produced and tested in PalFs. A15P-A20P 
mutant, where the alanine residues at position 15 and 20 had been converted to a 
proline (which has the property of forcing a bend in the main chain and disrupting an 
a-helix) and A15G-A20G mutant, where the same alanine residues were mutated to 
glycine residues, a conservative mutation which should not disrupt an a-helical 
conformation. While A15G-A20G showed low trans-activation of the cyclin A 
promoter but still significantly above background, A15P-A20P failed to activate the 
cyclin A promoter (Ashrafi, 1998). These data suggest that substitution of two amino 
acids could alter the a-helix conformation of the hydrophobic domain with 
consequences for cyclin A promoter activation and also emphasise the importance of 
the nature of these residues for E5 functions.
The use of mutant forms of BPV-4 E5 has allowed the segregation of its 
several transforming functions. Thus the ability to induce substrate-independent 
growth can be separated from the ability to form foci or to prevent cell cycle exit in 
low serum while focus formation and growth in low serum still co-segregate. 
Moreover these studies showed that the different transforming phenotypes conferred 
by the E5 mutants correlate with their ability to transactivate the cyclin A promoter: 
E5 mutants that transcativate cyclin A promoter confer to PalF cells the ability to 
grow in suspension and mutants that strongly transactivate the promoter permit cell 
growth in low serum (Ashrafi, 1998; O'Brien et al., 1999).
The transforming activities of E5T mutant have also been analysed in 
NIH3T3 cells. Contrary to E5 wild type, E5T is incapable of transforming NIH3T3 
cells, active transcription of the cyclin A promoter or de-regulates expression of 
cyclin A, underlying once more the existing correlation between transformation and 
cyclin A de-regulation (O'Brien and Campo, 1998).
As detailed in Chapter 1, BPV-4 E5 transforms primary bovine fibroblasts in 
collaboration with BPV-4 E7, HPV-16 E6 and an activated Ras. On the contrary in 
NIH3T3 cells E5 expression is sufficient for cell transformation, consequently we 
wanted to analyse E5 mutants in established murine fibroblasts to expand the 
information on the transformation ability of this viral protein and its correlation with 
the regulation of cyclin A expression.
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It has been shown that in the PalFs cells the altered phenotypes observed for 
E5 mutants do not depend on the expression level or stability of the proteins and 
there is no correlation between amount of protein and cell transformation (O'Brien et 
al., 1999).
In order to establish if a mis-location of the mutants may be an explanation 
for their different transforming ability, we generated fusion forms of these peptides 
with GFP. (A panel summarising the mutant forms of E5 is shown in Figure 6.1).
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Figure 6.1 E5 wt and its mutant forms
N17S, N17A, N17Y and E5T mutants have been made by Dr. R. Anderson. 
A15P-A20P and A15G-A20G mutants have been made by Dr. H. Ashrafy. 
E5/KDEL and E5/GGEV have been made by Dr. Vincent O’Brien. All constructs 
are HA tagged.
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6.2 Experimental results and discussion
6.2.1 Localisation of GFP-E5 mutants in transient transfectants
In order to obtain fusion forms of BPV-4 E5 mutants their sequences were 
cloned into pEGFPC3, at the 3’ end of the GFP gene using a PCR cloning strategy 
(section 2.2.1). The constructs were sequenced to confirm their identity and called 
GFP-N17S, GFP-N17Y, GFP-N17A and GFP-E5T (Figure 6.2).
The constructs were transfected into COS-7 cells using the calcium phosphate 
method. Cells were fixed, mounted and visualised at the confocal microscope 
(section 2.2.4). Colocalisation studies were performed using an ER marker and a 
Golgi marker, as described in section 3.3.1.5.
All three point mutants at position 17 and the truncated form of E5 show the 
same perinuclear fluorescent distribution observed for the wild type protein (Figure 
6.3). Similarly to GFP-E5, when the location of the mutants were further investigated 
by colocalisation studies, GFP-N17S, GFP-N17Y, GFP-N17A and GFP-E5T were 
localised mainly in the Golgi apparatus and partially in the ER (Figure 6.4 a, b).
These studies show that all E5 mutants have a similar cellular location and 
consequently seem to exclude gross mis-location as a potential reason for their 
different transformation abilities.
163
G
FP
-N
17
S 
1 
23
8
'5H
UJ
r-
2
CuU.
O
X I
-o
00f*} «r>U
cuUu
O
V
t-L.
r- <r-
z z
O h
U h
a
CuUha
Hun
WI
CU
U ha
Ou3
■VH
v
3
-4-*C/5
fN
sd
a>
s-
3
OX)
164
Figure 6.3 Confocal images of GFP-E5, GFP-N17S, GFP-N17Y, GFP-N17A
and GFP-E5T
COS-7 cells were transfected with 0.1 pg of DNA, fixed with 3% paraformaldehyde and 
visualised at the confocal microscope 24 hr after transfection.
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Figure 6.3
GFP-E5
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Figure 6.4 a, b Colocalisation studies with GFP-N17S, GFP-N17Y, GFP-
N17A and GFP-E5T
COS-7 transiently expressing GFP fusion mutants were stained with an ER marker 
(anti PDI antibody) or a Golgi marker (BODIPY-TR ceramide) (black and white 
pictures). Pictures were captured with a 60X objective lens. Coloured pictures 
were magnified further in Microsoft Powerpoint. They present the result of the 
merge between the green and red channel, yellow colour indicates colocalisation.
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6.2.2 Detection of protein expression of GFP-E5 mutants in stable 
transformants
NIH3T3 cells stably expressing GFP-E5 mutants fused with GFP were 
produced in order to investigate the long-term expression of the fusion proteins. For 
each transfection class two 90 mm tissue culture dishes of 0.5xl06 NIH3T3 cells 
were prepared. Cells were transfected with 10 pg of each plasmids using the calcium 
phosphate method (section 2.2.2.6). After 21-28 days of G418 selection the resistant 
colonies were pooled together and expanded for further analysis. As control, NIH3T3 
expressing pEGFPC3 vector were produced and included in the studies.
Total protein extracts (100 pg) from the pooled population of GFP, GFP-E5, 
GFP-N17S, GFP-N17Y, GFP-N17A and GFP-E5T were subjected to western blot 
analysis as described in section 2.2.5. Lysates were fractionated by SDS-PAGE (10% 
polyacrylamide gel), transferred to a nitrocellulose membrane and probed with an 
anti-GFP antibody (Babco).
The results (Figure 6.5) demonstrate that E5 and its mutants are all expressed 
in NIH3T3, although at somewhat different levels. As previously demonstrated in 
PalFs (O'Brien et al., 1999), E5 wild type and its hypertransforming mutants (N17A) 
are expressed at lower level that non transforming mutants. Interestingly single point 
mutations in E5 hydrophobic body influence the protein electrophoretic mobility; 
similar observations were obtained when mutants were translated in vitro in the 
presence of microsomes and immunoprecipitated with an anti-HA monoclonal 
antibody (Ashrafi et al., 2000).
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6.2.3 Transformation studies with mutant forms of E5
During our investigations we have shown that BPV-4 E5 does not fully 
maintain its transforming ability when fused with GFP (Chapter 4 and 5). 
Consequently we decided not to use GFP fusion forms of E5 mutants for 
transformation studies in NIH3T3. Instead we carried out further investigations using 
HA-tagged E5 wt and mutants expressed in pZipneo vector system. These same 
constructs have been used previously for transformation studies in PalF cells 
(Ashrafi, 1998; O'Brien et al., 1999) and E5 wt and E5T have been also tested in 
NIH3T3 cells (O'Brien and Campo, 1998). Transient transfection experiments were 
performed first and NIH3T3 stable transformants were derived later.
6.2.3.1 Transactivation of the cyclin A promoter
NIH3T3 fibroblasts (2xl05^ ) were seeded in a six well plate. The following 
day cells were transfected with 1 pg of luciferase reporter plasmid for the human
cyclin a promoter (ptw929) and 2 pg of E5 wt and its mutants using calcium
phosphate method. One plate was used for each transfection class (Table 6.1). After 
16-18 hr, precipitates were washed off with 2 ml of PBS and cells incubated in low 
serum (LS; 0.5%) or growth serum (GM; 10%) medium for further 24 hr. Luciferase 
activity was determined using a microplate luminometer TR717.
Table 6.1 Short-term transfection classes
2 pg pZipneo + 1 pg luciferase reporter plasmid
2 pg pZipneo E5 + 1 pg luciferase reporter plasmid
2 pg pZipneo N17A + 1 pg luciferase reporter plasmid
2 pg pZipneo E5T + 1 pg luciferase reporter plasmid
2 pg pZipneo A15G-A20G + 1 pg luciferase reporter plasmid
2 pg pZipneo A15P-A20P + 1 pg luciferase reporter plasmid
All constructs are HA tagged; each transfection class was performed twice
Under normal growth conditions BPV-4 E5 wild type expression led to at
least a 9 fold increase in cyclin A promoter activity when compared to control cells 
transfected with pZipneo empty vector (Figure 6.6 top panel). Among the E5
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mutants, N17A showed higher transactivation ability than the wild type (40 fold the 
control cells; Figure 6.6 bottom panel), while A15G-A20G has a promoter 
transactivation comparable to the wild type. In cells transfected with E5T and A15P- 
A20P the promoter was transactivated up to 5 times (Figure 6.6 bottom and middle 
panel). When cells were maintained in low serum, E5 wild type, N17A and A15G- 
A20G show a promoter activity 5-6 times higher than the control, while E5T and 
A15P-A20P show a lower level of transactivation, less then 2 fold, compared to 
control cells (Figure 6.6).
These results are in concordance with what previously shown for E5 wild 
type and E5T in NIH3T3 and PalF cells (O'Brien and Campo, 1998; O'Brien et al., 
1999) and for N17A, A15G-A20G and A15P-A20P in PalFs (Ashrafi, 1998; O'Brien 
et al., 1999). In these cell types the different level of cyclin A promoter 
transactivation correlated with different transforming phenotypes (O'Brien and 
Campo, 1998; O'Brien et al., 1999). To test if this correlation held for E5 mutants 
expressed in NIH3T3, stable murine fibroblasts expressing E5 mutant forms were 
derived.
Table 6.2 Summering of cyclin A promoter transactivation in transient 
transfectants
Transient-transfection
classes
Cyclin A p 
transact 
GM
promoter
ivation
LS
pZipneo - -
BPV-4 E5 wt +++ +++
E5 N17A +++ +
E5T + -
A15G-A20G ++ +
A15P-A20P + -
6.2.3.2 E5 mutants stable transformants
NIH3T3 cells were seeded at 0.5xl06 in a 90 mm tissue culture dish the day 
before transfection, two dishes for each transfection class (Table 6.2). Cells were 
transfected with 10 pg of the appropriated plasmids by using the calcium phosphate 
method as detailed in section 2.2.2.6. After 21-28 days of drug selection, with 
medium containing 500 pg/ml of G418, resistant colonies were pooled together and 
population expanded. (Cell lines expressing pZipneo empty vector, E5 wild type, 
N17S, N17Y, N17A and E5T mutant have been produced by Dr. Vincent O’Brien,
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Figure 6.6 Trans-activation of the human cyclin A promoter by E5 wt and its 
mutants
The fold induction of luciferase activity is given after normalisation for cellular 
protein content [sample’s luciferase reading - background luciferase reading 
(Lysis buffer) + protein concentration of related samples] and, in each case, mean 
value from triplicate samples are given for a representative experiment. The 
reading obtained with control cells (NIH3T3 transiently transfected with pZipneo 
empty vector) was set at 1, and the luciferase reading of the samples were 
normalised to the control reading. Standard deviation (bar) was calculated for each 
transfection class. The experiments were performed at least twice.
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cell lines expressing E5/KDEL and E5/GGEV mutants have been produced 
by myself).
Table 6.3 Stable transfection classes
pZipneo
pZipneo E5
pZipneo N17S
pZipneo N17Y
PZipneo N17A
pZipneo E5T
pZipneo E5/KDEL
pZipneo E5/GGEV
N.B. All constructs are HA tagged
6.2.3.3 Detection of mutant transcripts by RT-PCR in stable transformants
There are no good antibodies against E5 protein and the detection of the HA 
tagged protein by western blot using an anti-HA antibody has never been successful 
thus the cell lines were analysed for E5 transcripts by RT-PCR (2.2.2.9).
Total cellular RNA was isolated using RNAzol extraction as detailed in 
section 2.2.2.9. 1 pg of RNA was used for RT-PCR using a Perkin Elmer Kit and 
0.15 pM of appropriated primers (Table 2.1). As control for DNA contamination (all 
samples had been treated with DNase) an identical reaction mix was prepared for 
each sample excluding reverse transcriptase. To verify that the products obtained had 
the correct length a PCR reaction was performed with pZipneoHAE5 plasmid as 
template. Finally, to check the reaction parameters and the quality of the RNA, 
parallel mixes were set up utilising the RNA samples with primers specific for actin 
mRNA.
The detection of the actin transcripts in all cell populations (Figure 6.7 a, b) 
and the absence of products in reactions without reverse transcriptase confirmed the 
success of the RNA extraction and DNase treatment procedures. In all transfectant 
classes with the exclusion, as expected, of the pZipneo cells, there were detectable 
products, which indicate that the E5 and its mutant genes were transcribed (Figure 
6.7 a, b).
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Figure 6.7 a, b Detection of E5 wt, N17S, E5T, E5/KDEL, E5/GGEV, N17Y 
and N17A transcripts by RT-PCR
Upper panels: RT-PCR was performed using 1 pg of total RNA and 0.15 pM of 
specific primers for E5 wt and its mutants; pZipHAE5 (plasmid) was used as 
template to confirm the correct length of the transcripts; a parallel reaction was 
performed using a mix minus MULV reverse transcriptase (-RT) to check for 
genomic DNA contamination. RT-PCR products of ~ 185 bp were detected for E5 
wt, the N17S, N17Y, N17S and E5T and these co-migrated with the plasmid 
control; because the addition of 18 bp at the 3’ end of E5 ORF, E5/KDEL and 
E5/GGEV amplicons showed a different electrophoretic mobility.
The lower panels show the products obtained from parallel mixes set up utilising 
the RNA samples (0.1 pg) with primers specific for actin mRNA (245 bp) to 
check the reaction parameters and the quality of the RNA. Also these reactions 
were performed plus (+RT) and minus (-RT) reverse transcriptase step.
All mutants were sequence verified.
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6.3 Conclusions
Studies using GFP tagged forms of E5 mutants demonstrate that all E5 
mutants analysed so far share with the wild type E5 their cellular location: the Golgi 
apparatus. Therefore a different cellular location cannot be the reason for the 
different transforming abilities among the mutants. Moreover, the fact that E5 wt and 
its partially transforming, non transforming and hypertransforming forms were all in 
the Golgi apparatus suggests that this cellular location may be necessary but is not 
sufficient for E5 transforming ability (see Chapter 7). It is interesting to note that the 
modification of the asparagine in position 17 to serine, tyrosine or alanine in the E5 
hydrophobic body, does not interfere with the Golgi location; the hydrophilic tail is 
not required for the Golgi location and the first 32 amino acids of E5 encode 
sufficient information to locate the GFP-E5T mutant to this cellular compartment. In 
addition, as observed in Chapter 3, the disruption of the a-helix does not interfere 
with the Golgi location of E5.
In NIH3T3 cells, E5 mutants show a similar profile of cyclin A promoter 
transactivation as seen in primary bovine fibroblasts. Moreover the promoter 
activation correlates with transformation ability (O'Brien and Campo, 1998). The 
study of the transformed phenotype of NIH3T3 stably expressing N17S, N17Y, 
N17A, E5/KDEL and E5/GGEV would add important information to our 
understanding of E5. Unfortunately this part of the project could not be completed 
because of unforeseen problems and lack of time.
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CHAPTER 7: DISCUSSION
7.1 Introduction
The human papillomaviruses (HPVs) are the most important aetiological 
agents of cervical squamous carcinoma and HPV-16 and HPV-18 have recently been 
declared as human carcinogens by the International Agency for Research on Cancer 
(LARC). It is clearly a major research interest to investigate how the virus 
(specifically its transforming proteins) interferes with its host to induce 
carcinogenesis. However many technical obstacles have made the studies difficult. 
The infection of human beings with HPV for experimentation is obviously unethical 
and HPVs do not reproduce or induce cancers when not in their natural host. 
Moreover, these viruses are not easy to culture in vitro. Although these difficulties 
have been partially overcome with the development of new technical approaches (i.e. 
rafts culture), the best alternative to investigate the virus properties remains the use 
of animal papillomaviruses. The Bovine Papillomavirus type 4 (BPV-4), in 
particular, is a valuable model for HPV-associated carcinogenesis. Like HPVs, BPV- 
4 is involved in cancer development in its own host, providing the opportunity to 
study carcinogenesis in a natural system. Moreover, BPV-4 infection is limited to the 
mucous epithelia of the alimentary tract and this tissue specificity is shared with 
HPVs. Finally, for BPV-4, the progression of papillomas to cancers has been 
experimentally reproduced.
One of the two transforming proteins of BPV-4 is E5, a small, 42 amino acids 
long, hydrophobic protein. E5 is localised to the endomembrane compartments of 
primary bovine fibroblasts (Pennie et al., 1993) and is expressed in the basal and 
suprabasal layers of early papillomas in vivo (Anderson et al., 1997). The small 
dimension, the high hydrophobicity and the membrane location are features shared 
with the members of the E5 family proteins from animal and human 
papillomaviruses.
E5s appear to transform cells by enhancing activation of the intrinsic tyrosine 
kinase activity of growth-factor receptors, interfering with the cell cycle machinery 
and disrupting pH homeostasis in endomembranes.
BPV-1 E5 transforms cells by activating the platelet-derived growth factor (3 
receptor (PDGFp-R) in a ligand dependent fashion; it induces receptor dimerisation 
and activation, trans-phosphorylation and recruitment of cellular signalling proteins 
to the receptor (Petti et al., 1991; Lai et al., 1998; Klein et al., 1998). HPV-16 E5 
affects the metabolism of EGF-R. Cells expressing HPV-16 E5 display elevated 
levels of EGF-R on their surface (Straight et al., 1993; Straight et al., 1995; Crusius 
et al., 1998), and a sustained activation of the mitogen activated protein kinase 
(MAPK) cascade in response to EGF treatment (Gu and Matlashewski, 1995; Ghai et 
al., 1996; Crusius et al., 1997). BPV-4 E5 transformation is correlated with 
transactivation of the cyclin A promoter, up-regulation of cyclin D and cyclin A 
expression and associated kinase activities and, unusually, with over-expression of 
the cyclin dependent kinase inhibitor p27 (OBrien and Campo, 1998; O'Brien et al., 
2001).
All E5s bind to the highly conserved 16 kDa subunit c/ductin (16K) a 
component of the vacuolar proton ATPase (V-H+-ATPase) and of the gap junction 
(Goldstein et al., 1991; Finbow et al., 1991; Conrad et al., 1993; Faccini et al., 1996). 
This physical interaction may impair V-H+-ATPase function and be responsible for 
the lack of acidification of endosomes and Golgi apparatus (Straight et al., 1995; 
Schapiro et al., 2000). Finally BPV-1 E5, BPV-4 E5 and HPV-16 E5 down-regulate 
gap junction intercellular communications (Oelze et al., 1995; Faccini et al., 1996; 
Ashrafi et al., 2000)
Understanding the mode of action of E5 proteins will help clarify viral 
transformation and replication mechanisms, cellular signal transduction pathways 
and organelle functions. This Thesis aims to contribute to these investigations 
expanding the information on BPV-4 E5 transforming mechanisms with regard to:
(i) The importance of the subcellular location of E5 for its transforming
activities.
(ii) The signal pathways utilised by E5 for cell transformation.
7.2 Cellular localisation of BPV-4 E5
The hydrophobic nature of BPV-4 E5 has rendered its purification extremely 
difficult because the protein is insoluble. Consequently antibody reagents directed 
against E5s are limited and not very efficient. In the attempt to obtain an efficient
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detection system for routinely visualising E5, two forms of the viral protein fused 
with the green fluorescence protein (GFP) were constructed (GFP-E5 and E5-GFP).
GFP-E5 is mainly localised in the Golgi apparatus and only partially present 
in endoplasmic reticulum (ER) (Figures 3.2 and 3.4). These results are in agreement 
with BPV-4 E5 subcellular location in transiently transfected PalFs (Pennie et al.,
1993) and consistent with the intracellular location of BPV-1 E5 and HPV E5s 
(Burkhardt et al., 1989; Conrad et al., 1993; Sparkowski et al., 1995; Schapiro et al., 
2000).
BPV-4 E5 has been subjected to a genetic analysis that revealed the crucial 
role of specific amino acids in cell transformation. Mutation of the asparagine (N) 
residue in position 17 to serine (N17S), tyrosine (N17Y) or alanine (N17A) produced 
forms of BPV-4 E5 partially transforming, non transforming and hypertransforming 
respectively; a truncated form of E5 (E5T), lacking the 12 hydrophilic amino acids, 
was transformation defective (O'Brien and Campo, 1998; O'Brien et al., 1999).
Our investigation on the cellular location of these different mutants revealed 
that they all localise mainly in the Golgi apparatus and apparently their distribution 
does not differ from wild type (Figures 6.3 and 6.4 a, b). These results show that the 
difference in transformation activities of the mutants is not dependent on their 
different cellular localisation, suggesting the conclusion that the presence in the 
Golgi apparatus may be necessary but is not sufficient for cell transformation. 
Moreover, a single modification in the hydrophobic body does not influence the cell 
location of the protein. Likewise all BPV-1 E5 mutants at position 17 have been 
localised in the Golgi compartment, confirming that mutations in the transmembrane 
domains are usually tolerated for Golgi location. Moreover the first 30 amino acids of 
BPV-4 E5 enclose the information required to target the protein to the Golgi, as the 
mutant lacking the last 12 amino acids still localises in this organelle.
The BPV-4 E5 mutant A15P-A20P also localises in the Golgi, therefore 
changing the alanine residues at position 15 and 20 to a proline, which has the 
property of forcing a bend in the amino acid chain and of disrupting the a-helix, does 
not interfere with the protein cellular location. These results suggest that an intact 
secondary structure is not required to localise E5 to the lipids bilayers and the high 
hydrophobicity of the N-terminus is sufficient to target the viral protein to 
endomembranes. Alternative it is possible that the introduction of the proline 
residues has not affected the a-helix conformation (Figure 3.7).
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The importance of the subcellular location and its relation to viral 
transformation ability has been thoroughly investigated in the case of BPV-1 E5. The 
use of a form of BPV-1 E5 bearing a KDEL retrieval signal (section 3.3.2) 
demonstrated that the Golgi location is required for BPV-1 E5 transforming abilities 
(Sparkowski et al., 1995). BPV-1 E5/KDEL was expressed in the ER and could not 
induce focus formation in mouse fibroblasts (Sparkowski et al., 1995). The authors 
hypothesised that the E5/KDEL-PDGFp-R complexes, although still detectable, were 
sequestered in the ER where the growth factor receptor was unable to transmit a 
mitogenic signal. On the contrary, the PDGFp-R in complex with the wild type form 
of E5 could be activated in the Golgi apparatus or move, with the viral protein, to the 
plasma membrane (Chapter 1). Although necessary, the presence in the Golgi 
apparatus is not the only requisite for cell transformation as demonstrated by mutants 
of BPV-1 E5 still located in the Golgi but unable to induce cell transformation.
The addition of the KDEL signal to the C-terminus of BPV-4 E5 has failed to 
retain the viral protein in the ER (Figure 3.6). There could be several reasons for why 
GFP-E5/KDEL is still localised mainly in the Golgi compartment: (i) it is known that 
proteins bearing the KDEL amino acids sequence although resident in the ER can yet 
slip out of it, they are in fact retrieved from Golgi in a sorting process that returns 
them to the ER. It is therefore possible that an over expression of ligands causes a 
saturation of the retrograde mechanism and allows protein to escape the control point 
and move towards the Golgi compartment; (ii) BPV-4 E5 could be a type I 
transmembrane protein with a cytoplasmic C-terminus. This means that the KDEL 
sequence is not facing the endomembranes lumen and it cannot be recognised by the 
KDEL-receptors, which reside in the ER-Golgi intermediate compartment. The last 
model is not in agreement with what previously hypothesised by O’Brien & Campo 
(1998) and need further experimental supports. It is unlikely that GFP contributes to 
the Golgi location of GFP-E5/KDEL. The use of GFP to tag transmembrane proteins 
(type I or type II) is widespread and GFP does not interfere with the protein 
assembly, or transport within the cell organelles (Girotti and Banting, 1996; 
Simonova et al., 1999); see below.
Further findings corroborate the importance of the Golgi location for BPV-4 
E5 and BPV-1 E5: a perfect correlation has been found between the ability of BPV-1
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E5 to induce Golgi alkalinisation and to transform cells (Schapiro et al., 2000). These 
results suggest that the disruption of the normal activity of the vacuolar ATPase in 
the acidification of endomembrane compartments plays a role in the oncogenic 
ability of BPV-1 E5. It is still unknown whether BPV-4 E5 can bind to Growth 
Factor Receptors (GFRs); however, it can complex, in vitro, with 16K protein 
(Faccini et al., 1996). Moreover, NIH3T3 expressing BPV-4 E5 show alkalinisation 
of the Golgi compartment (Schlegel, personal communications) pointing to the 
interaction with the V-H+-ATPase activity as a possible transforming mechanism also 
for BPV-4 E5.
Recently it has been shown that when expressed in fibroblasts (PalFs and 
NIH3T3) BPV-4 E5 induces down-regulation of the surface MHCI (histocompatibily 
complex class I) (Ashrafi et al., 2002). Although the specific mechanisms is 
unknown, it is possible that the transport of the MHC I to the surface is inhibited 
because of the Golgi location of E5 and/or the consequent Golgi alkalinisation.
Although all hypotheses of how the presence in the Golgi compartment could 
contribute to cell transformation by E5 are still under investigation, it is clear that this 
is an extremely strategic location to control or regulate the transport/processing of 
itinerant proteins and lipids, and to influence various cellular processes either by 
direct interaction with targeted proteins or indirectly by modifying the organelle 
environment (alkalinisation) (Shields and Arvan, 1999).
Specific amino acid motifs and/or conformation of particular proteins 
determine their destination to various cellular compartments. In the absence of such 
targeting information, a protein that is translocated into the ER follows a ‘default’ 
pathway, that leads, in animal cells, to the expression of membrane proteins on the 
cell surface. Surprisingly GFP-E5 could not be detected on the plasma membrane 
(section 3.3.4). However, the amino acid sequence of E5 does not present a known 
targeting motif for the ER or Golgi. It is known that a retention system for the Golgi 
compartment exist (Machamer, 1993; Munro, 1998), however unlike the ER 
localisation signals, which are usually exposed to soluble factors and are involved 
mainly in protein-protein interaction, Golgi localisation involves lipid-protein 
interaction as well as protein-protein interactions (Machamer, 1993). One proposed 
model for Golgi retention correlates the length of the transmembrane domains with 
the progressive enrichment of cholesterol in the plasma membrane over that in the
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ER (Bretscher and Munro, 1993). If cholesterol was gradually concentrated in 
transport vesicles throughout the secretory pathway, a cholesterol gradient would 
exist. Plasma membrane proteins usually have longer transmembrane segments and 
would be more likely to associate with thicker membranes and be transported 
forward, whereas Golgi-resident proteins, which have shorter transmembrane domain 
on average, would be excluded from the transport vesicles and thus be retained in the 
Golgi. This mechanism, which is non-saturable and independent on the exact 
sequence of transmembrane domain, could explain the retention of BPV-4 E5 in the 
Golgi compartment.
Similarly to BPV-4 E5, other members of E5 family are located principally 
within subcellular compartments (Burkhardt et al., 1989; Conrad et al., 1993) and 
appear at the cell surface only when overexpressed, although this aspect has not been 
extensively investigated. It has been hypothesised that, at least in the case of BPV-1 
E5, the progression to the cell surface may not be required for cell transformation. 
BPV-1 E5 could, for example, activate PDGFp-R from the Golgi apparatus, without 
necessarily moving to the plasma membrane. There are contradictory reports in 
literature on the ability of GFRs to signal from an intracellular compartment. In some 
studies the v-sis oncogene has been shown to transform cells through an autocrine 
activation of PDGFp-R; in these studies the receptor activation occurs in intracellular 
compartments, before receptor maturation is complete and before the receptor has 
reached the cell surface (Keating and Williams, 1988). Others, however, 
demonstrated that v-sis/PDGF-R interaction could not signal functionally from the 
proximal Golgi apparatus (Fleming et al., 1989) leaving the subject an open matter.
The influence of the GFP tag in the retention of E5 in the Golgi could not be 
definitely excluded, however it could be considered unlikely for different reasons. 
First, both GFP-E5 and E5-GFP proteins localised in the Golgi apparatus, suggesting 
that E5 itself is the target sequence for this organelle. Second, we used a fragment 
(PEP; 50 amino acids) of the rabbit neutral endopeptidase 24.11 (Simonova et al., 
1999), that presents similar size to BPV-4 E5, fused with GFP. We demonstrated that 
GFP does not interfere with PEP trafficking through cell compartments despite the 
difference in size between the two proteins (Figure 3.10). We conclude that it is 
unlikely that GFP affects BPV-4 E5 cellular location.
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7.3 Cell transformation by BPV-4 E5
The decision to divide and progress through the cell cycle requires the 
integration of extracellular and intracellular signals (see below). The environmental 
signals are the presence/absence of particular growth factors and of the extracellular 
matrix (ECM). Growth factors and ECM proteins stimulate signal-transduction 
pathways by binding to their receptors, typically tyrosine kinase receptors (RTKs) 
and integrins. Ultimately these pathways transduce information to the cell cycle 
machinery.
In normal cells the presence of growth factors and the attachment to substrate 
are necessary for cell division, in contrast tumour cell proliferation is generally 
independent of both adhesion and growth factors. Indeed, many or most oncogenes, 
such as v-Ras or simian virus 40 (SV40) Large T, induce cells transformation that 
leads to anchorage and serum-independent proliferation.
Accordingly NIH3T3 cells expressing BPV-4 E5 do not exit the cell cycle 
after serum withdrawal and proliferate when maintained in suspension. However, 
two mutants of the viral protein, N17S and the chimera 1E5N-4E5C (Chapter 6), 
induce anchorage-independent growth in PalFs but do not allow cell proliferation in 
absence of mitogens, suggesting the existence of two independent mechanisms by 
which E5 confers these phenotypes. Here we show for the first time that the 
segregation of the two phenotypes occurs also in NIH3T3. GFP-E5 cells can grow in 
suspension culture (Figure 4.6), demonstrating that the sole expression of GFP-E5 is 
sufficient to transform NIH3T3, as judged by growth in suspension. Thus GFP-E5 
can override the control mechanisms that arrests anchorage-dependent cells in late 
G1 phase when maintained in suspension (O'Brien and Campo, 1998; O'Brien et al., 
1999). However anchorage-independent, 3T3-GFP-E5 are not able to proliferate in 
low serum (Figures 4.4 and 4.5) demonstrating that the addition of GFP at the N- 
terminus of E5 disturbs the ability of the wild type protein to maintain cell cycle 
progression in the absence of mitogens (O'Brien and Campo, 1998; O'Brien et al.,
1999). GFP-E5 is a fundamental tool to study how this segregation occurs in NIH3T3 
cells, a system that allows studies of the viral protein transforming mechanisms 
without the influence of other viral oncoproteins. Moreover, contrary to N17S or 
1E5N-4E5C mutants, it is possible to verify GFP-E5 protein expression through
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direct visualisation by confocal/fluorescence microscopy and, for the first time, by 
western blotting detection (Figure 4.2).
7.4 BPV-4 E5 and the cell cycle
The progression through the cell cycle is dependent on phosphorylation of 
key regulatory proteins by cyclin dependent kinases (CDKs), which in turn are 
regulated in a complex fashion by association with cyclins, phosphorylation and 
dephosphorylation and binding to CDK inhibitors (CKIs) (Sherr and Roberts, 1995). 
One of the most important targets of cyclin/CDK phosphorylation activity is the 
retinoblastoma protein (pRb). pRb phosphorylation releases the transcription factors 
E2F, and this event, at the mid-Gl-phase, determines the cell irreversible 
commitment to cell division (Chapter 1 and Chapter 5).
DNA viruses are dependent on their host replicative machinery and must 
induce cells to enter the S phase to create the environment necessary to viral DNA 
synthesis. The ability of adenovirus, papillomavirus, SV40, and other viruses to 
extend the proliferative capacity of their host cells is a direct result of expression of 
viral proteins that override growth-suppressive signals that control cell cycle 
progression. Adenovirus E1A, SV40 Large T and HPV E7 can all form complexes 
with pRb and cause the release of E2F, bypassing the requirement for cyclin D- 
associated kinase activity (Munger et al., 1989b; Wang et al., 1993; DeCaprio et al., 
1988); moreover, adenovirus E1B, SV40 Large T and HPV E6 interact and inactivate 
p53 protein (Zantema et al., 1985; Werness et al., 1990; Funk and Galloway, 1998). 
Clearly these three different viruses have adopted very similar strategies to de­
regulate cell growth.
It has emerged recently that tumour suppressors are not the only victims of 
viral opportunism and that both CKIs and cyclins are vulnerable to disruption by 
several viral gene products (reviewed in Swanton and Jones, 2001). HPV E7 affects, 
by direct binding, the activity of p27 and p21, leading to an increase in CDK2- 
associated kinase activity (Zerfass-Thome et al., 1996; Jones et al., 1997; Funk et al.,
1997). In NIH3T3 cells, E7 leads to constitutive expression of cyclin E and cyclin A 
proteins and their associated kinase activity (Zerfass et al., 1995). In addition, E7 
induces anchorage-independent growth via activation of cyclin A expression and 
prevention of the inhibition of cyclin E dependent kinase activity (Schulze et al.,
1998).
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BPV-4 E5 influences the cell cycle progression via up-regulation of cyclin A 
(O'Brien and Campo, 1998; O'Brien et al., 1999). E5 expression in NIH3T3 cells 
promotes transcription of a heterologous cyclin A promoter, increases the expression 
of endogenous cyclin A protein and elevates the cyclin A-associated kinase activity 
in growth conditions where cyclin A expression is diminished in control cells 
(O'Brien and Campo, 1998). In PalF cells E5 expression promotes transcriptional 
transactivation of a heterologous cyclin A promoter in all growth conditions tested 
(Ashrafi, 1998; O'Brien et al., 1999). A strong relationship exists between cyclin A 
promoter transactivation and cell transformation: mutants of E5 able to transactivate 
cyclin A promoter confer to cells the ability to grow in suspension and mutants that 
strongly transactivate the promoter permit growth in low serum.
This relationship is maintained in GFP-E5 cells: proliferation of GFP-E5 cells 
in normal serum or in suspension is always accompanied by increased cyclin A 
promoter activity and conversely the lack of cyclin A promoter transactivation is 
associated with the failure of the cells to proliferate in low serum (Figures 5.3 and 
5.9). Moreover, cyclin A expression and associated kinase activity present the same 
pattern, being elevated in suspension and down-regulated in low serum (Chapter 5). 
These observations support the conclusion that E5-mediated cell transformation is 
due to the ability of the viral protein to de-regulate cyclin A expression and 
associated kinase activity.
During the cell cycle, cyclin A gene expression is strictly regulated at the 
level of transcription: the protein is expressed at the Gl/S transition and through the 
S phase (Henglein et al., 1994). It has been shown that the adhesion requirement is 
likely to reflect a cell cycle check-point in late G1 phase of the cell cycle (Guadagno 
and Assoian, 1991). Cells arrested by suspension fail to produce cyclin A, however 
ectopic expression of cyclin A enables the cells to bypass the adhesion requirement, 
implicating cyclin A as the major target of cell cycle control by anchorage-signalling 
pathway (Guadagno et al., 1993). In agreement with these observations also in the 
case of E5 transformed cells it is the up-regulation of cyclin A that mediates their 
ability to grow in suspension.
In NIH3T3 cells the expression of cyclin D1 and cyclin E is anchorage- 
independent, however, their associated kinases are inactivated, mainly by the 
inhibiting activity of p27 (Schulze et al., 1996). As a consequence pRb is not
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hyperphosphorylated/inactivated, E2F is not released and cyclin A is not expressed. 
In E5 and GFP-E5 transformed cells the situation is different. Although cyclin D1 
and cyclin E are expressed in suspension, no hyperphosphorylated forms of pRb 
could be detected, suggesting that the cyclins/CDKs complexes are not active. 
However, a form of pl07 with a different electrophoretic mobility, probably due to 
protein phosphorylation, is observed in E5 and GFP-E5 cells. Cyclin E/CDK2 kinase 
activity is only slightly higher than in control cells and probably not sufficient to 
induce pRb deactivation, but nevertheless cyclin A is up-regulated. Therefore cyclin 
A expression and associated kinase activity are independent from cyclin D i­
associated kinase activity and pRb deactivation (Chapter 5). It is known that pocket 
proteins regulate cyclin A expression but their exact mechanisms remains to be 
elucidated (Schulze et al., 1995; Philips et al., 1998). Some reports indicate 
pl07/E2F complexes as the principal effectors (Schulze et al., 1995; Zerfass-Thome 
et al., 1997) and exclude the requirement of an inactivated pRb (Henglein et al.,
1994). However, experiments with pRb-null and pl07-null mouse embryo fibroblasts 
emphasize that pRb is important for cyclin A gene expression (Philips et al., 1998; 
Philips et al., 1999). In agreement with the former model, pl07/E2F complexes in E5 
transformed cells could regulate cyclin A expression.
The independence of cyclin A expression from cyclin D1 is supported by the 
data obtained using MAPK inhibitors. The mitogens-activated protein kinase 
(MAPK) cascade, Ras-Raf-MEK-ERK, is a well characterised response to both 
receptor tyrosine kinase (activated by growth factors) and integrins activation (by 
ECM) (Danen and Yamada, 2001). Several studies have established a link between 
ERK activation and cell proliferation: expression of dominant negative ERK or 
antisense ERK inhibits proliferation of fibroblasts (Pages et al., 1993). Activation of 
MEK/ERK pathways leads to the induction of cyclin D1 mRNA and the use of a 
MEK inhibitor (PD98059) or a dominant negative ERK, results in decreased 
expression of cyclin D1 mRNA and protein (Weber et al., 1997; Balmanno and 
Cook, 1999). In E5 cells cyclin D1 expression is independent from MAPK 
activation: in suspension cyclin D1 expression level is unaltered after the addition of 
MEK inhibitors (Figure 5.13). Moreover, cyclin A expression is independent from 
MAPK activity and cyclin D1 expression. In E5 cells not only the normal sequential 
activation of cyclins is altered but the transduction cascade that links the extracellular
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signals to intracellular signals is dispensable. In our knowledge this is the first report 
of ERK 1/2-independent cyclin A expression.
In has been previously hypothesised that in E5 cells, cultured in adhesion, the 
principal cyclin-dependent kinase companion of cyclin A is CDK2 (O'Brien and 
Campo, 1998). In suspension, no CDK2 could be detected in complex with cyclin A 
in E5 and GFP-E5 cells, and only cdc2 could be precipitated with cyclin A. In normal 
cells cyclin A/cdc2 kinase activity is required for passage through G2 and enter in 
mitosis (Pagano et al., 1992). At this moment it is not known if, in E5 transformed 
cells, cyclin A/cdc2 complexes are active also in S phase or only in G2/M phase.
In light of these results it is important to establish which cyclin-dependent 
kinase is associated with cyclin A in adhesion culture.
BPV-4 E5 transformation is accompanied by a surprisingly up-regulation of 
p27 in all condition tested (O'Brien and Campo, 1998), although the cells continue to 
proliferate. In adherent E5 cells, the up-regulated and active cyclin Dl/CDK 
complexes sequester p27 and prevent its repressing activity on CDK2 activity 
(O'Brien et al., 2001). In suspension p27 is associated mainly with cyclin E/CDK2 
complexes and to a lesser extent with cyclin A/cdc2 (Figure 5.12). This difference 
could explain why the kinase activity of cyclin A is higher than the activity of cyclin 
E. GFP-E5 cells do not present an up-regulation of p27. Both cyclin E/CDK2 and 
cyclin A/cdc2 complexes are equally associated with p27 although they show a 
difference in kinase activity (Figure 5.12). p27 acts in GO and early G1 to inhibit G1 
cyclins/CDKs, with the primary target being cyclin E/CDK2 complexes (Slingerland 
and Pagano, 2000), it is possible therefore that p27 is not active as an inhibitor of 
cyclin A/cdc2 complexes in G2 and M phases of the cell cycle. A recent report, 
however, shows that p21 (a CKI structurally related to p27) contributes to the 
regulation of the G2/M transition (Niculescu et al., 1998). It is known that 
cyclin/CDK complexes must overcome an inhibitory threshold of p27 expression 
level to become catalytically active (Polyak et al., 1994). It is therefore possible that 
in GFP-E5 cells the stochiometric balance between p27 and cyclin A/cdc2 complexes 
is in favour of the latter, allowing cell cycle progression.
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7.5 Conclusions
Work with GFP-E5 reveals that E5 has at least two transforming 
mechanisms: 1) via sustained activation of cyclin D1 and cyclin Dl-associated kinase 
activity and 2) via up-regulation of cyclin A and cyclin A-associated kinase activity. 
Activation of cyclin A and expression of cyclin D1 are mitogens and adhesion- 
independent. However, the kinase activation of cyclin D1 appears to be dependent on 
adhesion to substratum. Previous studies have already revealed that in E5 cells cyclin 
E protein level and associated kinase activity are not up-regulated (O'Brien and 
Campo, 1998), suggesting an alternative way to bring about transcriptional activation 
of cyclin A gene. Here we show that ERK 1/2 activation and cyclin D1 are 
dispensable for cyclin A expression at least in suspension culture. The cyclin A- 
associated activity detected in transformed cells appears to be associated mainly, if 
not exclusively, with cdc2 (Chapter 5).
We propose that the up-regulation of cyclin A and associated kinase activity 
(mainly cdc2) is the fundamental requisite for anchorage-independent growth of E5 
transformed cells. This activation occurs independently from MAPK pathway and 
cyclin D1 expression and activation. The state of the cell cycle components in E5 
transformed cells is summarised in Tables 7.1, 7.2, 7.3.
It has been shown recently that another viral oncoprotein, BPV-1 E5, 
transforms NIH3T3 cells without inducing ERK phosphorylation (Suprynowicz et al.,
2000), although the interaction and activation of PDGFp-R is considered the 
principal transforming pathway of the viral protein (Chapter 1), (Petti et al., 1991; 
Petti and DiMaio, 1994; Goldstein et al., 1994). This suggests that downstream 
effectors of growth factors, other than the MAPK, are responsible for cell cycle 
progression in E5 transformed cells. Interestingly, mutants of BPV-1 E5, not able to 
induce PDGFp-R transphosphorylation, can sustain phosphorylation of PI3-K and 
induce anchorage-independent growth, but not proliferation in low serum 
(Suprynowicz et al., 2000). These results suggest a link between PI3-K activation and 
promotion of anchorage-independent growth. Moreover, inducible expression of a 
constitutively active PI3-K in rat embryo fibroblasts promotes anchorage- 
independent growth but does not eliminate the growth factor requirements (Klippel et 
al., 1998). In light of this observation, PI3-K pathway becomes a potential candidate 
to explain the ability BPV-4 E5 cells to grow in suspension independently from the
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MAPK pathway. PI3-K phosphorylates the 3’-OH position of the inositol ring of 
inositol phospholipids, activating a cascade of events that leads to the 
phosphorylation of various targets such as Protein Kinase B (PKB/AKT) and to the 
activation of the Rho family of small G-proteins (including CDC42, Rac, and Rho). 
PKB/AKT, a serine/threonine kinase, is involved in cell survival, through a putative 
downstream target p70S6K required for G1 progression in a variety of cells (Chung 
et al., 1994). The Rho family has pleitropic functions: control actin cytoskeleton, 
regulate stress-activated Map kinase p38 and JNKs and activation of transcription 
factors (reviewed in Cantrell, 2001). Moreover, constitutive activation of FAK, 
CDC42 and Rho leads to cell proliferation that is anchorage-independent but growth 
factor-dependent (Schwartz, 1997).
It has been shown that mitogens and the cytoskeleton play different roles in 
cyclin A expression. Mitogens are required to phosphorylate and activate CREB, an 
transcription activator of cyclin A promoter (Figure 7.1), but disruption of 
cytoskeleton does not influence this step. However, phosphorylation occurs well 
before promoter activity is detected, thus a second “stimulating” step, sensitive also 
to cytoskeleton disruption, is required to time cyclin A expression (Bottazzi et al.,
2001). It is possible that the requirement of mitogens in GFP-E5 cells reflects the 
need to free cyclin A promoter from the repressor, however the second event may 
occur independently from the state of the cytoskeleton.
Considering all the above observation we propose the following model for E5 
transformation. The Golgi is a critical location for controlling membrane trafficking 
and cell signalling. E5 targets key regulators of signalling complexes that assemble 
and/or are en route through the organelle. The Golgi could become the new 
decisional centre, freeing the cells from extracellular constrains (nutrients and 
adhesion) and leading to cell transformation.
7.6 Future prospective
More data are required to validate the model proposed. It is important to define 
what pathways, other that MAPK, are de-regulated by E5 and determine the ones 
involved in cell transformation. As mentioned above PI3-K is considered to be the 
first candidate. Using a PI3-K specific inhibitor (LY 294002) it will possible to verify 
the role of PI3-K in the anchorage- and mitogens-independent cell progression of E5
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expressing cells. This will elucidate the pathway/s responsible for Golgi-nucleus 
communication. Moreover, it is necessary to clarify how the sequential events of the 
cell cycle have been deranged by E5. Further investigations are required to prove the 
independence of cyclin A expression from pocket protein deactivation. The use of a 
dominant negative form of pRb could be extremely informative. This form of pRb 
presents mutated CDKs phosphorylation sites and it cannot be inactivated by 
hyperphosphorylation (Zhang et al., 2000). It would be interesting to express this 
form of pRb in E5 cells and to analyse their cell cycle profile.
The surprising observation that only cyclin A/cdc2 complexes could be 
detected in E5 cells needs to be confirmed. Moreover the principal CDK companion 
of cyclin A in adherent E5 cells needs to be determined.
Here we have established that residence of E5 in the Golgi apparatus is not 
the only requirement for cell transformation. Moreover, this subcellular location has 
not yet been proved necessary for BPV-4 E5 transforming activities. It will be 
important to create a form of E5 that does not localise in the Golgi and to study its 
effect on cell transformation. A fusion form of GFP-E5 with the fragment of the 
rabbit neutral endopeptidase (PEP) could be a good candidate. In addition, the effect 
of transforming and non-transforming E5 mutants on Golgi alkalinisation will help to 
clarify the association between this event and cell transformation by E5.
Finally, GFP-E5 can be used to detect proteins that interact with BPV-4 E5. 
This has been difficult to pursue until now, due to the absence of good antibodies 
against E5.
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Table 7.1 Expression level and associated kinase activity of cyclins in cells 
cultured in 0.5% serum
Cyclin D1 Cyclin E Cyclin A
Express Kinase Express Kinase Express Kinase
Z3T3 4 4 1* 4 1
E5 t T 1* t t
GFP 4 4 N/D N/D 4 1
GFP-E5 4 4 N/D N/D 4 1
Table 7.2 Expression level and associated kinase activity of cyclins in cells 
cultured in suspension
Cyclin D1 Cyclin E Cyclin A
Express Kinase Express Kinase Express Kinase
Z3T3 4 N/D = = 1 1
E5 T N/D = = t t
GFP 4 N/D = = 1 1
GFP-E5 T N/D = = t t
Table 7.3 Expression level and associated kinase activity of cyclins in cells 
cultured in suspension after treatment with MAPK inhibitors
Cyclin D1 Cyclin E Cyclin A
Express Kinase Express Kinase Express Knase
Z3T3 4 N/D N/D N/D 1 N/D
E5 t N/D N/D N/D t N/D
GFP 4 N/D N/D N/D 1 N/D
GFP-E5 4 N/D N/D N/D t N/D
I down-regulated 
t  up-regulated 
= no or little change 
N/D =not determined 
* (O'Brien and Campo, 1998)
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